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ABSTRACT 
 
 Dehorning is a commonly performed husbandry procedure in cattle to limit injury 
and conform to modern facility design. Prior research provides evidence that dehorning 
results in increased nociception and stress through changes in behavioral, 
neuroendocrine, and physiological responses. Alterations in these actions allow 
investigators to evaluate pain and stress reducing practices. In addition to improved 
welfare strategies including institution of polled breeding programs and conducting the 
procedure on young animals, calves may benefit from the administration of analgesics 
including local anesthetics, non-steroidal anti-inflammatory drugs (NSAIDs), and α2-
agonists. Reviews of the literature have indicated a multimodal approach including local 
anesthetics and NSAIDs may be the optimal strategy to mitigate the negative response 
following dehorning. Since no analgesic products are currently labeled for cattle in the 
United States, providing an appropriate and effective analgesic remains challenging. As 
such, we have studied the pharmacokinetics and clinical efficacy of different NSAIDs in 
calves undergoing cautery dehorning. Initially, we evaluated the pharmacokinetics and 
clinical efficacy of firocoxib following cautery dehorning in calves. Although this 
NSAID was well absorbed orally in calves and inhibited prostaglandin for 48 h compared 
to placebo treated controls, minimal analgesic effects were observed using a study dose 
of 0.5 mg/kg. Subsequently we evaluated the pharmacokinetics and clinical efficacy of 
carprofen in a similar cautery dehorning study. Using the approved anti-inflammatory 
dose of 1.4 mg/kg in the European Union, oral carprofen was well absorbed and 
moderately inhibited prostaglandin for up to 96 h, however minimal analgesic effects 
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were observed. Following descriptions of the pharmacokinetics and effects of oral 
carprofen and firocoxib, a comparison of four NSAIDs (carprofen, flunixin meglumine, 
firocoxib, and meloxicam) orally administered at 2.0 mg/kg was conducted as a field 
trial. Although responses indicative of pain and stress reduction varied among the 
treatment groups, evidence from the field trial indicate meloxicam may have superior 
potency compared to the other evaluated NSAIDs. Moreover, the use of oral meloxicam 
provides optimal analgesia for 24 h following a one-time dose of 2.0 mg/kg.          
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CHAPTER 1 
GENERAL INTRODUCTION 
 
 
Introduction section modified from a manuscript published in Veterinary Clinics of North 
America: Food Animal Practice
1
 
 
Dissertation organization 
 The following dissertation is constructed using the alternate thesis organization 
guidelines. The second chapter is a literature review of pertinent methods used to 
evaluate pain and stress in calves as well as a summary of previously studied analgesics 
following cautery dehorning. Its content is primarily derived from a previously published 
chapter in Veterinary Clinics of North America: Food Animal Practice, “Bovine 
dehorning: Assessing pain and providing analgesic management.” Additional 
contributions to this chapter can be found in another Veterinary Clinics of North 
America: Food Animal Practice chapter, “Clinical Pharmacology of analgesic drugs in 
cattle.” The third chapter describes the pharmacokinetics of oral and intravenous 
firocoxib in calves, which is published in the Journal of Veterinary Pharmacology and 
Therapeutics. The fourth chapter details the analgesic effects of oral firocoxib following 
cautery disbudding, which has been accepted for publication in the Journal of Dairy 
Science. Chapter 5 describes both the pharmacokinetics and clinical efficacy of carprofen 
administered orally and subcutaneously immediately prior to cautery dehorning. This 
paper has been submitted to the Journal of Animal Science for review. In chapter 6, we 
                                                 
1
 Stock ML, Coetzee JF. Clinical pharmacology of analgesic drugs in cattle. Vet Clin North Am Food 
Anim Pract. 2015;31:113-38. 
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compared the clinical efficacy of carprofen, flunixin meglumine, firocoxib, and 
meloxicam on pain and stress associated with cautery dehorning in a field trial. This 
chapter has been prepared for submission to the Journal of Animal Science. Chapter 7 
details the derivation of a pain-stress index, which compiles and analyzes the responses 
reported in chapter 6 using one summary variable. A summary of the results including 
future areas of research are proposed in chapter 8.        
 Many contributions have been made by co-authors. Johann (Hans) F. Coetzee is 
the major professor of this dissertation and was involved in all aspects of the study 
including study design and subsequent analysis. Suzanne Millman was involved in study 
design, data collection and analysis. In addition to overall guidance on laboratory sample 
analysis, immunoassay development and analysis were derived by Walter Hsu. Laura 
Barth provided expertise in data collection, study design, and study logistics. Chong 
Wong provided the statistical model for statistical analysis. Larry Wulf provided sample 
analysis using LC-MS and guidance on additional laboratory analysis. Nick Van Engen, 
Erica Voris, Rebecca Parsons, Lea Labeur conducted sample collection and input in study 
design. Sarah Baldridge and Dee Griffin assisted in the construction of the literature 
review including in figure and table preparations.   
 
Introduction 
Pain states in cattle are common. Both iatrogenic pain due to livestock 
management procedures such as dehorning or castration and disease-associated pain 
including lameness, abdominal disorders, or sepsis are frequently encountered. 
Regardless of the origin, a noxious insult is typically translated into a chemical and 
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electric signal where it is modulated in the dorsal horn of the spinal cord and perceived in 
the brain (Muir and Woolf, 2001; Gottschalk and Smith, 2001).   This initial phase is 
often associated with acute pain; however, a second prolonged and diffuse phase often 
results in local hypersensitivity (Gottschalk and Smith, 2001). Persistency of this delayed 
response may cause systemic hypersensitivity known as central sensitization (“wind-up” 
pain)(Gottschalk and Smith, 2001; Kissin, 2000) clinically manifesting as hyperalgesia 
(i.e. increased pain from a painful stimulus) and allodynia (i.e. pain from a non-painful 
stimulus) (Ochroch et al., 2003).  Analgesics are provided, if possible, to mitigate both 
the acute and prolonged phases of pain associated with the noxious stimuli. 
When evaluating pain relievers such as non-steroidal anti-inflammatory drugs 
(NSAID) for clinical analgesia, the Food and Drug Administration’s Center for 
Veterinary Medicine (FDA-CVM) recommends effectiveness be determined by the 
control of clinical signs of pain associated with a disease (Guidance for Industry #123, 
2006). Although the pain state is iatrogenically induced, evaluation of an analgesic in a 
post-dehorning model may conform to the recommendation by the FDA-CVM due to the 
frequency of the procedure performed in the dairy industry. Furthermore, demonstrating 
an analgesic effect using a pain state induced from a common industry practice will 
support its adoption and use in clinical practice compared to more controlled model of 
inflammation such as a subcutaneous deposition of formalin.   It is important to note that 
in order to determine analgesic efficacy, GFI #123 recommends the use of validated 
methods of pain assessment in the target species.  
Pain associated with dehorning results in both the described acute and delayed 
responses. Following the initial noxious insult either from a surgical incision (e.g. Barnes 
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dehorners) or cautery, stress as determined by cortisol concentrations peaks 
approximately 30 minutes post procedure (Stafford and Mellor, 2005a,b) Subsequently, a 
delayed response occurs as evidenced by increased sensitivity and behavioral, 
physiological, immunological changes that may persist for up to 44 hours (Coetzee, 2013; 
Stafford and Mellor, 2011; Heinrich et al, 2010). Recently, both Ballou and colleagues 
(2013) and Sutherland and colleagues (2013) reported that amputation dehorning results 
in a more acute painful response compared to surgical castration as determined by 
cortisol concentrations obtained under the same experimental conditions. Furthermore, 
dehorning 2 to 3 weeks post-castration resulted in an increased stress response and 
decreased ADG compared to animals that were amputation dehorned first and later 
castrated (Mosher et al., 2013).  
Providing analgesia to cattle is not without its challenges. Primarily, from a 
regulatory perspective, no analgesic drugs are specifically approved for the alleviation of 
pain in livestock (Smith et al., 2008). The Animal Medicinal Drug Use Clarification Act 
(AMDUCA) of 1994 permits extra-label drug use (ELDU) in order to relieve suffering in 
cattle (FDA, 1994). As such, analgesics would be permitted under AMDUCA given the 
criteria for ELDU are followed. In addition to these regulations, pain medications can be 
costly, difficult to administer, short-acting requiring frequent administration, and 
controlled substances necessitate a veterinary license (Coetzee, 2013). Moreover, cattle 
do not overtly demonstrate signs of pain, making it difficult for some producers to 
observe the value in providing pain relief especially given a lack of support for economic 
gain (Coetzee, 2013).  
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In spite of these challenges, analgesics have demonstrated benefits to cattle during 
pain states. Following dehorning, analgesics have reduced the physiologic, behavioral 
and neuroendocrine changes that occur subsequent to the noxious stimuli (Stock et al., 
2013). Although, translation of these responses into economic gains continue to be 
difficult, activation of the sympathetic nervous system has demonstrated 
immunosuppressive effects that may incite and progress systemic infections (Wong et al., 
2011). Although this relationship has not been elucidated in cattle, it may offer an 
explanation of the reduced pull-rate and bovine respiratory disease morbidity for cattle 
receiving meloxicam following castration upon arrival to a feedlot (Coetzee et al., 2012). 
Previous comprehensive reviews of the literature have reported that effective 
analgesia in cattle is achieved through a multimodal approach (Stafford and Mellor, 
2005b; Stock et al., 2013). Administering different pharmaceuticals to antagonize or 
attenuate the transmission, modulation and perception of the pain signal optimizes pain 
relief (Muir and Woolf, 2001). Furthermore, the provision of a combination of 
compounds with different onsets and duration of action addresses both the acute and 
delayed phases of pain. With a multimodal approach, effective drug concentrations may 
be optimized to coincide with the occurrence of pain.  Analgesia is maximized by 
combining local anesthesia, nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, α2-
agonists, N-methyl D-aspartate (NMDA) receptor antagonists, and neuropathic pain 
antagonists. These analgesic options are reviewed in Chapter 2 with special attention 
towards evidence-based compounds investigated with randomized, placebo controlled 
trials (RCT).  
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 The conclusions from reviews strongly support the use of both an NSAID and 
local anesthetic at the time of or prior to dehorning to mitigate the associated distress and 
nociception (Stafford, and Mellor, 2011; Stock et al., 2013). Given the positive results of 
a study treating dehorning pain with meloxicam, an NSAID with a prolonged half-life in 
cattle, I worked under the hypothesis that a persistently acting NSAID would be the most 
useful in providing pain relief to calves immediately post-dehorning (Heinrich et al., 
2010). Moreover, oral medications were investigated as their potential to be the most 
practical on-farm method of analgesic administration.  
Scant information is publically available evaluating oral NSAIDs in cattle. As 
such, I investigated NSAIDs available in the United States with oral formulations in other 
species with reported persistent concentrations or effects. Firocoxib is a COX-1 sparing 
NSAID available in both dogs and horses to treat osteoarthritis with once daily dosing as 
a result of a lengthy half-life in these species. To determine if similar pain relieving 
effects and prolonged concentrations were observed in cattle, the pharmacokinetics were 
determined and described in chapter 3 and the analgesic efficacy results of a preliminary 
dehorning study are detailed in chapter 4. 
In addition to firocoxib, the pharmacokinetics of intravenous and subcutaneous 
carprofen in calves indicates a half-life greater than 40 hours (Delatour et al., 1996). In 
addition, it is approved for the treatment of pain associated with osteoarthritis in dogs. 
Given the reported pharmacokinetic properties in calves and analgesic effects in dogs, 
oral carprofen was compared with a subcutaneous dose in a preliminary dehorning trial 
detailed in chapter 5. Included in this chapter is a description of the pharmacokinetics of 
subcutaneous and oral carprofen. 
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Following the preliminary studies of firocoxib and carprofen in calves, I 
compared the clinical efficacy of carprofen, firocoxib, flunixin meglumine, and 
meloxicam to placebo treated controls following dehorning in a field trial. This study is 
presented in Chapter 6.  Previous studies have evaluated the oral pharmacokinetics of 
meloxicam and flunixin meglumine in calves (Mosher et al., 2012; Odensvik, 1995). 
Moreover, the analgesic effects of meloxicam have been reported in prior dehorning 
studies (Henrich et al., 2010; Allen et al., 2013). The primary purpose of this study was to 
potentially determine the optimal NSAID administered orally to control pain and distress 
following cautery dehorning in a field setting.    
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CHAPTER 2 
LITERATURE REVIEW 
 
Modified from a combination of two manuscripts published in Veterinary Clinics of 
North America: Food Animal Practice
12
 
 
Matthew L. Stock 
 
Abstract 
Dehorning or disbudding in cattle is performed for a variety of reasons including: 
safety for handling, decreased incidence of carcass wastage due to bruising, less feeding 
trough space needed, decreased risk of injury to other cattle, increased value of the 
animal, and fewer aggressive behaviors exhibited. There are a variety of dehorning 
methods employed to effectively remove cornual tissue from cattle including: amputation 
employing a cutting tool, cautery using a hot iron, and chemical application of a caustic 
paste. Pain associated with this procedure has been mostly evaluated through behavioral, 
physiological, and neuroendocrine changes following dehorning. In general, following 
dehorning, an immediate acute stress or painful response is observed during the first 30 
min which plateaus for approximately 6 hours before returning to baseline 7 to 8 hours 
following the procedure; however additional behavior data has suggested a more 
prolonged period of pain.  Analgesics including local nerve blockades, anti-
inflammatories, and opioids have demonstrated an effective attenuation of the cortisol 
                                                 
1
 Stock ML, Baldridge SL, Griffin D, Coetzee JF. Bovine dehorning: assessing pain and providing 
analgesic management. Vet Clin North Am Food Anim Pract. 2013;29:103-33. 
2
 Stock ML, Coetzee JF. Clinical pharmacology of analgesic drugs in cattle. Vet Clin North Am Food 
Anim Pract. 2015;31:113-38. 
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response. Although local anesthesia aids in the reduction of a cortisol response in the 
immediate post-dehorning period, a delayed cortisol increase is typically observed most 
likely associated with the loss of anesthetic effect. Non-steroidal anti-inflammatory drugs 
have demonstrated continued effective analgesia following this period of acute cortisol 
rise as evidenced by the moderation of a prolonged cortisol response. Additionally, 
sedatives with analgesic properties have demonstrated a transient attenuation of the acute 
phase of pain associated with dehorning. Following a literature review, and similar to 
pain management of other routine procedures performed in cattle such as castration, a 
multimodal approach to analgesia is recommended for dehorning procedures including 
the use of a local anesthetic and anti-inflammatory. 
 
Literature Review 
Dehorning is a commonly performed practice in both beef and dairy cattle 
industries. Dehorning or disbudding in cattle is performed for a variety of reasons 
including: safety for handling, decreased incidence of carcass wastage due to bruising, 
less feeding trough space needed, decreased risk of injury to other cattle, increased value 
of the animal, and fewer aggressive behaviors exhibited (AVMA, 2012).  Disbudding is a 
method of removing horns in calves up to around 8 weeks old when horn buds are 5 – 10 
mm long (Stafford and Mellor, 2005).  Once horns grow longer, they become attached to 
the underlying frontal sinus. For the purpose of clarity, all disbudding and dehorning will 
be collectively referred to as dehorning throughout the chapter. 
Although cattle are naturally horned for protective purposes, modern commercial 
industries decrease the necessity of these defenses. Within these production systems, for 
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reasons listed above, cattle without horns can be more desirable. Horn growth is a 
genetically heritable autosomal recessive trait (Medugorac et al., 2012). Polled cattle, 
which are hornless animals, result from an autosomal dominance pattern, which has been 
shown recently to be a result of allelic heterogeneity of the polled locus (Medugorac et 
al., 2012). Since the polled genetic inheritance reflects that of an autosomal dominant 
inheritable trait, artificial genetic selection could result in the decline of this undesirable 
characteristic of intensively raised cattle. This artificial selection for polled cattle has 
been used in the beef industry to reduce horned calves by 58% from 1992 to 2007 due to 
producers breeding for polled animals (USDA, 2009a). However, this breeding selection 
has not translated into the dairy industry with a reported 94% of dairy operations in the 
United States still dehorning calves (USDA, 2009b). Breeding strategies have recently 
been modeled to determine the effect of increasing polled genetics within a dairy herd 
while evaluating the impact on genetic merit (Spurlock et al., 2014). 
An increased societal concern and awareness for food animal welfare has 
influenced discussions regarding the humane treatment of livestock (Rollin, 2012). 
Routine procedures in cattle such as dehorning can have a negative public perception. 
Consequently, several countries including those belonging to the European Union, 
Australia and New Zealand have created dehorning welfare legislation (Stafford and 
Mellor, 2005). In North America, The Canadian Code of Practice for Dairy Cattle 
recommends the use of a local anesthetic combined with analgesia and sedation for 
dehorning calves; however there are no current regulations for analgesic use in the United 
States (Bradley and MacRae, 2011). Although it should be noted that the AVMA 
“supports the use of procedures that reduce or eliminate the pain of dehorning and 
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castrating of cattle” and suggests that “available methods of minimizing pain and stress 
include application of local anesthesia and the administration of analgesics” (AVMA, 
2008). Moreover, the American Association of Bovine Practitioners has recently released 
guidelines, which include the use of local anesthesia and systemic pain relief to enhance 
the welfare of cattle undergoing dehorning (AABP, 2014).  
Survey evidence in the United States suggests that dehorning and castration are 
often performed together (92%) and usually completed without the use of analgesics 
(Coetzee et al., 2010). A survey of North-Central and North-Eastern United States dairy 
producers indicated that 12.4% use a local anesthetic nerve block and only 1.8% use 
systemic analgesia at the time of dehorning (Fulwider et al., 2008). Additionally, in 
another survey of United States veterinarians, 49% reported administering an analgesic to 
beef cattle less than 6 months of age during dehorning whereas 63% of the respondents 
used analgesics in dairy cattle at dehorning calves of the same age (Fajt et al., 2011). A 
Canadian survey indicated that approximately 72% of veterinarians provided analgesia at 
the time of dehorning calves (Hewson et al., 2007). Interestingly, additional positive 
influences for providing analgesia to calves at dehorning included geography where 
significant public outreach for animal welfare has occurred (Hewson et al., 2007).  
The use of analgesics such as local anesthesia, systemic anti-inflammatories, and 
sedatives have been investigated by several studies following dehorning using behavioral, 
physiological, and neuroendocrine responses for pain assessment (Stafford and Mellor, 
2011). Generally, when using cortisol concentrations as an indicator of stress, evidence 
exists of a rapid cortisol increase following dehorning peaking within the first 30 
minutes. Cortisol concentrations then plateau from 1-6 h and then decline returning to 
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baseline 7 to 8 h following dehorning (Figure 1). Local anesthetics mitigate the cortisol 
response for their respective duration of action (i.e. lidocaine: 2 h; bupivacaine: 4 h) 
following the procedure but a delayed cortisol response is observed presumably once 
sensitivity returns to the anesthetized area (Petrie et al., 1996; McMeekan et al., 1998; 
Sutherland et al., 2002). Anti-inflammatories have aided in the reduction of this delayed 
cortisol response (Sutherland et al., 2002; McMeekan et al., 1998; Stilwell et al., 2009; 
Milligan et al., 2004; Allen et al, 2013; Glynn et al., 2013). Additionally, the use of 
sedatives may contribute to the reduction of the initial cortisol response; however the 
delayed inflammatory response is unaffected (Stafford et al., 2003; Stilwell et al., 2010). 
Most studies evaluating stress and pain responses in dehorned cattle investigate the acute 
response; however very few studies have examined chronic pain or stress responses 
following dehorning.  
Sufficient challenges to accurately assess and manage pain in food animals exist 
within the United States. The following review will assess tools specifically utilized in 
the evaluation of the effectiveness of pain relief following dehorning. Additionally, 
supportive evidence evaluating analgesics will be detailed. Studies included in this 
analysis were identified as those that addressed the pain associated with dehorning using 
either analgesic-treated or placebo-treated controls. Pain responses determined in these 
studies were used to determine a percent change associated with a drug treatment (Table 
1 and 2). The numerical values of the biomarker used for comparison included: maximum 
concentration (Cmax), area under the effect curve (AUEC), and specific time point 
concentrations. Additionally, these values were further summarized following 
categorization by analgesic regimen when applicable (Figure 2 and 3). Of the nineteen 
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dehorning studies included in these summary graphs, seven trials were explicitly stated as 
masked. Additional discussions of studies with an undocumented masking status have 
been included as descriptive data.       
Following this summary analysis, a multimodal approach using local anesthetics 
and non-steroidal anti-inflammatory drugs is recommended for the most effective 
reduction of pain response in cattle following dehorning. These recommendations are 
similar with other reviews concerning the management of pain in cattle following 
dehorning (Stafford and Mellor, 2011).   
 
Methods of assessment 
 The study of pain and stress in animals is complex. Investigations into the 
treatment of a noxious event remain challenging due to our continued poor assessment of 
the pain response (Flecknell, 2008). Furthermore, studies of analgesics may prove 
circular as “analgesics are those substances that eliminate signs of pain which are those 
signs eliminated by analgesics” (Bateson, 1991). Nevertheless, evaluation of several pain 
indices has been suggested to improve pain assessment in animals (Molony and Kent, 
1997). Through a combination of responses evaluating the behavior, autonomic nervous 
system (heart rate, ocular temperature), the hypothalamic-pituitary-adrenal-axis (cortisol), 
and tissue sensitization (mechanical nociception threshold) leading to release of pain 
neurotransmission (substance P), several indices can be measured to collectively assess 
the pain in animals following dehorning. Evaluating the combination of multiple pain-
related indices potentially allows the induced pain state (i.e. cautery dehorning) to be 
examined not merely as reflexive nociception but as a response involving cerebral and 
  
15 
emotional perception. In addition, the use of a variety of responses may help to account 
for the individual variations of responses typically observed in pain and stress studies.  
 
Behavior 
Behavior changes are often monitored and recorded in studies involving pain and 
stress.  The observed changes have been suggested as a more sensitive marker for pain 
compared to other physiological markers such as cortisol (Anil et al., 2002). Behavior 
indices have been recorded using videography (Graf and Senn, 1999; Milligan et al., 
2004; Morisse et al., 1995; Faulkner et al., 2000; Vickers et al., 2005; Heinrich et al, 
2010; Doherty et al., 2007; Duffield et al, 2010), chute behavior (Baldridge et al.,2011), 
accelerometers (Theurer et al.,2012), and remote triangulation devices (Theurer et al., 
2012). Head shaking, ear flicking, head rubbing, transition between standing and lying, 
inert lying, vocalization, and grooming are all behavioral changes frequently recorded in 
an ethological evaluation of cattle following dehorning (Grøndahl-Nielsen et al., 1999; 
Stilwell et al., 2009; Morisse et al., 1995; Faulkner and Weary et al., 2000; Vickers et al., 
2005).  
Although behavioral responses can be objective and collected with reliable 
quantitative methods, differences may exist in regard to interpretation. In the case of 
dehorning, reliable behavioral indicators of pain to assess cattle following dehorning with 
and without analgesia have been examined (Faulkner and Weary, 2000; Heinrich et al., 
2010; Duffield et al., 2010). For example, it has been suggested that head rubbing may be 
a result of increased nociception or indicative of irritation, itching or healing (Duffield et 
al., 2010). A correlation between behavior responses and changes to cortisol 
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concentrations has been reviewed supporting a strong association (Stafford and Mellor, 
2005).  
Recently, Heinrich and colleagues evaluated the behavior changes following 
cautery dehorning (Heinrich et al., 2010). Based on behavioral changes, the authors 
determined that pain may be present for up to 44 h following the procedure, which 
corresponded to the end of the study period. Other studies have indicated a continuation 
of painful or decreased normal behaviors for up to 72 h after dehorning (Stafford and 
Mellor, 2011; Faulkner and Weary, 2000). The duration of pain observed in these studies 
beyond other physiologic or neuroendocrine parameters further supports the necessity to 
provide long-lasting effective analgesia for cattle following dehorning. Additional 
research should include investigations into chronic pain responses associated with 
dehorning.    
 
Physiology 
Changes in physiology response are frequently observed following dehorning. 
Serum cortisol, heart rate, respiratory rate, and average dairy gain (ADG) are often used 
in studies evaluating the efficacy of analgesics in painful or stressful procedures such as 
dehorning. Cortisol concentrations should be interpreted with caution due to variations in 
cortisol response following a stressor as well as a wide variety of inciting causes that can 
activate the hypothalamus-pituitary-adrenal (HPA) system responsible for cortisol release 
(Molony and Kent, 1997; Mellor and Stafford, 1997). However, cortisol changes over 
time have been used frequently as a parameter assessing stress in cattle following 
  
17 
dehorning (Graf et al., 1999; Petrie et al., 1996; Sutherland et al., 2002; Stilwell et al., 
2008; Allen et al., 2013).  
In cattle dehorned without analgesia, most studies indicate an initial peak in 
cortisol is observed within the first 30 minutes and subsequently plateaus at an elevated 
concentration until returning to baseline approximately 7 to 8 h following the procedure 
(Sylvester et al., 1998; Schwartzkopf-Genswein et al, 2005; Stafford and Mellor, 2011). 
It has been hypothesized that the initial peak in cortisol is a result of a significant noxious 
nociception due to the removal of the horn tissue whereas the observed plateau results 
from pain associated with inflammation (McMeekan et al., 1998). The anti-inflammatory 
potential of cortisol has been suggested to result in the attenuation of the inflammatory 
mediated pain response (McMeekan et al., 1998; Sutherland et al., 2002).   
Cortisol responses may vary with age. In a study investigating the analgesic 
effects of ketoprofen in dehorned calves 2 days to 2 weeks of age, older calves within the 
study had significantly lower serum cortisol concentrations pre and post dehorning 
(Milligan et al., 2004). In contrast, Dockweiler and colleagues (2013) determined that 
cortisol concentrations were elevated in 6 month old calves compared to ≤ 8 week old 
calves following castration.  Although the insult differed, age may be of consideration in 
evaluating studies using different aged subjects. 
Heart rate has been monitored and recorded in dehorning studies as an indicator 
of physiological stress (Grøndahl-Nielsen et al., 1999; Heinrich et al., 2009; Stewart et 
al., 2008; Stewart et al., 2009; Coetzee et al., 2012). Compared to either sham dehorned 
calves, calves included in the study, which were not dehorned, or baseline values, heart 
rate remained elevated for at least 3 h in dehorned calves receiving no analgesia 
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(Grøndahl-Nielsen et al., 1999; Stewart et al., 2009; Heinrich et al., 2009). Additional 
studies have indicated a decreased heart rate acutely following treatment with an 
analgesic compared to dehorned calves treated with a placebo (Stewart et al., 2009; 
Coetzee et al., 2012).  
Previous literature has provided equivocal data for an increased average daily 
gain (ADG) following dehorning with analgesia. Studies have indicated an increased time 
spent at the grain feeder and an increase ADG following the use of a non-steroidal anti-
inflammatory at the time of dehorning when compared to those not treated with any 
analgesia (Faulkner and Weary, 2000; Heinrich et al., 2010; Baldridge et al., 2011; 
Coetzee et al., 2012; Glynn et al., 2013). Although Grøndahl-Nielsen and colleagues 
(1999) did not observe any difference in ADG or feed intake in the 7 days following 
dehorning, there was a significant difference in animals treated with analgesics at the 
time of dehorning initiating rumination more quickly than those without analgesics 
provided. This improved rumination has also been reported in other studies with extended 
observation periods (Sylvester et al., 2004).  
Other physiologic parameters have been evaluated in cattle following dehorning 
indicating a pain response (Table 3). Plasma adrenocorticotropic hormone (ACTH), 
vasopressin, noradrenaline, and adrenaline concentrations increased acutely following 
dehorning and remained elevated for up to 1 h (Graf et al., 1999; Mellor et al., 2002).       
 
Neuroendocrine response 
Neuroendocrine changes have been assessed in many studies evaluating 
nociception following dehorning including: substance P (Coetzee et al., 2012), 
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electrodermal activity (Baldridge et al., 2011), infrared thermography (Stewart et al., 
2009), heart rate variability (Stewart et al., 2009), and electroencephalography (EEG) 
(Gibson et al., 2007).  
Substance P is a neuropeptide expressed within portions of the neuroaxis involved 
with pain, stress, and anxiety (Coetzee, 2011). Increased concentrations are found in 
cattle following castration compared to those sham castrated, thus potentially supporting 
its use as biomarker of a pain response (Coetzee et al., 2008). A study investigated 
substance P concentrations following scoop dehorning in 16 to 20 week old calves treated 
with an anti-inflammatory at the time of dehorning (Coetzee et al., 2012). Animals 
treated with meloxicam had a significant reduction in mean substance P concentrations 
compared to the placebo treated controls following scoop dehorning. In addition, there 
were no significant differences observed in cortisol concentrations between the two 
groups, thereby suggesting an improved sensitivity of using substance P as a biomarker 
of pain in comparison with cortisol.  It should be noted that substance P is a very unstable 
peptide requiring immediate processing which may be difficult to complete in field 
designed trials (Mosher et al., 2014).  
Heart rate variability has been suggested to reflect a measurement of the 
autonomic nervous system through the assessment of sympathetic and parasympathetic 
activity, thus potentially providing an evaluation of distress (von Borell et al., 2007). 
Using heart rate variation, the control of the intervals between consecutive beats is 
increased through vagal tone (increased HRV, high frequency (HF) power) or 
sympathetic (decreased HRV, low frequency (LF) power). In 4-5 week old calves 
dehorned using a cautery dehorning unit, changes in heart rate variation illustrated a 
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sympatho-vagal imbalance coinciding with reported pain associated with dehorning 
(Stewart et al., 2009).  
Additionally, a decreased ocular temperature has been suggested as a 
neuroendocrine response mediated by sympathetic vasoconstriction of conjunctival blood 
vessels upon the induction of pain (Stewart et al., 2008). Stewart and colleagues (2009) 
investigated ocular temperature concurrently with heart rate variability and reported a 
decrease in ocular temperature during the same time period as the changes in heart rate 
variations further supporting the sympatho-vagal imbalance. However, this response has 
not been reported by other dehorning studies using scoop or cautery methods (Glynn et 
al., 2013; Allen et al 2013; Stock et al., 2015) 
Analysis of an EEG following a painful procedure has been validated for 
detection of acute pain in dehorning (Gibson et al., 2007). Acute noxious sensory stimuli 
produce changes within EEG frequencies reflecting the cerebral cortical electrical activity 
perceiving the nociception (Gibson et al., 2007). Mean EEG frequencies were evaluated 
in calves 24 to 36 weeks of age following amputation via scoop dehorning (Gibson et al., 
2007). EEG frequencies were recorded following the induction of minimal anesthesia in 
the calves using intravenous ketamine and propofol. Although the use of injectable 
anesthesia may have confounded the results, specific wavelengths were significantly 
altered following dehorning indicative of noxious nociception. Animals in which a local 
nerve block was administered had significantly less changes in EEG frequencies 
potentially supporting the reported decreased nociception following dehorning compared 
to dehorned controls (Gibson et al., 2007).  
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Mechanical Nociception Threshold (MNT) 
  Following an acute injury, inflammatory mediators such as prostaglandins, 
bradykinin, serotonin, and histamine will accumulate at the site of injury. These 
molecular changes result in the increased nociceptor sensitivity associated with allodynia 
and hyperalgesia in pain states. This change in nociceptor sensitivity has been evaluated 
using different methods and techniques including pressure algometry for mechanical 
threshold determination or CO2 laser or concentrated areas of heat for thermal threshold 
determination. Mechanical nociception thresholds have been investigated in rodent burn 
models indicating a prolonged recovery of up to 28 days to return to baseline nociception 
thresholds (Summer et al., 2007).  
 In cattle dehorning studies, MNT has been previously measured to evaluate an 
analgesic effect of NSAIDs (Heinrich et al., 2010; Glynn et al., 2013; Allen et al., 2013; 
Stock et al., 2015) and local anesthetics (Tapper et al., 2011). Heinrich and colleagues 
(2010) reported a 31% increase in MNT following administration of IM meloxicam. 
Moreover, Tapper and colleagues (2011) indicated up to 83 h of increased MNT 
following administration of an ethanol nerve block. Minimal effects on MNT were 
observed following administration of oral meloxicam (Glynn et al., 2013; Allen et al., 
2013), intravenous flunixin (Glynn et al., 2013), and oral firocoxib (Stock et al., 2015). 
The tested dose or data collection, which included repeat handling and blood collection 
may have heightened the avoidance response during MNT determination potentially 
explaining the incongruity between studies. 
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Dehorning analgesic strategies and their effects on pain responses 
Dehorning methods 
Management practices have been adopted to dehorn animals in order conform to 
modern facility designs. There are three primary methods to dehorn cattle: 1) Amputation 
using equipment such as Barnes, Keystone, gauges, saws and  gigli wire; 2) Cautery 
using a hot iron electrically, gas, or battery powered and 3) Chemical application of 
caustic paste usually consisting of a strongly alkaline agent such as sodium hydroxide or 
calcium hydroxide.  
Several studies have evaluated the different dehorning techniques on relative 
changes in pain responses.  Sylvester and colleagues (1998) compared the differences in 
cortisol concentrations in calves dehorned by 4 different methods of dehorning: Barnes 
scoop dehorning, guillotine shears, a butcher’s saw, and embryotomy wire. This study 
found no differences among treatment groups during the 36 hours post dehorning for 
cortisol, except calves dehorned by guillotine shears had a significantly lower cortisol at 
2 to 2.5 hours post procedure.  The cortisol Cmax and integrated cortisol response was not 
statistically different among treatment groups. Another study investigated differences in 
cortisol response to variations in performing the technique of scoop dehorning 
(McMeekan et al., 1997). Shallow scoop dehorning versus deep scoop dehorning were 
performed in 14 to 16 week old Friesian calves and no significant difference was found 
between rises in cortisol concentrations or the integrated cortisol response from 0.25 
hours after dehorning to 5 hours after dehorning.  The only difference noted was cortisol 
concentrations in calves undergoing shallow scoop dehorning returned to control values 
by 8 hours while deep scoop dehorning calves returned by 6 hours. 
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Several studies have investigated cautery as a means to destroy or remove tissue. 
In lambs, an attenuated cortisol response was observed following tail docking using a 
thermocautery device compared with a knife (Lester et al., 1991). It was suggested that 
the tissue damage caused by the heat from the hot iron destroyed the nociceptors adjacent 
to the wound, thus mitigating the cortisol response (Stafford and Mellor, 2005). This 
reported cortisol variation was also observed while comparing cautery dehorning with 
amputation. A study using scoop versus cautery dehorning by Petrie and colleagues 
(1996) using 6 to 8 week old Friesian calves found scoop dehorning without the provision 
of anesthesia or analgesia produced a significantly higher cortisol AUC from -70 minutes 
to 2 hours post procedure as compared to cautery dehorning. The examination of two 
different electric cautery dehorning methods using 3 to 4 week old Holstein calves 
indicated no difference in Cmax (Wohlt et al., 1994).  
Chemical dehorning methods have also been recently evaluated (Morisse et al., 
1995; Vickers et al., 2005; Stilwell et al., 2008). Using behaviors such as head shaking, 
head rubbing, and lying to standing transitions, Vickers and colleagues (2005) 
determined that caustic paste resulted in less behavior changes compared with a hot iron 
in 10 to 35 d old calves treated with a sedative and a local anesthetic. However, in an 
earlier study, 4 week old calves dehorned with caustic paste had increased plasma cortisol 
concentrations in comparison with 8 week old calves dehorned using a hot iron (Morisse 
et al., 1995). It is reported that the application of the caustic paste is not painful; however 
within an hour both cortisol and behavioral changes indicate a pain or stress response 
persisting for up to 24 h following paste application.  
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Without the provisions of analgesics, it has been recommended to dehorn cattle 
with cautery rather than amputation or chemical methods (Stafford and Mellor, 2005). 
This conclusion was recommended as a result of an extensive review of the published 
literature indicating a decreased cortisol response in cautery dehorning; however it was 
suggested more research needs to be completed comparing the cautery and chemical 
dehorning methods (Stafford and Mellor, 2005).  
  
Local anesthetics  
The most commonly used analgesics in cattle are local anesthetics. By blocking 
sodium channels within nerve cells, the conduction and transmission of the pain signal is 
inhibited (Webb and Pablo, 2009).  As such, the region where the anesthetic is deposited 
is devoid of sensation. Of benefit to the patient experiencing a noxious stimulus, 
stimulated nerves are more sensitive to local anesthesia. Moreover, nerves responsible for 
pain and temperature are blocked prior to those fibers involved with touch, pressure, and 
motor activity (Catterall and Mackie, 2011).  
Although the observed effect is reversible, its duration of action depends on the 
length of contact time with the nerve (Catterall and Mackie, 2011). Therefore, innate 
chemical properties that determine rates of absorption and tissue distribution as well as 
metabolism are heavily involved in determining the length of desensitization. Moreover, 
the addition of vasoconstrictor compounds (e.g. epinephrine) to increase contact time 
through reduction of both absorption and metabolism may be beneficial (Catterall and 
Mackie, 2011). However, as local environment is crucial to the activity of a local 
anesthetic, infected tissues with a decreased pH may reduce the effect. 
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Most commonly performed nerve blocks consist of infiltrating the perineural 
space surrounding the cornual nerve, a branch of the zygomaticotemporal portion of the 
ophthalmic division of the trigeminal nerve, with a local anesthetic; however, other local 
nerve blocks have been used in dehorning studies such as ring blocks or caudal horn 
blocks in efforts to increase the likelihood the effective anesthesia (Figure 4) (Skarda, 
1986; Graf and Senn, 1998; Doherty et al., 2007; Faulkner and Weary, 2000). The 
cornual nerve block has been described by several studies and textbooks. Briefly, a 2.5 
cm 18 or 20 gauge needle is inserted lateral to the palpable temporal ridge of the frontal 
bone and 2.5 cm cranial to the base of the horn (Figure 4). Following a negative 
aspiration confirming the needle is placed subcutaneously, five to ten milliliters of 2% 
lidocaine is injected directing the needle towards the horn for desensitization of the area 
(Skarda, 1986). In cattle with larger horns, cutaneous branches of the second cervical 
nerve will need to be desensitized using a local anesthetic infiltration caudal to the horn 
(Skarda, 1986). Proper restraint is necessary in order to deliver the local anesthetic to the 
correct location for complete cessation of nociception (Figure 5). This procedure can be 
performed using plastic disposable syringes or automatic syringes for multiple animals 
(Figure 5). 
Several administration routes are available for local anesthetics including 
injection via a needle or needle-free techniques and topical.  When injected, the onset of 
activity for lidocaine is fairly rapid, occurring within 2 to 5 minutes and persisting for 
approximately 90 minutes (Coetzee, 2013). This duration is prolonged (median 304 min; 
range: 107-512 min) with the addition of epinephrine (0.01 mg/ml) (Fierheller et al., 
2012).  Additional injectable anesthetics such as bupivacaine may provide superior 
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duration of activity (5-8 h); however onset may be delayed (20-30 min) (Webb and 
Pablo, 2009). Recently, a gel-based topical local anesthetic consisting of lidocaine, 
bupivacaine, adrenaline (epinephrine) and cetrimide (Tri-Solfen, Bayer Animal Health, 
Australia) demonstrated desensitization of the dehorning area (Espinoza et al., 2013). 
Regional anesthesia via epidural administration of lidocaine (0.2 mg/kg) produces fairly 
rapid (5 min) desensitization of the perineal region for a time interval of 10-115 min 
(Muir et al., 1995).   
The administration technique may contribute to the duration of activity. A recent 
study using 2-month-old dairy calves examined the efficacy of lidocaine with epinephrine 
using four local anesthetic delivery techniques including: cornual nerve block, ring block, 
percutaneous injection via a needle free drug delivery system (JET), and a topical eutectic 
mixture of local anesthetics containing 2.5% lidocaine and 2.5% prilocaine (EMLA) 
(Fierheller et al., 2012). Although the calves in the study were not dehorned, a peripheral 
variable output nerve stimulator was used to evaluate anesthetic efficacy. There was no 
difference in onset time between the cornual nerve block (2 min) compared to a ring 
block (3.25 min); however, the mean duration of the cornual nerve block was 
approximately 2.5 hours longer than that of the ring block (304 min vs 147 min, 
respectively). Both the JET delivery system and the EMLA cream failed to provide 
consistent, effective local anesthesia.  
Sufficient evidence supports the use of a local anesthetic in reducing the stress 
response observed immediately following dehorning (McMeekan et al., 1998; Sutherland 
et al., 2002; Heinrich et al., 2009). Local anesthetics mitigate the cortisol response for 
their respective duration of action (i.e. lidocaine: 2 h; bupivacaine: 4 h) following the 
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dehorning procedure but a delayed cortisol response is observed presumably once 
sensitivity returns to the anesthetized area (McMeekan et al., 1998; Sutherland et al., 
2002; Heinrich et al., 2009). In addition to cortisol changes, imbalances of the autonomic 
nervous system are also reported. Heart rate variability and ocular temperatures indicate 
an imbalance 2 – 3 hrs post dehorning with lidocaine administration, coinciding with the 
expected loss of anesthetic activity (Stewart et al., 2009). Notably, average daily gain 
(Grøndahl-Nielsen et al., 1999), heart rate (Grøndahl-Nielsen et al., 1999), immune 
function (Doherty et al., 2007), and lying time (Morisse et al., 1995) were minimally 
affected by administration of a only a local anesthetic 
 
Lidocaine 
Two percent lidocaine is the most commonly used analgesic in dehorning studies 
(Table 1 – 3). Pharmacokinetics studies following an inverted L nerve block using a local 
lidocaine infusion in mature cattle indicated a serum elimination half-life of 4.19 ± 1.69 h 
(Sellers et al., 2009). Clinically, studies on assessing the analgesic duration of lidocaine 
conclude an approximate 2 h duration based on both behavioral and physiological 
changes (Stafford and Mellor, 2005). Although integrated cortisol concentrations are 
typically not significantly different between cattle dehorned using local anesthesia 
compared to non-treated controls, consistent cortisol changes are significantly reduced or 
eliminated during the acute phase of the pain response (McMeekan et al., 1998; 
Sutherland et al., 2002). Generally, once the desensitization associated with lidocaine 
local infusion has diminished, cortisol concentrations significantly increase compared 
with those dehorned without lidocaine (McMeekan et al., 1998; Sutherland et al., 2002).  
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Many studies look at the effects of nerve blocks on cortisol response to dehorning 
(Tables 1 - 3). Although few studies have indicated no difference in the pain or stress 
response following the provision of a local anesthetic prior to dehorning, most studies 
support the use due to a near elimination of the acute behavior and physiological changes 
that are typically observed (Stafford and Mellor et al., 2005). Graf and Senn (1999) found 
a cornual nerve block with 2% lidocaine significantly diminished the cortisol response in 
4 to 6 week old calves as compared to those injected with saline from 20 to 90 minutes 
post dehorning. A study investigated the use of cautery following amputation dehorning 
and local lidocaine anesthesia in 20 to 24 week old calves (Sylvester et al., 1998b). The 
integrated cortisol response over a 9 h period indicated a significant reduction using 
lidocaine local anesthesia prior to amputation dehorning. In addition to the use of 
lidocaine anesthesia, cautery following amputation dehorning significantly diminished 
the cortisol response by 75% (Table 1).  
The effects of scoop dehorning versus scoop dehorning with cautery, both with 
and without the addition of local anesthesia have been evaluated (Sutherland et al., 
2002b).  This study found calves undergoing dehorning had significant elevations in 
cortisol compared with control calves from 0.5 h to 6 h and then again at 13 to 15 h.  
Interestingly, while administering local anesthesia with lidocaine 15 minutes prior to the 
procedure and then with bupivacaine again at 1 h and 45 min post-procedure, a rise in 
cortisol concentrations from 0 to 5 h was abolished and calves experienced a significant 
increase in cortisol response that was greater than calves dehorned without anesthesia at 6 
and 7 h.  Calves receiving local anesthesia plus cautery in addition to scoop dehorning 
had almost no change in cortisol concentrations throughout the 24 h period measured.  
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Doherty and colleagues (2007) found that 10 to 12 week old Holstein calves 
experienced a significantly lower cortisol response at 30 and 60 minutes post dehorning 
after a cornual nerve block of either 10 mL of 5% lidocaine or 10 mL of 2% lidocaine 
administered 30 minutes prior to dehorning as compared to untreated, dehorned calves. 
No significant difference was noted between the 5% and 2% lidocaine solutions on 
cortisol response. 
Interestingly, studies involving chemical dehorning indicated a decreased duration 
of analgesia efficacy using local lidocaine anesthesia alone (Stilwell et al., 2009; Vickers 
et al., 2005). Following dehorning using a caustic paste and local lidocaine anesthesia in 
3 to 5 week old calves, behavioral signs of distress were attenuated for the first hour but 
then became evident for the next 5 h (Stilwell et al., 2009). It was hypothesized that the 
alkalotic paste may have increased the pH of the surrounding tissue thus affecting the 
equilibrium of the anesthetic solution and disrupting its function (Vickers et al., 2005).  
 
Bupivacaine 
In addition to lidocaine, bupivacaine has been used in several dehorning studies 
mostly due to a prolonged clinical duration of analgesia compared with lidocaine 
(McMeekan et al., 1998a; Sutherland et al., 2002a; Sutherland et al., 2002b). Clinical 
analgesic efficacy in one study was reported to be approximately 4 h as confirmed by a 
lack of behavioral reaction to a needle-prick of the skin adjacent to the horn (McMeekan 
et al., 1998a).  
McMeekan and colleagues (1998a) evaluated the effect of timing of cornual nerve 
block administration using 0.25% bupivicaine on cortisol response in 3 to 4 month old 
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calves.  They found calves administered a cornual nerve block at 20 min prior to 
dehorning and then again 4 h post dehorning experienced a significantly lower cortisol 
AUC than control calves dehorned without analgesia, calves administered the cornual 
nerve block only at 20 min prior, and calves administered the cornual nerve block 
immediately prior.  Another study by McMeekan and colleagues (1998b) found that 
calves undergoing scoop dehorning with a cornual nerve block using bupivacaine 
administered 20 min prior and 4 h post had a significantly lower AUC from 0 to 9.33 h 
for cortisol as compared to the calves dehorned with only a cornual nerve block 20 min 
prior, immediately prior, or with no analgesia (McMeekan et al., 1998b).  However for 
the first 3.83 h, all calves receiving a cornual nerve block experienced a significantly 
lower AUC cortisol response as compared to scoop dehorning without treatment.   
 
Non-steroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs primarily inhibit cyclo-oxygenase (COX) isoenzymes subsequently 
reducing the production of prostaglandins (PG) from arachidonic acid (Ochroch et al., 
2003). In addition to contributing to the inflammatory response through vasodilation and 
inflammatory cell recruitment, PG, in concert with other cytokines and neuropeptides 
decrease the action potential threshold in nociceptors and propagate the pain signal 
(Grosser et al., 2011). Peripherally, this causes a local hyperalgesia or peripheral 
sensitization. Moreover, COX isoenzymes present in the spinal cord produce excess PG 
following acute noxious stimuli leading to central sensitization and chronic pain (Grosser 
et al., 2011). This is clinically indicated by hyperalgesia and allodynia. Both isoenzymes, 
COX-1 and COX-2, are thought to be responsible for the inflammatory response, with the 
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initial effects a result of COX-1 derived PG and the delayed effects due to upregulation 
of COX-2 expression (Svensson and Yaksh, 2002). As such, NSAIDs that target both 
isoenzymes may be advantageous for both immediate and prolonged pain; however, 
increased inhibition of COX-1 is associated with renal and gastrointestinal adverse 
effects (Grosser et al., 2011).  
NSAIDs are typically weak acids with a low pKa resulting in good oral 
bioavailability in monogastrics (Lees, 2009). With the exception of firocoxib, NSAIDs 
commonly used in veterinary species generally have a low volume of distribution most 
likely due to the high plasma protein binding, which may impact overall tissue 
distribution (Lees, 2009). Elimination can occur through the renal system following 
metabolism in the liver; however, reports of biliary secretion leading to fecal elimination 
is observed in other species (Lees, 2009; Rubio et al., 1980). Compounds known as 
COX-2 selective or COX-1 sparing were developed to reduce the potential for adverse 
effects associated with COX-1 inhibition; although evidence for an improved safety 
profile in veterinary medicine is lacking. These molecules were designed with side chains 
too large to bind to the smaller COX-1 active site, therefore only physically able to bind 
COX-2 (Grosser et al., 2011). Table 4 summarizes the unique properties and 
pharmacokinetics of NSAIDs available in the United States.  
An extensive review of the literature suggests, in general, NSAIDs mitigate the 
overall AUEC cortisol response by a greater magnitude than their ability to reduce peak 
cortisol concentrations following dehorning (Figure 2 and 3). Moreover, NSAIDs alone 
may not be adequate enough to control the associated distress post-dehorning (Figure 2 
and 3); although this conclusion should be interpreted with caution as it is drawn from a 
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small number of studies. The analgesic effect of NSAIDs is amplified with the use of a 
local anesthetic for dehorning (Figure 2 and 3).  Primarily, NSAIDs provide analgesia 
during the delayed phase of pain observed post-operatively in dehorning procedures. 
 
Carprofen 
Carprofen is an NSAID in the propionic acid class (Lees, 2009) and is 
administered as a racemic (50:50) mixture of RS± enantiomers (Delatour et al., 1996). 
For cattle in the European Union, carprofen is indicated as an adjunct to antimicrobial 
therapy associated with respiratory disease and mastitis. Prior pharmacodynamic studies 
evaluating analgesia in an inflammatory model in non-ruminants indicated carprofen to 
have a greater anti-inflammatory and analgesic potential compared to phenylbutazone 
and aspirin (Strub et al., 1982). Pharmacokinetics are presented in Table 4. Unique 
pharmacokinetic properties of carprofen in cattle include a prolonged half-life, slow 
clearance, and possibly biliary drug secretion as observed in dogs (Rubio et al., 1980).  
Interestingly, the pharmacokinetics of carprofen are age dependent with a prolonged half-
life in younger animals (<10 weeks) most likely due to the decreased clearance common 
to neonates (Delatour et al., 1996).  
Stilwell and colleagues (2012) report carprofen (1.4 mg/kg) in combination with a 
lidocaine block administered 15 minutes prior to cautery disbudding resulted in an 
attenuation of the acute cortisol concentration at 1 hour post-disbudding in comparison to 
placebo treated calves. However, this reduction of cortisol was transient as untreated 
controls had a reduced cortisol at 24 hours compared to calves receiving carprofen 
(Stilwell et al., 2012). A study conducted by our group evaluating 6 to 8 week old calves 
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either sham dehorned or cautery dehorned following administration of carprofen (1.4 
mg/kg) subcutaneously, orally, or a placebo in a randomized controlled trial did not 
indicate overall group treatment differences in measured analgesic response variables 
including cortisol, substance P, mechanical nociception threshold, and ocular temperature 
(Stock et al., 2014). However, calves receiving carprofen regardless of route tended to 
tolerate more pressure around the horn bud for the 96 hour study duration compared to 
placebo-treated controls (P=0.09) (Stock et al., 2014).  
 
Firocoxib 
Firocoxib is an NSAID of the coxib class. This is a newer group of NSAIDs 
demonstrating COX-2 selectivity in dogs and horses, thereby potentially limiting adverse 
effects caused by COX-1 inhibition (Lees, 2009). Currently, firocoxib is indicated for the 
treatment of pain and inflammation associated with osteoarthritis for dogs and horses in 
the United States. Limited information is known about firocoxib in cattle with only one 
study conducted in preweaned calves (Stock et al., 2015). Pharmacokinetic parameters 
for firocoxib are presented in Table 4. Unique pharmacokinetic properties in preweaned 
calves include high oral bioavailability, prolonged terminal half-life, and an extensive 
tissue distribution (high volume of distribution).   
A RCT was conducted on 4 to 6 week old calves evaluating oral firocoxib (0.5 
mg/kg) administered in combination with a lidocaine cornual nerve block administered 
10 minutes prior to cautery dehorning (Stock et al, 2015). Although the acute effects of 
cautery dehorning as determined by physiologic and nociception changes were unaffected 
by treatment, firocoxib calves tended to have an overall reduced integrated cortisol 
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response compared to placebo-treated controls suggesting a potential role for firocoxib in 
the control of the delayed distress response. 
 
Flunixin Meglumine  
Derived from nicotinic acid in the anthranilic acid NSAID class, flunixin is the 
only FDA approved NSAID for cattle in the United States (Smith et al., 2008). Currently, 
flunixin is indicated for the control of fever associated with respiratory disease or 
mastitis, and fever and inflammation associated with endotoxemia. Pharmacokinetic 
properties are presented in Table 4. Given its anti-inflammatory properties, it has been 
evaluated as a pain reliever. 
Flunixin administration provided benefits to calves during the acute distress and 
painful phase following dehorning. Flunixin meglumine (2 mg/kg) administered to calves 
following a cornual nerve block reduced cortisol concentrations for 3 and 6 hrs compared 
to untreated controls in calves undergoing chemical (Stilwell et al., 2009) and amputation 
dehorning (Ballou et al., 2013), respectively. Moreover, in addition to a local anesthetic, 
flunixin (2.2 mg/kg) administered to calves preoperatively and again 3 hours post cautery 
dehorning had a significantly reduced integrated cortisol concentration over an 8 hour 
study period with significant reductions at 0.5 and 2 hours compared to dehorned controls 
(Huber et al., 2013).   However, heart and respiratory rates were unaffected. The 
alleviation of the initial pain response is consistent with flunixin concentrations that 
suppress ex-vivo PGE2 concentrations up to 12 hrs in calves surgically dehorned 
(Fraccaro et al., 2013).  
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In addition to analgesic effects observed in the acute pain period, cortisol 
concentrations and average daily gains were significantly improved over 7 days for 
flunixin (2.2 mg/kg) treated calves compared to untreated calves (Glynn et al., 2013). 
With IV administration, analgesic concentrations may have been rapidly achieved 
potentially reducing central sensitization; however, evidence for this effect in cattle is 
scarce (Stilwell et al., 2008). One study reported equivocal analgesic response in calves 
receiving an NSAID 12 hours prior to versus immediately before dehorning, indicating 
the pain response was not alleviated with pre-emptive analgesia (Allen et al., 2013). 
Interestingly, flunixin (2 mg/kg) combined with a cornual nerve block was protective 
against the observed leukocytosis post-amputation dehorning for up to 24 hours 
compared to untreated controls (Ballou et al., 2013). The persistence of effect may be due 
to an IM route of administration or as a result of a hysteretic response of certain immune 
mediators.    
 
Ketoprofen 
Ketoprofen, an NSAID of the propionic acid class, has EU and Canada approval 
as an adjunctive therapy for fever, pain, and inflammation associated with mastitis and 
inflammatory and painful conditions of bones and joints (USP, 2004). Pharmacokinetic 
properties are presented in Table 4. Ketoprofen is administered as a racemic mixture 
(50:50) with chiral RS± enantiomers. Interestingly, the R(-) enantiomer will undergo 
chiral inversion to S(+) which is clinically relevant since the S(+) enantiomer is a more 
potent PGE2 inhibitor (Aberg et al., 1995). Given the short half-life (0.42 h) due to rapid 
metabolism and elimination, efforts to sustain analgesia may require multiple doses. 
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Nevertheless, many studies have investigated the analgesic potential of ketoprofen 
(Faulkner and Weary, 2000; Sutherland et al., 2002; McMeekan et al., 1998b; Milligan et 
al., 2004; Duffield et al., 2010).  
Ketoprofen (3 mg/kg) administration in combination with a local anesthetic 
resulted in the amelioration of the acute cortisol response with effects persisting up to 5 
hours compared to untreated controls (Sutherland et al., 2002; McMeekan et al., 1998b; 
Milligan et al., 2004; Duffield et al., 2010). With ketoprofen (3 mg/kg) administration 
without local anesthesia, the typically observed cortisol plateau was attenuated; however, 
peak cortisol concentrations were only mildly reduced (McMeekan et al., 1998). A 
tendency for improved weight gains following multiple doses and increased starter 
consumption has also been reported over a 24-hour period in ketoprofen treated calves 
compared to control calves (Duffield et al., 2010; Faulkner and Weary, 2000); although it 
is noteworthy that the analgesic regimen in these trials also included local anesthesia 
(Duffield et al., 2010; Faulkner and Weary, 2000) and xylazine (Faulkner and Weary, 
2000) for all calves dehorned.  
 
Meloxicam  
Meloxicam is a member of the oxicam class of NSAIDs. It has approval for use in 
the European Union and Canada for adjunctive therapy of acute respiratory disease, 
diarrhea, acute mastitis, and as an analgesic to relieve pain following dehorning in calves. 
Moreover, meloxicam is approved in the United States to control pain associated with 
osteoarthritis in humans, dogs, and cats. The pharmacokinetics of meloxicam are 
presented in Table 4. Notably, the pharmacokinetics of meloxicam in cattle indicates a 
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prolonged half-life and a high bioavailability when administered orally (Coetzee et al., 
2009). Due to these favorable pharmacology properties for providing practical analgesia 
in cattle, many studies have recently investigated oral meloxicam as an analgesic.   
Several recent studies have provided support for the analgesic effect of 
meloxicam in cattle after dehorning or disbudding. Significant reductions in cortisol 
concentrations have been reported in cattle receiving a local anesthetic in combination 
with IM meloxicam (0.5 mg/kg) compared to placebo-treated cattle only receiving a 
lidocaine cornual nerve block (Heinrich et al., 2009). This effect persisted for up to 6 hrs 
post cautery dehorning (Heinrich et al., 2009). In contrast, another study reported no 
effects on cortisol concentrations following administration of only IV meloxicam (0.5 
mg/kg) compared to placebo-treated controls immediately prior to surgical dehorning 
(Coetzee et al., 2012) Taken together, this provides additional support for the use of a 
multimodal approach to reduce the distress associated with dehorning. Furthermore, 
physiologic variables including heart rate (Heinrich et al., 2009; Coetzee et al., 2012), 
respiratory rate (Heinrich et al., 2009), and time spent standing (Theurer et al., 2012) 
were elevated in placebo-treated calves compared with those administered meloxicam. 
Maintenance of the autonomic nervous system including heart rate variability and 
reduced changes to ocular temperature was observed in 4-5 week old dairy calves 
receiving IV meloxicam (0.5 mg/kg) compared to placebo following cautery dehorning 
(Stewart et al., 2009). In addition, placebo treated calves are reported to be nearly twice 
as sensitive post-cautery disbudding compared with calves treated with IM meloxicam 
(0.5 mg/kg) (Heinrich et al., 2010). A reported reduction in substance P, a pain 
neurotransmitter, provides further support for the reduced pain sensitivity following 
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scoop dehorning in 4 month old calves treated with IV meloxicam (0.5mg/kg) compared 
with untreated controls. Production parameters were also improved in meloxicam treated 
cattle compared to placebo treated controls with an increased average daily gain (Coetzee 
et al., 2012) potentially due to increased feed consumption or time spent near the feeder 
(Heinrich et al, 2010; Theurer et al., 2012). In summary, IV or IM meloxicam (0.5 
mg/kg) may effectively attenuate dehorning pain and distress. 
More recently, oral (PO) meloxicam (1.0 mg/kg) has been evaluated in 8 to 10 
week old calves at the time of cautery dehorning demonstrating reduced cortisol at 4 
hours and substance P at 120 hours compared to placebo-treated controls (Allen et al., 
2013). Furthermore, 6 month old calves undergoing amputation dehorning demonstrated 
improved ADG when treated with oral meloxicam (1.0 mg/kg) compared with placebo 
treated controls (Glynn et al., 2013). However, pain sensitivity, ocular temperature, and 
haptoglobin were not affected (Glynn et al., 2013; Allen et al., 2013). Oral meloxicam 
administration may exert a persistent analgesic effect as evidenced by concentrations 
significantly inhibiting ex-vivo production of prostaglandin E2 for 48 hours compared to 
placebo-treated controls (Allen et al., 2013). This effect is more prolonged when 
meloxicam is administered at the time of dehorning compared with 12 hours prior (Allen 
et al., 2013).  
 
Phenylbutazone 
Although phenylbutazone is not approved for cattle in the United States and is 
illegal to use in dairy cattle greater than 20 months of age, historically, it has been used as 
an analgesic in cattle (Smith et al., 2008). Given its weak anti-inflammatory properties in 
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comparison with ketoprofen, there is little evidence to suggest its efficacy to reduce 
dehorning pain (Lees et al., 2004; Lees et al., 2004). Calves treated with phenylbutazone 
(4.0 – 5.3 mg/kg) in addition to local anesthesia did not show a significant attenuation of 
the delayed cortisol response following return of sensitivity to the anesthetized area 
(Sutherland et al., 2002a).  
 
Salicylic Acid Derivatives 
Both aspirin (acetylsalicylic acid) and sodium salicylate have historically been 
used in cattle as anti-inflammatory, anti-pyretic and analgesic agents. Despite its common 
use and label claims, the FDA Center for Veterinary Medicine has never formally 
approved the drug (USP, 2004). As such, the use of salicylic acid derivatives should be 
used with caution due to the lack of tissue residue studies, which provide withdrawal 
intervals. The pharmacokinetics of salicylic acid derivatives (Table 4) are associated with 
limited tissue distribution, slow oral absorption, and rapid elimination (Smith, 2013). Due 
to the availability and previous practices, studies have evaluated its use as an analgesic.    
Sodium salicylate metered in water (2.5-5 mg/ml) initiated 3 days prior to 
simultaneous castration and dehorning of calves and continued for 2 more days, resulted 
in improved average daily gains for 13 days as well as a decreased integrated cortisol 
concentrations from 1 to 6 hours post-procedure compared to untreated controls 
(Baldridge et al., 2011). These acute stress reduction effects did not persist past 6 hours; 
however ADG was increased over a 13 day period (Baldridge et al., 2011). It is 
noteworthy that water palatability may have been affected as cattle receiving salicylate 
had decreased water consumption. 
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Sedative-analgesic drugs  
Pharmaceutical agents such as α-2 agonists and opioids have been investigated to 
determine the potential effects on pain biomarkers following dehorning. Potential 
benefits of these analgesics including the attenuation of the acute cortisol response can 
aid in the reduction of prolonged handling stress associated with dehorning; however, 
there is no evidence of continued analgesia following this initial period (Figure 2 and 3) 
(Grøndahl-Nielsen et al., 1999; Stafford et al., 2003; Stilwell et al., 2010).  
 
Alpha-2 Adrenergic Agonists 
Alpha-2-adrenergic agonists produce a dose-dependent analgesic effect by 
inhibiting the amplification of norepinephrine (NE) release from the presynaptic nerve in 
the brainstem and spinal cord (Posner and Burns, 2009). Analgesia is achieved through 
this reduction of NE thereby inhibiting the afferent pain pathway (Posner and Burns, 
2009).
 
Adverse effects can include decreased cardiac output, a centrally mediated 
decreased respiratory rate, and depressed gastrointestinal motility. Pharmacokinetics of 
xylazine are detailed in Table 4. Given its common use in cattle, previous studies have 
evaluated its potential as an analgesic. 
The response of xylazine administered perioperatively to calves being dehorned is 
temporary (Stafford et al., 2003). Compared to dehorned controls, the acute peak cortisol 
response is reduced in calves treated with IV xylazine (0.1 mg/kg); however, this effect 
does not persist past 3 hours (Stafford et al., 2003). With the addition of lidocaine to 
calves, the cortisol peak was further mitigated but still the same cortisol profile was 
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observed over time (Stafford et al., 2003). In contrast, Stillwell and colleagues (2010) 
reported no difference in cortisol concentrations in calves treated with IM xylazine (0.2 
mg/kg) for the first hour post-disbudding compared to saline treated controls. 
Furthermore, in combination with local anesthesia and an opioid, no treatment effect was 
observed 10 minutes after dehorning in 4 to 6 week old calves (Grøndahl-Nielsen et al., 
1999). The use of xylazine alone should be avoided for the development of dehorning 
analgesic protocols.      
It is noteworthy that the use of an α-2 antagonist to reverse the sedative effects of 
an α-2 agonist administered 5 minutes after dehorning resulted in a significant increase in 
cortisol concentrations (Stafford et al., 2003). This response was greater than 
concentrations of those animals dehorned without analgesia and persisted for 8 hours; 
however, the AUEC was not significantly different (Stafford et al., 2003).
 
 
Tramadol 
Tramadol (1RS, 2RS)-2[(dimethylamino-methyl]-1-(3-methoxyphenyl)-
cyclohexanol is a centrally acting multimodal analgesic primarily used in humans and 
companion animals to treat mild to moderated pain (Reeves and Burke, 2008; Kukanich 
and Papich, 2011). Analgesia is suggested to be a result of a dual mechanism involving 
both opioid receptor activation and increased serotonin and norepinephrine transmission 
(Reeves and Burke, 2008). Although pharmacokinetic and pharmacodynamics values 
have not been determined in cattle, one study evaluated its anti-nociceptive potential 
following chemical dehorning in 3 week old dairy calves using an intravenous dose of 4 
mg/kg or a rectal dose of 200 mg (Braz et al., 2012). Following an evaluation of pain 
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associated behaviors while using a numerical rating scale, tramadol administered at the 
investigated dosages and routes did not provide adequate analgesia for controlling pain 
related to chemical dehorning. 
 
Neuropathic pain analgesic drugs 
Gabapentin 
Gabapentin is a γ-aminobutyric acid (GABA) analogue historically used as an 
anti-seizure medication. In addition, an improved management of chronic, neuropathic 
pain is reported. This is likely due to a decreased excitatory neurotransmitter release as a 
result of modulation of voltage-gated calcium channels (Taylor et al., 2009). 
Furthermore, analgesic activity can be enhanced with the addition of an NSAID due to a 
reported synergism (Hurley et al., 2002; Picazo et al., 2006). Pharmacokinetic properties 
are listed in Table 4. As control of chronic pain is challenging, gabapentin has been 
investigated to address this concern. 
Gabapentin (15 mg/kg) alone or in combination with meloxicam (1 mg/kg) has 
demonstrated an increased average daily gain in 6 month-old cattle following scoop 
dehorning; however additional physiologic responses were not different compared with 
placebo-treated controls (Glynn et al., 2013).  
 
Conclusions 
The literature focusing on pain management in cattle during dehorning is 
plentiful.  As demonstrated, there have been several studies looking at the effects of 
dehorning on plasma cortisol concentrations.  Additionally, several analgesic regimens 
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have been used in efforts to relieve pain during these procedures, with varying results. 
Following this review, the authors suggest a multimodal approach using local anesthetics 
and NSAIDs to best provide analgesia to cattle following dehorning (Tables 1 – 3). Local 
anesthetics aid in the attenuation of the immediate cortisol response and NSAIDs mitigate 
the observed inflammation associated pain. As with all extra label drug use in food 
producing species, valid Veterinary-Client-Patient-Relationships must be maintained and 
appropriate withdrawal times must be followed. Further research should be implemented 
to determine safe, long-lasting, and cost effective analgesics to food animals following 
noxious procedures. 
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Table 1. Summary of the scientific literature examining the effect of analgesic drug administration on plasma cortisol response in 
dehorned calves.  
Reference Procedure 
Study 
Population 
Analgesic Regiment 
Outcome 
parameter 
Percent 
change in 
cortisol 
(%) 
Significance 
Boandl, 
1989 
Cautery 
(electric) 
dehorning 
7 -16 weeks 
Dairy 
Lidocaine local anesthesia (cornual 
nerve, 5 ml/horn), 5 min prior to 
dehorning 
Cortisol (30 m) -13.41 NS 
Morisse, 
1995 
Chemical paste 
dehorning 
4 weeks 
Dairy 
Lidocaine local anesthesia (cornual 
nerve, 4 ml/horn), 15 min prior to 
dehorning 
Cortisol (1 h) -19.34 NR 
Cortisol (4 h) -57.26 NR 
Cortisol (24 h) -6.45 NR 
Cautery 
(electric) 
dehorning 
8 weeks 
Dairy 
Lidocaine local anesthesia (cornual 
nerve, 4 ml/horn), 15 min prior to 
dehorning 
Cortisol (1h) -18.03 NR 
Cortisol (4h) 234.48 NR 
Cortisol (24h) 101.56 NR 
Petrie, 1996 
Amputation 
(Scoop) 
dehorning 
6-8 weeks 
Dairy 
Lidocaine local anesthesia (cornual 
nerve, 3 ml/horn), 20 min prior to 
dehorning 
Cortisol 
(AUEC:0-2 h) 
-53.64 <0.05 
Cortisol 
(AUEC:2-9.5 h) 
53.94 NS 
Cortisol 
(AUEC:0-9.5h) 
10.92 NS 
Cautery (gas) 
dehorning 
Lidocaine local anesthesia (cornual 
nerve, 3 ml/horn), 20 min prior to 
dehorning 
Cortisol 
(AUEC:0-2 h) 
-23.37 NS 
Cortisol 
(AUEC:2-9.5 h) 
22.78 NS 
Cortisol 
(AUEC:0-9.5 h) 
2.28 NS 
 
5
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McMeekan, 
1998
18 
Amputation 
(Scoop) 
dehorning 
12-16 
weeks 
Dairy 
Bupivacaine local anesthesia (cornual 
nerve, 6 ml/horn), 20 minutes prior to 
dehorning 
Cortisol 
(AUEC:0-3.83 
h) 
-61.00 <0.05 
Cortisol 
(AUEC:3.84-
9.33 h) 
109.71 NS 
Cortisol 
(AUEC: 0-9.33 
h) 
-10.24 NS 
Bupivacaine local anesthesia (cornual 
nerve, 6 ml/horn),immediately prior to 
dehorning 
Cortisol 
(AUEC:0-3.83 
h) 
-72.82 <0.05 
Cortisol 
(AUEC: 3.84-
9.33 h) 
47.35 NS 
Cortisol 
(AUEC: 0-9.33 
h) 
-37.07 NS 
 
 
 
 
Bupivacaine local anesthesia (cornual 
nerve, 6 ml/horn),20 min prior to 
dehorning & 4 h later 
 
 
 
Cortisol 
(AUEC:0-3.83 
h) 
-80.69 <0.05 
Cortisol 
(AUEC: 3.84-
9.33h) 
31.97 <0.05 
Cortisol 
(AUEC: 0-
9.33h) 
-47.18 <0.05 
Table 1 cont. 
5
3
 
 
54 
5
4
 
 
Sylvester , 
1998
54 
Amputation 
(Scoop) 
dehorning  
20-24 
weeks 
Dairy 
Lidocaine local anesthesia (cornual 
nerve, 6 ml/horn), 30 min prior to 
dehorning 
Cortisol AUEC  -50.48 <0.05 
Lidocaine local anesthesia (cornual 
nerve, 6 ml/horn), 30 min prior to 
dehorning, cauterize wound following 
amputation 
Cortisol AUEC  -75.24 <0.05 
Sutherland, 
2002b 
Amputation 
(scoop) dehorn 
12-16 
weeks 
Dairy 
Lidocaine local anesthesia (cornual 
nerve, 6 ml/horn) 15 min prior to 
dehorning; bupivacaine (cornual 
nerve, 6 ml/horn) 2 hours following 
lidocaine injection 
Cmax -6.57 NS 
Sutherland, 
2002a
 
Amputation 
(scoop) dehorn 
12-16 
weeks 
Dairy 
Lidocaine local anesthesia (cornual 
nerve, 6 ml/horn) 15 min prior to 
dehorning; bupivacaine (cornual 
nerve, 6 ml/horn) 2 hours following 
lidocaine injection 
Cortisol AUEC 
(0-24 h)* 
-13.14 
NS 
Cmax -6.57 NR 
Lidocaine local anesthesia (cornual 
nerve, 6 ml/horn), phenylbutazone 
4.0-5.3 mg/kg, IV 15 minutes prior to 
dehorning; bupivacaine (cornual 
nerve, 6 ml/horn) 2 hours following 
initial lidocaine injection 
Cortisol AUEC 
(0-24 h)* 
-8.89 NS 
Cmax 2.92 NR 
Lidocaine local anesthesia (cornual 
nerve, 6 ml/horn), ketoprofen 3.0-3.75 
mg/kg, IV 15 minutes prior to 
dehorning; bupivacaine (cornual 
nerve, 6 ml/horn) 2 hours following 
initial lidocaine injection 
Cortisol AUEC 
(0-24 h)* 
-21.41 NS 
Cmax -52.55 NR 
Table 1 cont. 
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Mellor, 
2002 
Amputation 
(scoop) dehorn 
10 weeks 
Dairy 
Lidocaine local anesthesia (cornual 
nerve, 5 ml/horn) 20 minutes prior to 
dehorning 
Cortisol (30 
min) 
-36.90 NR 
Stafford, 
2003* 
Amputation 
(scoop) dehorn 
12 weeks 
Dairy 
Lidocaine local anesthesia (cornual 
nerve, 5 ml/horn) & Ketoprofen 
3mg/kg IV 15 minutes prior to 
dehorning 
Cortisol AUEC -55.17 NS 
Xylazine 0.1 mg/kg IV, 20 min prior 
to castration 
Cortisol AUEC 3.45 NS 
Xylazine 0.1 mg/kg IV, 20 minutes 
prior to dehorning & lidocaine local 
anesthesia (cornual nerve, 5 ml/horn) 
15 minutes prior to dehorning 
Cortisol AUEC 6.90 NS 
Xylazine 0.1 mg/kg IV, 20 minutes 
prior to dehorning & lidocaine local 
anesthesia (cornual nerve, 5 ml/horn) 
15 minutes prior to dehorning; 
tolazoline 2 mg/kg 5 min after 
dehorning 
Cortisol AUEC 81.03 NS 
Doherty, 
2007* 
Cautery 
(electric) 
dehorning 
10-12 
weeks 
Dairy 
Lidocaine (2%) local anesthesia 
(cornual branch of zygomatic-
temporal n., 3 ml/horn; cornual branch 
of infratrochlear n.; 4 ml/horn rostral 
to horn base) 
Cortisol (30 
min) 
-25.00 <0.05 
Lidocaine (5%) local anesthesia 
(cornual branch of zygomatic-
temporal n., 3 ml/horn; cornual branch 
of infratrochlear n.; 4 ml/horn rostral 
to horn base) 
 
Cortisol (30 
min) 
-56.25 <0.05 
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Stilwell, 
2008 
Chemical paste 
dehorning 
1.5 - 6 
weeks 
Dairy 
Flunixin meglumine 2 mg/kg IV, 5 
min prior to dehorning 
Cortisol (1h) 0.37 NS 
Cortisol (3h) -58.47 NS 
Cortisol (6h) -52.08 NS 
Cortisol (24 h) 37.70 NS 
Flunixin meglumine 2 mg/kg IV, 60 
min prior to dehorning 
Cortisol (1h) -8.08 NS 
Cortisol (3h) -2.18 NS 
Cortisol (6h) 21.83 NS 
Cortisol (24 h) 96.48 NS 
Stilwell, 
2009 
Chemical paste 
dehorning 
3-5 weeks 
Dairy 
Lidocaine local anesthesia (cornual 
nerve, 5 ml/horn) 5 min prior to 
dehorning 
Cortisol (10 m) -25.18 NS 
Cortisol (30 m) -59.63 <0.05 
Cortisol (50 m) -65.19 <0.05 
Cortisol (1 h) -47.51 <0.05 
Cortisol (3h) -5.50 NS 
Cortisol (6h) 7.89 NS 
Cortisol (24h) 34.68 NS 
Flunixin meglumine 2.2 mg/kg IV & 
Lidocaine local anesthesia (cornual 
nerve, 5 ml/horn), 5 min prior to 
dehorning 
Cortisol (10 m) -9.40 NS 
Cortisol (30 m) -50.06 <0.05 
Cortisol (50 m) -53.21 <0.05 
Cortisol (1 h) -77.68 <0.05 
Cortisol (3h) -67.85 <0.05 
Cortisol (6h) -24.64 NS 
Cortisol (24h) -25.61 NS 
Lidocaine local anesthesia (cornual 
nerve, 5 ml/horn) 5 min prior to 
dehorning 
Cortisol (90 m) -42.47 <0.05 
Cortisol (120 
m) 
-51.26 NS 
Cortisol (150 
m) 
39.80 NS 
Cortisol (180 
m) 
59.19 <0.05 
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Baldridge, 
2011 
Amputation 
(scoop) 
dehorning 
followed by 
surgical 
castration 
2 - 4 month 
Dairy 
Sodium salicylate at 2.5 to 5 mg/mL 
in the drinking water (13.62 to 151.99 
mg of salicylate/kg bodyweight)  
Cortisol (Cmax) 1.60 NS 
Cortisol AUEC 
(0 - 1h) 
-9.27 NS 
Cortisol AUEC 
(1 - 6h) 
-36.90 p<0.05 
Cortisol AUEC 
(6 - 24h) 
-22.83 NS 
0.025 mg/kg butorphanol, 0.05 mg/kg 
xylazine, 0.1 mg/kg ketamine co-
administered IM immediately prior to 
castration 
Cortisol (Cmax) -12.00 NS 
Cortisol AUEC 
(0 - 1h) 
-28.90 p<0.05 
Cortisol AUEC 
(1 - 6h) 
-5.82 NS 
Cortisol AUEC 
(6 - 24h) 
-0.01 NS 
Sodium salicylate at 2.5 to 5 mg/mL 
in the drinking water (13.62 to 151.99 
mg of salicylate/kg bodyweight) and 
0.025 mg/kg butorphanol, 0.05 mg/kg 
xylazine, 0.1 mg/kg ketamine co-
administered IM immediately prior to 
castration 
Cortisol (Cmax) -3.46 NS 
Cortisol AUEC 
(0 - 1h) 
-20.89 NS 
Cortisol AUEC 
(1 - 6h) 
-24.19 NS 
Cortisol AUEC 
(6 - 24h) 
-15.69 NS 
Coetzee, 
2012 
Amputation 
(scoop) 
followed with 
cautery 
(electric) 
dehorning 
16-20 
weeks 
Dairy 
Meloxicam 0.5 mg/kg IV immediately 
prior to dehorning 
Cortisol AUEC -7.95 NS 
Cortisol (Cmax) 3.66 NS 
Table 1 cont. 
58 
5
8
 
 
Ballou, 
2013 
Amputation 
(scoop) 
followed by 
cautery 3 mo Dairy 
Lidocaine local anesthesia (cornual 
nerve and ring, 12 ml/horn) + flunixin 
meglumine 2 mg/kg IM immediately 
prior to dehorning 
Cortisol (Cmax) -42.97 p<0.05 
Sutherland, 
2013 
Amputation 
(scoop) 
followed by 
cautery 3 mo Dairy 
Lidocaine local anesthesia (cornual 
nerve and ring, 12 ml/horn) + flunixin 
meglumine 2 mg/kg IM immediately 
prior to dehorning 
Cortisol 
(AUEC)* 
-70.59 P<0.05 
 
Percent change in cortisol was calculated using the formula [(Mean of analgesic group/ Mean of control group) – 1]*100 
AUEC: Area under the effect curve for cortisol. Cmax: Maximum plasma concentration; * indicates values were estimated from 
published graphical representation of the data; NR: values not reported  
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Table 2. Summary of the scientific literature examining the effect of analgesic drug administration on plasma cortisol response in 
dehorned calves using local anesthesia in the control group.  
Reference Procedure 
Study 
Population 
Control Analgesic 
Regimen 
Analgesic 
Regimen 
Outcome 
Parameter 
Percent 
change in 
cortisol (%) 
Significance 
(P-value) 
Milligan, 
2004 
Cautery 
(gas) 
dehorning 
2d - 2 
weeks 
Dairy 
Lidocaine local 
anesthesia (cornual 
nerve, 5 ml) 10 min 
prior to dehorning 
Ketoprofen 3 
mg/kg IM, 10 
min prior to 
dehorning 
Cortisol (3 h) -24.91 NS 
Cortisol (0-3 h) -224.02 <0.05 
Cortisol (6 h) 14.55 NS 
Cortisol (3-6 h) 336.79 NS 
Heinrich, 
2009 
Cautery 
(electric) 
dehorning 
6-12 weeks 
Dairy 
Lidocaine local 
anesthesia (cornual 
nerve, 5 ml) 10 min 
prior to dehorning 
Meloxicam 0.5 
mg/kg IM, 10 
minutes prior to 
dehorning 
Cortisol (0-6 h) -80.88 <0.01 
Cortisol (24 h) 0.86 NS 
Duffield, 
2010 
Cautery 
(electric) 
dehorning 
4-8 weeks 
Dairy 
Lidocaine local 
anesthesia (cornual 
nerve, 5 ml) 10 min  
prior to dehorning 
Ketoprofen 3 
mg/kg IM, 10 
min prior to 
dehorning 
Cortisol (3h) 4.62 NS 
Cortisol (6 h) 10.45 NS 
Stilwell, 
2010 
Cautery 
(gas) 
dehorning 
5-6 weeks 
Dairy 
 
 
 
 
Xylazine 0.2 mg/kg IM, 
10 min prior to 
dehorning 
 
 
 
 
 
Lidocaine local 
anesthesia 
(cornual nerve, 5 
ml) 8 min prior 
to dehorning 
Cortisol (10 m) -8.94 NS 
Cortisol (25 m) 5.07 NS 
Cortisol (40 m) 17.41 NS 
 
Cortisol (60 m) 
 
 
53.65 NS 
60 
Huber, 
2013 
Cautery 
(electric) 
dehorning 
5-9 weeks 
Procaine local 
anesthesia (cornual 
nerve, 10 ml) 20 min 
prior to dehorning 
Flunixin 
meglumine 2.2 
mg/kg, IV, 20 
min prior to 
dehorning 
Cortisol 
(AUEC) 
-26.62 NS 
Flunixin 
meglumine 2.2 
mg/kg, IV, 20 
min + 3 h prior 
to dehorning 
Cortisol 
(AUEC) 
-43.46 P<0.05 
Glynn, 
2013 
Amputation 
(scoop) 
followed 
by cautery 
6 mo Dairy 
Lidocaine local 
anesthesia (cornual 
nerve, 3 ml) 10 min 
prior to dehorning 
Flunixin 
meglumine 2.2 
mg/kg IV, 1 
minute prior to 
dehorning 
Cortisol 
(overall) 
-50.83 
 
 
P<0.05 
Stock, 2015 
Cautery 
(gas) 
dehorning 
4-6 weeks 
Dairy 
Lidocaine local 
anesthesia (cornual 
nerve, 5 ml) 10 min 
prior to dehorning 
Firocoxib 0.5 
mg/kg PO, 10 
minutes prior to 
dehorning 
Cortisol 
(AUEC) 
-32.20 P=0.09 
 
Percent change in cortisol was calculated using the formula [(Mean of analgesic group/ Mean of control group) – 1]*100 
AUEC: Area under the effect curve for cortisol; NS: not significant  
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Table 3. Summary of scientific literature examining the effect of analgesic drug administration on other outcomes in dehorned calves 
 
Reference Procedure 
Study 
Population 
Analgesic Regiment Outcome parameter 
Percent 
change  
(%) 
Significance 
Morisse, 1995 
Chemical 
paste 
dehorning 
4 weeks 
Dairy 
Lidocaine local 
anesthesia (cornual 
nerve, 4 ml/horn), 15 
min prior to dehorning 
Lying time 3.50 NS 
Cautery 
(electric) 
dehorning 
8 weeks 
Dairy 
Lidocaine local 
anesthesia (cornual 
nerve, 4 ml/horn), 15 
min prior to dehorning 
Lying time 7.88 NS 
Graf, 1999* 
Cautery 
(electric) 
dehorner  
4-6 weeks 
Dairy 
Lidocaine local 
anesthesia (cornual 
nerve, 5 ml; caudal 
horn bud SQ, 5 ml; 
medial horn bud, 3 ml), 
20 min 
Vasopressin (Cmax) -90.00 <0.05 
ACTH (Cmax) -72.50 <0.05 
Saline injection 
(cornual nerve, 5 ml; 
caudal horn bud SQ, 5 
ml; medial horn bud, 3 
ml), 20 min 
Vasopressin (Cmax) 125.00 NS 
 
 
 
ACTH (Cmax) 
 
 
 
 
62.50 NS 
6
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Grøndahl-
Nielsen, 1999
*
 
Cautery 
(electrical) 
dehorner 
4-6 weeks 
Dairy 
 
 
Lidocaine local 
anesthesia (cornual 
nerve, unknown 
amount), 20 minutes 
prior to dehorning 
 
 
ADG (0-7d) NR NS 
Feed intake (0-7d) NR NS 
Heart rate (0-4h) NR NS 
Rumination (0-4h) NR NS 
Rumination latency -58.33 <0.05 
 
 
Xylazine 0.2 mg/kg & 
butorphanol 0.1 mg/kg, 
IM, 20 min prior to 
dehorning 
 
 
ADG (0-7d) NR NS 
Feed intake (0-7d) NR NS 
Heart rate (0-4 h) NR NS 
Rumination (0-4h) NR NS 
Rumination latency -37.50 <0.05 
 
Xylazine 0.2 mg/kg & 
butorphanol 0.1 mg/kg, 
IM, 20 min prior to 
dehorning; Lidocaine 
local anesthesia 
(cornual nerve, 
unknown amount), 15 
minutes prior to 
dehorning 
 
ADG (0-7d) NR NS 
Feed intake (0-7d) NR NS 
Heart rate (0-4h) NR NS 
Rumination (0-4h) NR NS 
Rumination latency -46.67 <0.05 
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Faulkner and 
Weary, 2000 
Cautery 
(electrical) 
dehorner 
4-8 weeks 
Dairy 
 
Ketoprofen 3 mg/kg PO 
2 h prior to dehorning, 
2 h post dehorning, & 7 
h after dehorning 
 
Weight gain (0-24 h) 500.00 NS (p=0.07) 
 
 
[Analgesic control:  
Xylazine 0.2 mg/kg IM 
20 min prior to 
dehorning & Lidocaine 
local anesthesia 
(cornual nerve & ring 
block 4.5 ml/side) 10 
min prior to dehorning] 
 
 
Mellor, 2002* 
Amputation 
(scoop) 
dehorn 
10 weeks 
Dairy 
 
 
 
Lidocaine local 
anesthesia (cornual 
nerve, 5 ml/horn) 20 
minutes prior to 
dehorning 
 
 
 
 
Noradrenaline (Cmax) -16.00 NS 
Adrenaline (Cmax) -9.09 NS 
Table 3 cont. 
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Doherty, 2007 
Cautery 
(electric) 
dehorning 
10-12 
weeks 
Dairy 
 
 
Lidocaine (2%) local 
anesthesia (cornual 
branch of zygomatic-
temporal n., 3 ml/horn; 
cornual branch of 
infatrochlear n.; 4 
ml/horn rostral to horn 
base) 
 
 
Neutrophil % 9.53 NS 
Lymphocyte % -10.04 NS 
N:L % -19.83 NS 
Fibrinogen NA NS 
α1-acid glycoprotein NA NS 
 
Lidocaine (5%) local 
anesthesia (cornual 
branch of zygomatic-
temporal n., 3 ml/horn; 
cornual branch of 
infratrochlear n.; 4 
ml/horn rostral to horn 
base) 
 
Neutrophil % 0.23 NS 
Lymphocyte % 1.70 NS 
N:L % -21.49 NS 
Fibrinogen NA NS 
α1-acid glycoprotein NA NS 
Heinrich, 2009 
Cautery 
(electric) 
dehorning 
6-12 weeks 
Dairy 
 
Meloxicam 0.5 mg/kg 
IM given 10 min prior 
to dehorning; Analgesic 
control: lidocaine local 
anesthesia (cornual 
nerve, 5 ml/horn) 
 
Heart Rate -20.43 <0.05 
Respiratory rate -100.00 <0.05 
Table 3 cont. 
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Stewart, 2009* 
Cautery (gas) 
dehorning 
4-5 weeks 
Dairy 
Lidocaine local 
anesthesia (cornual 
nerve, 5 ml/horn & ring 
block, 3-4 ml/horn ) 10 
minutes prior to 
dehorning 
Eye temperature (2 - 3 h 
post dehorning 
difference) 
-610.00 <0.001 
Heart Rate (0-5 min) -22.22 <0.05 
HRV: LF Power (2-3h) 13.16 <0.05 
HRV: HF power (2-3h) -35.90 <0.05 
HRV: LF:HF ratio (2-3h) 500.00 <0.05 
 
 
Meloxicam 0.5 mg/kg 
IV, 55 min prior to 
dehorning & Lidocaine 
local anesthesia 
(cornual nerve, 5 
ml/horn & ring block, 
3-4 ml/horn ) 10 
minutes prior to 
dehorning 
 
 
Eye temperature (2 - 3 h 
post dehorning 
difference) 
-.00 NS 
Heart Rate (0-5 min) -26.98 <0.05 
HRV: LF Power (2-3h) 7.89 <0.05 
HRV: HF power (2-3 h) -15.38 <0.05 
HRV: LF:HF ratio (2-3 h) 166.67 NS 
Heinrich, 2010 
Cautery 
(electric) 
dehorning 
6-12 weeks 
Dairy 
Meloxicam 0.5 mg/kg 
IM given 10 min prior 
to dehorning; Analgesic 
control: lidocaine local 
anesthesia (cornual 
nerve, 5 ml/horn) 
Accelerometer (0-5 h) -10.26 <0.05 
Pressure algometry 31.48 <0.05 
Feed Consumption 300.00 NS (p=0.07) 
Table 3 cont. 
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Baldridge, 2011 
Amputation 
(scoop) 
dehorning 
after surgical 
castration 
2 - 4 month 
Dairy  
 
Sodium salicylate at 2.5 
to 5 mg/mL in the 
drinking water (13.62 
to 151.99 mg of 
salicylate/kg 
bodyweight)  
 
ADG (0- 13 d) -1111.22 < 0.05 
Chute exit speed 0.97 NS 
 
0.025 mg/kg 
butorphanol, 0.05 
mg/kg xylazine, 0.1 
mg/kg ketamine co-
administered IM 
immediately prior to 
castration 
 
ADG (0- 13 d) -729.98 NS 
Chute exit speed -77.81 < 0.05 
 
Sodium salicylate at 2.5 
to 5 mg/mL in the 
drinking water (13.62 
to 151.99 mg of 
salicylate/kg 
bodyweight) and 0.025 
mg/kg butorphanol, 
0.05 mg/kg xylazine, 
0.1 mg/kg ketamine co-
administered IM 
immediately prior to 
castration 
 
ADG (0- 13 d) -1095.92 < 0.05 
Chute exit speed -94.97 < 0.05 
Table 3 cont. 
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Theurer, 2012* 
Cautery 
(electric) 
dehorning 
10 weeks 
Dairy 
Meloxicam 0.5 mg/kg 
PO immediately after 
dehorning 
Lying down % (1-4d) 20.13 <0.05 
Hay feeder % (0-1d) -40.86 <0.05 
Grain feeder % (0-1d) -50.00 <0.05 
Grain feeder % (1-2d) 80.00 <0.05 
Coetzee, 2012 
Amputation 
(scoop) 
followed by 
cautery 
(electric) 
dehorning 
16-20 
weeks 
Dairy 
Meloxicam 0.5 mg/kg 
IV, immediately before 
the start of dehorning 
Substance P -37.79 <0.05 
Lying time % -97.06 <0.01 
Heart Rate (8 & 10 h) NR <0.05 
ADG (0-10 d) 162.50 <0.05 
Glynn, 2013 
Amputation 
(scoop) 
followed by 
cautery 
6 month 
Dairy 
 
 
 
Analgesia (Meloxicam 
1 mg/kg PO or 
Gabapentin 15 mg/kg 
PO or Meloxicam 1.0 
mg/kg + Gabapentin 15 
mg/kg PO) 
immediately prior to 
dehorning); lidocaine 
local anesthesia to all 
calves 
 
 
 
 
Substance P -53.86 <0.05 
Haptoglobin NA NS 
Ocular temperature NA NS 
Mechanical Nociception 
Threshold 
NA P=0.074 
ADG (7d) 275 P<0.0001 
Table 3 cont. 
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Allen, 2013 
Cautery 
dehorning 
8- 10 
weeks 
 
 
Meloxicam 1.0 mg/kg 
PO immediately after 
dehorning or 12 hrs 
prior to dehorning; 
lidocaine local 
anesthetic 
 
 
 
Substance P NA 
NS; 
Decreased @ 
120 h P<0.05 
Haptoglobin NA NS 
Ocular temperature NA NS 
Mechanical Nociception 
Threshold 
NA 
NS; 
decreased @ 
1 h P<0.05; 
increased @ 
6 h P=0.073 
ADG (7d) NA NS 
Huber, 2013 
Cautery 
(electric) 
dehorning 
5-9 weeks 
 
 
 
 
 
 
Flunixin meglumine 2.2 
mg/kg, IV, 20 min or 
20 min + 3h prior to 
dehorning; Procaine 
local anesthesia 
(cornual nerve, 10 ml) 
20 min prior to 
dehorning 
 
 
 
 
 
Heart rate NA NS 
Respiratory Rate NA NS 
Table 3 cont. 
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Ballou, 2013* 
Amputation 
(scoop) 
followed by 
cautery 
3 month  
Dairy 
Lidocaine local 
anesthesia (cornual 
nerve and ring, 12 
ml/horn) + flunixin 
meglumine 2 mg/kg IM 
immediately prior to 
dehorning 
TNF-α 31.94 P<0.05 
Neutrophil oxidative 
burst 
16.51 P<0.05 
Neutrophil L-selectin 
(0.5h) 
-5.33 NS 
Neutrophil L-selectin 
(24h) 
32.26 NS 
Total Leukocytes (0.5h) -18.18 NS 
Total Leukocytes (6h) -36.67 P<0.05 
Total Leukocytes (24h) -29.79 P<0.05 
Total Leukocytes (72h) -2.13 NS 
Neutrophil:Lymphocyte 
(0.5h) 
-20.00 NS 
Neutrophil:Lymphocyte 
(6h) 
-60.53 P<0.05 
Neutrophil:Lymphocyte 
(24h) 
-36.36 NS 
Neutrophil:Lymphocyte 
(72h) 
10 NS 
Haptoglobin (24h) -38.18 NS 
Haptoglobin (72h) 0 NS 
Sutherland, 
2013 
Amputation 
(scoop) 
followed by 
cautery 
3 month  
Dairy 
 
Lidocaine local 
anesthesia (cornual 
nerve and ring, 12 
ml/horn) + flunixin 
meglumine 2 mg/kg IM 
immediately prior to 
dehorning 
 
Eating 187.93 P<0.05 
Drinking 42.31 NS 
Lying -4.57 NS 
Standing 4.8 NS 
  
  
Table 3 cont. 
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Stock, 2015 
Cautery (gas) 
dehorner 
4-6 week 
Dairy 
Firocoxib 0.5 mg/kg 
PO, 10 minutes prior to 
dehorning; Lidocaine 
local anesthesia 
(cornual nerve, 5 ml) 
10 min prior to 
dehorning to all calves 
MNT 19.79 NS 
OT 0.53 NS 
Substance P 9.13 NS 
Heart Rate -0.27 NS 
ADG 0 NS 
 
Percent change in cortisol was calculated using the formula [(Mean of analgesic group/ Mean of control group) – 1]*100 
ADG: Average daily gain in bodyweight; HRV: heart rate variability; LF: Low frequency; HF: High frequency; * indicates values 
were estimated; NR: values were not reported 
Table 3 cont. 
  
7
0
 
 
71 
Table 4. Analgesic compounds available for use in cattle. 
Drug Approved 
Species 
Indications Dose 
(mg/kg) 
Route T ½ (h) F (%) Tmax 
(h) 
Withhold 
time 
Comments 
NSAID 
Flunixin 
meglumine 
Cattle 
horses pigs 
Antipyretic, 
Anti-
inflammatory 
2.2 IV 3-8 h   
Meat- 4 d 
Milk- 36 h 
 
 
 IV only 
approved route 
 PO / IM: 
Prolonged 
withhold 
 IM: tissue 
necrosis 
 
 
2.2 PO 6.2 h 60% 3.5± 1.0 
Not 
approved 
route for 
cattle 
Phenyl-
butazone 
Horses and 
dogs 
Anti-
inflammatory 
4 
IV 
ONLY! 
40 – 55 h   
Not 
approved 
in cattle in 
the USA 
 
 
 ELDU 
prohibited for 
dairy cattle 
≥20 mo 
 Use strongly 
discouraged 
 
 
4 – 8 PO 57.9±6.5 
54-
69% 
8.9-11.7 
7
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Ketoprofen 
Horses and 
dogs; EU 
approval in 
EU and 
Canada 
Anti-
inflammatory; 
adjunctive 
therapy of 
fever, pain, and 
inflammation 
associated with 
mastitis (EU) 
3 IV, IM 0.42 h   
Not 
approved 
in cattle in 
the USA 
 Concentrates 
in 
inflammatory 
exudates 
 Consists of 
racemic RS ± 
enantiomers 
 S(+) > R(-) 
inhibiting 
PGE2 
 Multiple doses 
may be 
required to 
maintain 
analgesia 
 
Aspirin / 
sodium 
salicylate 
 
No formal 
FDA approval 
cattle and 
horses 
Reduction of 
fever 
Relief of minor 
muscle aches 
and joint pain 
50 – 100 
PO  3.7±0.4 h <20% 
 
No formal 
FDA 
approval 
Not for 
use in 
lactating 
cattle 
 PO: Rumen 
acts as 
reservoir for 
slow 
absorption 
 Limited tissue 
distribution 
(low Vd) 
 Not associated 
with clotting 
deficits in 
cattle 
 
IV 0.5  
 
Table 4 cont. 
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Carprofen 
Dogs; EU 
approval in 
cattle 
 
Anti-
inflammatory, 
Antipyretic; 
Adjunctive 
therapy of 
acute 
respiratory 
disease and 
mastitis 
1.4 IV, SC 
<10 weeks: 
R(-): 
49.7±3.9 h 
S(+): 
37.4±2.4 h 
 
Adult: 
RS± 
30.7±2.3 h 
  Not 
approved 
in cattle 
the USA 
 Consists of 
racemic RS ± 
enantiomers 
 S(+) > R(-) 
inhibiting 
PGE2 
 
Meloxicam 
Dogs and 
cats; EU 
and 
Canadian 
approval in 
cattle 
 
Adjunctive 
therapy of 
acute 
respiratory 
disease; 
diarrhea and 
acute mastitis; 
pain associated 
with dehorning 
(Canada) 
0.5 
 
IV, SC 
 
22 ± 3 h   
Not 
approved 
in cattle in 
the USA 
 Both 
injectable and 
oral 
formulations 
available 
 
0.5 – 1.0 PO 
27 h 
(20 – 43 h) 
100% 11.6 h 
Firocoxib 
Horses and 
dogs  
Anti-
inflammatory 
0.5 PO 
18.8 h (14.2 
– 25.5 h) 
98% 4 h 
Not 
approved 
in cattle in 
the USA 
 Evaluated in 
preweaned 
calves 
 
 
 
 
 
 
Table 4 cont. 
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Opioids 
Butorphanol 
Dogs, cats, 
horses 
Analgesia; 
Sedation 
0.025 IM 71±8 min  
9.5±0.5 
m 
Not 
approved 
in cattle in 
the USA 
 PK data 
following 
administration 
with ketamine 
and xylazine 
Nalbuphine 
No known 
veterinary-
labeled 
product 
Analgesia 0.4 IV 
41m (32-47 
m) 
  Not 
approved 
in cattle in 
the USA 
 Plasma 
samples 
undetectable 
after 3h 
Alpha2 agonist 
Xylazine 
Dogs, cats, 
horses, 
deer, and 
elk; EU 
approval in 
cattle 
 
Sedation; 
Analgesia 
0.05 – 
0.3 
IM 96±20 m  9.5±0.5 
m 
Not 
approved 
in cattle in 
the USA 
 PK data 
following 
administration 
with ketamine 
+ butorphanol  
 Dose-
dependent 
response: 
Higher doses 
result in 
recumbency 
 Fast to prevent 
rumen 
tympany; 
aspiration of 
rumen contents 
Table 4 cont. 
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NMDA antagonist 
Ketamine Cats 
Sedation; 
Analgesia 
0.1 
IM 67±11m 
 
10±1m 
Not 
approved 
in cattle in 
the USA 
 PK data 
following 
administration 
with xylazine 
alone (IV) or 
with xylazine 
and 
butorphanol 
(IM) 
 Metabolite 
norketamine 
may contribute 
to analgesia 
IV 29.4±4.5m  
Neuropathic pain analgesic 
Gabapentin No known 
veterinary-
labeled 
product 
Neuropathic 
analgesia 
15 PO 7.9 h (6.9-
12.4h) 
 7.2h (6-
10h) 
Not 
approved 
in cattle in 
the USA 
 Plasma 
concentrations 
above those 
reported as 
therapeutic in 
humans for up 
to 15 hrs 
Table 4 cont. 
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Figure 1. Constructed graphic representation of cortisol change over time in cattle 
following amputation (scoop) dehorning (derived from Stafford and Mellor, 2005 and 
currently published in Stock et al., 2013). Local anesthesia (bupivacaine) with NSAID 
(ketoprofen) administration provides a reduction in measured cortisol concentrations, 
although a delayed cortisol response is evident without the addition of an anti-
inflammatory. The double headed arrow along the x-axis represents the duration of the 
local anesthesia provided by bupivacaine. 
 
77 
 
Figure 2. Mean (±SEM) percent reduction in AUEC or overall mean cortisol 
concentrations following dehorning in analgesic treated calves compared with a control 
group. Number in parentheses indicates studies reviewed. Percent change in cortisol was 
calculated using the formula [(Mean of analgesic group/Mean of control group)-1]*100. 
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Figure 3. Mean (±SEM) percent reduction in peak plasma cortisol concentrations 
following dehorning in analgesic treated calves compared with a control group. Number 
in parentheses indicates studies reviewed. Percent change in cortisol was calculated using 
the formula [(Mean of analgesic group/Mean of control group)-1]*100. 
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Figure 4. Diagram of cornual nerve anatomy including approximate locations for local 
anesthetic injection as illustrated by Skarda, 1986.
80 
 
Figure 5. Steps for providing local anesthetic for dehorning using a cornual nerve block: (A) Anatomy of the cornual innervation; (B) 
Palpation of the temporal ridge; (C) Insert the needle below the ridge and aspirate; (D) Inject 5- 10 mL of lidocaine; Automatic 
syringe: (E) Palpate the frontal ridge and insert needle attached to automatic syringe; (F) Inject 5 – 10 ml of lidocaine using an 
automatic syringe.  
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CHAPTER 3 
PHARMACOKINETICS OF FIROCOXIB IN PREWEANED CALVES AFTER 
ORAL AND INTRAVEOUS ADMINISTRATION 
 
Modified from a manuscript published in the Journal of Veterinary Pharmacology and 
Therapeutics 
 
Matthew L. Stock
1
, Ronette Gehring
2
, Laura A. Barth
3
, Larry W. Wulf
4
, Johann F. 
Coetzee
4,5 
 
Abstract 
The objective of this study was to determine the pharmacokinetics of intravenous 
and oral firocoxib in 10 healthy preweaned calves. Firocoxib (0.5 mg/kg) was initially 
administered IV to calves and following a 14-day washout period, animals received 
firocoxib orally prior to cautery dehorning. Firocoxib concentrations were determined by 
liquid chromatography tandem mass spectrometry. Changes in hematology and plasma 
chemistry were determined using automated methods. Computer software was used to 
estimate pharmacokinetic parameters best described with a two-compartment model for 
IV administration and a one-compartment model for PO administration. Following IV 
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dosing, the geometric mean (range) T1/2K10 and T1/2β were 6.7 (4.6 – 9.7) and 37.2 (23.5 – 
160.4) hours, respectively, Vss was 3.10 (2.10 – 7.22) L/kg, and CL was 121.6 (100.06 – 
156.7) mL/h/kg. Following oral administration, geometric mean (range) Cmax was 127.9 
(102.5 – 151.3) ng/mL, Tmax was 4.0 (2.6 – 5.6) hours, and T1/2K10 was 18.8 (14.2 – 25.5) 
hours. Bioavailability of oral firocoxib was calculated using the AUC derived from both 
study populations to be 98.4% (87.1% – 117.6%). No adverse clinical effects were 
evident following firocoxib administration. Pharmacokinetic analysis of IV and PO 
firocoxib indicates high bioavailability and a prolonged terminal half-life in preweaned 
calves. 
 
Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs)
 6
 in veterinary medicine have 
been effectively used to control pain associated with conditions such as post-surgical 
procedures and osteoarthritis (Davila et al., 2013; Orsini et al., 2012). More recently, a 
newer class of NSAIDs known as the coxibs, have been evaluated as selective inhibitors 
of cyclooxygenase-2 (COX-2)
7
 isoenzyme in horses and dogs (McCann et al., 2002; 
McCann et al., 2004). This specificity is mediated by steric hindrance to the COX-1 
isoform and provides anti-inflammatory benefits with a potentially reduced risk for 
gastrointestinal irritation (Bergh et al, 2005). As young animals are at risk for developing 
gastric ulcers with a multifactorial etiology, NSAIDs demonstrating COX-2 selectivity 
and thus a COX-1
8
 sparing effect may be ideal for use in calves requiring analgesic and 
                                                 
6
 NSAID: non-steroidal anti-inflammatory drugs 
7
 COX-2: cyclooxygenase-2 
8
 COX-1: cyclooxygenase-1 
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anti-inflammatory therapy (Marshall, 2009). However, pharmacokinetic profiles are 
species dependent requiring studies involving target species (Lees, 2004). 
Currently, firocoxib is formulated as an intravenous injectable solution and oral 
paste in horses or oral tablet in dogs to control osteoarthritis pain and inflammation. 
Pharmacokinetics of firocoxib following a one-time oral dose indicates bioavailability 
and clearance values similar to other NSAIDs of veterinary use (Kvaternick et al, 2007; 
McCann et al., 2004).  Conversely to other NSAIDs, a large volume of distribution is 
reported for firocoxib, potentially attributed to its lipophilic property and neutrality 
charge at physiologic pH (Kvaternick et al., 2007; McCann et al., 2004; Letendre et al., 
2008). Consequently, firocoxib has a long half-life. In conjunction with this prolonged 
half-life, pharmacodynamic data support once daily dosing in horses, dogs, and cats 
(McCann et al., 2002; McCann et al, 2004; McCann et al., 2005)   
Routine husbandry procedures including dehorning and castration as well as 
painful disease states such as septic arthritis often affect calves. As such, analgesic 
treatment may be helpful in management and control of the pain associated with these 
conditions.  Although the pharmacokinetics has been described in horses, dogs and cats, 
there is a gap in knowledge regarding the pharmacokinetic profile in calves. The 
objective of this study was to determine the pharmacokinetics of firocoxib in preweaned 
calves following IV and PO administration dosed at 0.5 mg/kg. 
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Materials and Methods 
Animals 
 Ten Holstein calves (males and females) with a mean ± SD weight of 44.5± 4.3 
kg and age of 20.7 ± 4.1 days for period 1 and 55.5 ± 5.3  kg and age of 34.7 ± 4.2 days 
for period 2 were included in this study. Calves were obtained from the Iowa State 
University Dairy. All calves were determined healthy by a physical examination and 
normal findings on a complete blood count and serum chemistry.  This study protocol 
was approved by the Institutional Animal Care and Use Committee at Iowa State 
University (IACUC #: 10-12-7443-B). 
 Calves were individually housed with other preweaned dairy calves in an 
enclosed facility on the Iowa State University Dairy.   Study animals were maintained 
in individual three sided pens (1.22 m x 1.82 m) bedded with straw added daily. 
Pasteurized waste milk collected from mature cattle was fed to the calves at 3 L twice 
daily for the length of the study. Water and grain, consisting of primarily pelleted corn, 
oats, molasses and protein/vitamin/mineral supplement, were fed to the calves ad 
libitum.  Animals were examined daily by a veterinarian including the monitoring of 
milk consumption and a subjective assessment of grain and water consumption 
throughout the study period.  
 
Study Design 
 A parallel design using the same animals (n=10) with 2 treatment periods 
separated by a 14-day washout period was utilized for this investigation. During the 
first period, study animals received firocoxib (0.5 mg/kg) intravenously. Following the 
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washout period, during the second study period animals were given firocoxib orally at 
the same dose (actual dose 0.5 mg/kg; 0.48-0.52 mg/kg) and subsequently cautery 
dehorned.   
 In both periods, a jugular catheter was placed for the purpose of blood sample 
collection. In addition, during the first period, a second jugular catheter was placed in 
the contralateral jugular vein for intravenous drug administration. Placement of the 
jugular catheter occurred approximately 12 hours prior to the start of the investigation. 
Calves were restrained by a handler during the process of catheter placement. The area 
over the jugular vein was clipped and surgically prepared with alternating scrubs of 
70% isopropyl alcohol and povidone iodine. The catheter site was infiltrated with 2% 
lidocaine injection, 1 mL subcutaneously (VetOne®, Boise, ID) (NDC: 13985-222-04) 
(Lot #: 120200).  Using sterile technique, an 18 G x 55 mm intravenous catheter 
(SURFLO®, Terumo Medical Corp., Somerset, NJ) with injection plug (Hospira Inc, 
Lake Forest, IL) was inserted into the vein and sutured to the skin using #3 nylon suture 
(Ethilon™, Ethicon, San Lorenzo, PR).  Catheter patency was maintained by flushing 
with 2 mL of a heparin saline solution containing 3 USP units heparin sodium/mL 
saline (Heparin Sodium Injection, Baxter Healthcare, Deerfield, IL). The catheter port 
was disinfected with an alcohol swab prior to sample collection. 
 During the first period of the study, animals were administered firocoxib (0.5 
mg/kg) (Equioxx® Injection, 20 mg/mL; NADA 141-313, Merial LLC, Lot #: 0VP03, 
Exp. date: 11/2013) via an intravenous catheter designated for drug administration. The 
dose was rounded to the nearest tenth milliliter and administered in a three milliliter 
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syringe. Following drug injection, the catheter was flushed using 10 mL of 0.9% saline 
(Sterile Saline, Vet One®, Boise, ID) and then removed.  
 Following a 14 day washout period, calves previously receiving intravenous 
firocoxib were administered oral firocoxib (Equioxx® Oral Paste, NADA 141-
253,Merial LLC, Lot #: AB015/12, Exp. date: 06/2015) at a calculated dose of 0.5 
mg/kg prior to cautery dehorning. Oral firocoxib was administered in a commercially 
provided dosing syringe, which was weighed before administration and after to confirm 
the amount of firocoxib administered. The dose was rounded to the nearest increment 
provided on the syringe, which was equivalent to 10 pounds (4.54 kg) based on the 
target dose. Using a concentration of 0.82% firocoxib, a dose of 0.5 mg/kg (range: 0.48 
– 0.52 mg/kg) was administered to the calves as an oral paste in the dosing syringe. 
 
Dehorning 
All calves were dehorned in this study during the second period, 10 minutes 
following administration of PO firocoxib. Additionally, all calves received a local 
anesthetic cornual nerve block in both periods of the study to reduce the potential for 
confounding interactions between the periods. Desensitization of the cornual tissue was 
provided via a cornual nerve block using 2% lidocaine (VetOne®, Boise, ID) (NDC: 
13985-222-04) (Lot#120200) (5 ml / site) as described by Stock et al. (2013). This was 
performed immediately following drug administration. Cautery dehorning was initiated 
10 minutes following administration of the local anesthetic and drug delivery by one 
experienced veterinarian and one handler to minimize variation as detailed in Glynn et al 
(2013).  
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Blood sample collection 
 Animals were restrained during blood collection by trained handlers. Baseline 
samples were obtained immediately prior to drug administration. During period 1, 
blood samples were collected for animals receiving intravenous firocoxib or placebo 
via the catheter at  3, 6, 10, 20, 30, 45 minutes and 1, 2, 4, 6, 8, 12, 24, 48, 72, and 96 
hours. During period 2, blood samples were collected at 15, 30 minutes and 1, 2, 4, 6, 8, 
10, 12, 24, 48, 72, and 96 hours following oral firocoxib administration and dehorning. 
Samples were immediately transferred to heparinized blood collection tubes 
(Vacutainer®, BD Diagnostics) and stored on ice before processing. Blood samples 
were centrifuged for 10 minutes at 1,500g. Collected plasma was placed in cryovials 
and frozen at -70 °C until analysis. 
 
Plasma chemistry and complete blood count data 
Plasma chemistry was performed by the Iowa State University Clinical Pathology 
Laboratory by automated methods using a Vitros® 5.1 FS Chemistry System (Ortho 
Clinical Diagnostic, Johnson & Johnson Co., Rochester, NY). Additionally, a complete 
blood count was determined by automated methods using an ADVIA® 120 hematology 
system (Siemens Medical Solutions USA, Inc., Malvern, PA) with a program for bovine 
blood.  
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LCMS-MS analysis 
 Plasma concentrations of firocoxib were measured with high-pressure liquid 
chromatography –tandem mass spectrometry utilizing a TSQ Quantum Discovery Max 
triple quadrupole mass spectrometer coupled to a Surveyor Pump and Autosampler 
(Thermo Scientific, San Jose, CA, USA). Plasma samples or plasma standards were 
prepared as detailed in Letendre et al. 2007 with slight modifications: Briefly, frozen 
samples or standards were thawed at room temperature and rigorously vortexed once 
completely thawed. A 200 µL plasma sample was added to 400 µL 5% (v/v) acetic 
acid. The entire diluted sample was applied to a solid phase extraction (SPE)
9
 cartridge, 
Strata X (60 mg/3 mL, Phenomenex, Torrance, CA, USA) which was preconditioned 
prior with methanol (2 ml) and equilibrated with water (2 ml). The sample was then 
gravity filtered through the SPE tubes and subsequently washed with 1 ml 5% (v/v) 
acetic acid, followed by 1 ml of 25% (v/v) methanol in water.  Firocoxib was eluted 
with 2 x 0.75 mL portions of acetonitrile into a glass test tube.  Samples were 
evaporated to dryness at 48°C under a stream of nitrogen, reconstituted with 200 µL 
25% (v/v) acetonitrile in water and transferred into an injection vial for LC-MS/MS 
analysis with the injection volume set to 10 μL. The mobile phases consisted of A: 
0.1% formic acid in water and B: 0.1% formic acid in acetonitrile at a flow rate of 0.25 
mL/min. The mobile phase began at 40% B with a linear gradient to 95% B at 6 
minutes, which was maintained for 1.5 minutes, followed by re-equilibration to 40% B.  
Separation was achieved with an Intersil ODS-4 column (75 mm x 2.1 mm, 3 µm 
particles, GL Sciences, Torrance, CA, USA) maintained at 40°C.  
                                                 
9
 SPE: solid phase extraction 
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 External standard calibration with matrix matched calibrates were used as no 
suitable internal standard was found following exploration of piroxicam and celecoxib. 
The standard curve of firocoxib concentration determined using bovine plasma was 
linear from 0.005 to 5.0 µg/mL and was accepted when the correlation coefficient 
exceeded 0.99 and measured values were within 15% of the actual values. The lower 
limit of quantification, defined as the lowest concentration on a linear standard curve 
with predicted concentrations within 15% of the actual concentration, was 0.005 
µg/mL.  Three SRM transitions were used for quantitation of firocoxib and piroxicam, 
respectively. The three ions (m/z) 130, 237, and 283 were monitored for analysis of 
firocoxib. Intraday accuracy of the assay for firocoxib in calf plasma was 99 ± 3% of 
the actual concentration, whereas the intraday coefficient of variation was 2%, as 
determined through replicates of 5 for each of the following firocoxib concentrations: 
0.015, 0.150, and 1.50 µg/mL. 
 
Pharmacokinetic analysis 
Firocoxib time concentration data were analyzed using a commercially available 
computer software program (Phoenix®, Pharsight Corporation, NC, USA). Using the 
value of Aikake’s Information Criterion and visual inspection of predicted versus 
observed data, the best models were selected for each route of administration. A two 
compartment model with first-order elimination best fit IV firocoxib administration 
whereas a one compartment model with first-order elimination best fit the PO route. 
Standard equations were used to calculate pharmacokinetic parameters (Gibaldi & Perrier 
1982).  
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Statistical analysis 
Statistical analysis was performed using JMP® Pro 10.0.2 analytical software 
(SAS Institute, INC, Cary, NC, USA). Distribution curves were examined for normality. 
Pharmacokinetic values are reported as geometric means, medians, and ranges due to log-
normal distributions. Plasma chemistry and complete blood count data were statistically 
analyzed using paired t-tests or Wilcoxon signed rank tests for normal or non-normal 
distributions, respectively. Significance was designated a priori  as p<0.05. 
 
Results 
Plasma chemistry and complete blood count analysis 
No adverse clinical effects including changes in appetite, water intake, or physical 
exam parameters were observed during either study period.  Significant differences were 
observed in both plasma biochemistry and hematology parameters obtained prior to and 
72 hours after firocoxib administration for both IV and PO routes (Table 1). Changes 
determined as significant observed during intravenous administration include minor 
decreases in hematocrit and γ-glutamyltransferase (GGT) and increases in total protein 
and albumin. Reported significant changes following oral administration include 
decreases in BUN, Creatinine, and GGT and increases in red blood cells, total protein, 
albumin, and AST.  Although these changes were significant, values remained either 
within or slightly below the reference ranges provided by the analyzing chemistry lab. 
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Pharmacokinetic analysis 
The time-concentration profile following IV administration at 0.5 mg/kg is best 
described with a 2-compartment model (Figure 1), whereas the profile following PO 
administration at 0.5 mg/kg (range 0.48 – 0.52 mg/kg) is best described as a 1-
compartment model (Figure 2).  This is because the absorption phase following PO 
administration overlaps with the rapid distribution phase, making the latter undetectable. 
Concentrations were detectable up to the last sampling point for both routes of 
administration. Oral drug absorption (F) was calculated using the AUC values derived 
from both IV and PO study populations to be 98.4% (range 83 – 118 %) (Table 2 and 3).  
 
Discussion 
The present study is the first to examine the IV and PO pharmacokinetics of 
firocoxib in preweaned calves. The oral preparation of firocoxib appears to be well 
absorbed as evidenced by a high bioavailability. Additionally, a prolonged terminal half-
life was observed in both routes of administration supporting a once a day treatment. 
These properties of firocoxib suggest the potential for use in calves. 
A limitation of this study was that PO and IV dosing was not randomly distributed 
between period 1 and 2 of the study. As such, influencing factors including increased 
weights, age, physiologic effects of dehorning, and environmental conditions were not 
controlled between periods essentially separating the two study periods into two study 
populations.  This study design was adopted because calves were enrolled in a second 
trial intended to determine the analgesic effects of oral firocoxib and therefore 
administration of IV firocoxib would have confounded the second trial. This potential for 
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increased total variability has been documented and supported in parallel 
pharmacokinetic studies for drugs having relatively long half-lives (Chow & Wang, 
2001). Although factors limiting variability were employed such as using the same 
analyzing lab and study animals, due to these limitations detailed, the pharmacokinetic 
parameters have been separated into two non-superimposable populations. The 
bioavailability calculation was determined using the AUC derived from these two 
populations notwithstanding the aforementioned limitations. 
The dose used in this experiment was based on previous studies in horses 
(Kvaternick et al., 2007, Letendre et al., 2008). In these studies, a dose of 0.1 mg/kg was 
given to horses as both a single administration and multiple doses reaching steady state. 
The goal in this study was to administer a single, higher dose to achieve maximal plasma 
concentrations that were comparable to those at steady-state in the horse without the need 
for repeated dosing. This desired increase in plasma concentrations was chosen for an 
expected single-time dose administration in calves whereas achieving effective steady 
state concentrations in the horse required multi-day administration (Letendre et al, 2008; 
Cox et al., 2013). This is comparable to a loading dose, which was recently evaluated in 
horses (Cox et al., 2013). The investigated 3X loading dose reduced the variability of 
onset of action and efficacy in horses supporting the use of a higher initial dose. Although 
linearity was not evaluated in this study, firocoxib has demonstrated linear kinetics 
following 0.5X and 2X recommended doses in horses (Kvaternick et al., 2007). 
Hematologic and plasma biochemical analytes obtained prior to and 72 h 
following administration primarily remained within the references ranges provided by the 
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Iowa State University Clinical Pathology Laboratory. The elevated GGT
10
 observed in 
the IV study population was most likely due to the proximity to colostrum ingestion as 
colostrum provides high concentrations of GGT (Perino et al., 1993). Although 
significant changes were observed in both plasma biochemistry and hematology analytes, 
these differences mostly were within reference ranges provided by the analyzing 
laboratory. A significant increase in total protein was observed 72 hrs post administration 
in both routes of administration which may indicate volume depletion; however, both 
BUN and Creatinine significantly decreased or were not altered suggesting a lack of renal 
stress. Moreover, hypoproteinemia is more commonly reported in NSAID toxicity (Kivett 
et al., 2013). Although a mild increase of AST is observed following PO administration, 
GGT significantly decreased following both routes of administration potentially 
suggesting an extrahepatic origin for the mild increase in AST.  Previous studies 
evaluating the safety of firocoxib in horses indicate the development of ulcers and 
nephropathies are associated with multiplicative increases in the recommended dose 
administered daily for a prolonged time period. Mild increases in BUN
11
 and creatinine 
were observed in horses receiving 1 – 5 X the dose for 42 days whereas additional 
increases in AST
12
, GGT, and ALT
13
 were reported in horses receiving 12.5 X the dose 
for 92 days (US FDA, 2005). Further studies evaluating the safety of firocoxib in calves 
are required.   
A prolonged half-life for both routes was observed in this study which was shorter 
than that reported in horses and longer than in dogs (Kvaternick et al., 2007; McCann et 
                                                 
10
 GGT: γ-glutamyltransferase 
11
 BUN: blood urea nitrogen 
12
 AST: aspartate aminotransferase 
13
 ALT: alanine aminotransferase 
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al., 2004). As such, administration of firocoxib in preweaned calves potentially supports a 
once daily administration.  In cattle, this dosing strategy related to its long half-life is 
more similar to meloxicam compared with other commonly administered NSAIDs with 
shorter half-lives such as flunixin meglumine (6 h) and ketoprofen (2 h) (Mosher et al, 
2012; Glynn et al, 2013; Igarza et al., 2004).  Taken together, the dosing strategy and 
ease of administration potentially promote treatment compliance.     
The reported half-life was most likely a result of a low clearance observed 
commonly with NSAIDs as well as the large volume of distribution observed for both PO 
and IV routes.  The large volume of distribution is also reported in horses and dogs and 
atypical of most NSAIDs due to their high protein binding (Kvaternick et al., 2007; 
McCann et al., 2004). Although protein binding percentage was not determined in this 
study, 97% of firocoxib is reported to be protein bound in the horse (Kvaternick et al., 
2007). Most likely the large volume of distribution is influenced by the lipophilic 
property of the compound. Moreover, a larger volume of distribution is observed in 
young animals potentially due to decreased protein concentrations resulting in increased 
concentrations of unbound drug (Notarianni, 1990).  
Firocoxib was well absorbed following oral administration. This high 
bioavailability is similarly reported in horses and dogs as well (Kvaternick et al., 2007; 
McCann et al., 2004). In the present study, the provided milk feedings may have 
impacted absorption and distribution of the PO administered firocoxib due to altered 
protein-feed binding in the digestive tract as observed with other NSAIDs (Mosher et al, 
2012; Toutain et al, 2004).  
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A mean Cmax
14
 of 128 ng/mL with a mean Tmax
15
 of 4 h was observed following 
oral administration. A comparison of dose-normalized Cmax following a single time or the 
first dose administered in horses indicates values that are approximately 1.75 – 3 X 
greater than determined in this study in calves (Kvaternick et al., 2007; Letendre et al., 
2008). However, AUC
16
 is similar between horses and calves in a dose-normalized 
comparison (Kvaternick et al., 2007; Letendre et al., 2008). Taken together, the extent of 
absorption appears similar between horses and calves, although the rate of absorption 
may be slower in calves.   
The suggestive advantages of a selective COX-2 inhibitor would provide 
continued mitigation of inflammatory mediator production with a decrease risk of side 
effects (Bergh et al., 2005).  The highly selective inhibition of COX-2 isoenzyme has 
been described in both the dog (384 X) and the horse (265- 643 X) (McCann et al., 2002; 
McCann et al., 2004; Kvaternick et al., 2007). Using data generated from an in-vitro 
LPS
17
-stimulation of whole equine blood, the IC50
18
 and IC80
19
 of COX-2 was calculated 
to be approximately 30 ng/ml and 67 ng/ml respectively (McCann et al., 2002; Letendre 
et al., 2008). Moreover, although these concentrations are achieved following 
administration of the labeled PO dose, clinical differences were not detected in 
chronically lame horses using a higher than labeled dose (Back et al., 2009). In the 
present study, mean concentrations of firocoxib in calves remained above these reported 
equine COX-2 IC50 and IC80 for 48 h and 24 h respectively following PO administration 
                                                 
14
 Cmax: maximum plasma concentration 
15
 Tmax: time to maximum concentration 
16
 AUC: area under the curve 
17
 LPS: lipopolysaccharide 
18
 IC50: 50% of maximum inhibitory concentration 
19
 IC80: 80% of maximum inhibitory concentration 
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and 12 h and 24 h, respectively following IV administration. Studies to evaluate both 
COX selectivity and inhibitory concentrations are needed in bovines.  
Given specific required guidelines are followed, extra-label drug use in the United 
States is permitted under Animal Medicinal Drug Use Clarification Act (AMDUCA)
20
 
 (US FDA, 1994). As there are no labeled pharmaceuticals for the treatment or control of 
pain in cattle and the currently labeled NSAID for cattle in the US has undetermined 
analgesic properties following a single administration in preweaned calves, the use of 
firocoxib would constitute extra-label drug use permitted under AMDUCA.  Importantly, 
no violative tissue residues may result from extra-label administration. Currently, the 
European Union regulatory agency recommends a slaughter withhold of 26 days in 
horses administered a dose 5 X less than that administered in this study (European 
Medicines Agency, 2010). Given the large volume of distribution and lipophilic 
properties of firocoxib, further studies evaluating tissue residues would need to be 
performed prior to recommendation of withholding times in preweaned calves.  
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Figure 1. Mean ± SE serum concentrations of firocoxib at various points after IV (0.5 
mg/kg) administration of the drug to 10 healthy calves. 
  
101 
 
 
 
Figure 2. Mean ± SE serum concentrations of firocoxib at various points after PO (mean 
dose, 0.5 mg/kg; range, 0.48 to 0.52 mg/kg; circles) administration of the drug to 10 
healthy calves. 
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Table 1. Mean ± SEM plasma biochemistry and hematology analytes obtained prior to (PRE) and 72 h following (POST) both IV and 
PO firocoxib administration in study calves (n=10).  
Parameter 
Reference 
Range 
IV PO 
Mean ± SEM 
(PRE) 
Mean ± SEM 
(POST) 
Mean ± SEM 
(PRE) 
Mean ± SEM 
(POST) 
White Blood Cell 
(x10
3
/ul) 
4.0- 12.0 7.9 ± 0.7 7.2 ± 0.6 8.2 ± 1.0 8.7 ± 1.0 
Neutrophils 
(x10
3
/ul) 
0.6- 4.0 3.0 ± 0.6 1.8 ± 0.3 3.0 ± 0.9 3.1 ± 0.6 
Lymphocyte 
(x10
3
/ul) 
2.5-7.5 4.2 ± 0.4 4.5 ± 0.3 4.3 ± 0.2 4.6 ± 0.2 
Red Blood Cells 
(x10
6
/ul) 
5.0 – 10.0 7.2 ± 0.5 7.0 ± 0.4 6.8± 0.3a 7.3 ± 0.3a 
Hematocrit (%) 24 – 46 25 ± 2a 24 ± 2a 20 ±2 21 ± 2 
BUN   (mg/dl) 10 – 25 12 ± 0.5 11 ± 0.6 7 ± 0.7a 5 ± 0.6a 
Creatinine 
(mg/dl) 
0.5 – 2.2 1.1 ± 0.04 1.1 ± 0.04 1.0 ± 0.04a 0.9 ± 0.03a 
Total Protein 
(gm/dl) 
6.7 – 7.5 6.5 ± 0.1a 6.8 ± 0.1a 6.5 ± 0.1a 6.9 ± 0.1a 
Albumin (gm/dl) 2.5 – 3.8 2.6 ± 0.04a 2.7 ± 0.05a 2.7 ± 0.04a 2.8 ± 0.05a 
AST     (IU/L) 55 – 125 53 ± 4 54 ± 3 44 ± 3a 50 ± 2a 
ALP     (IU/L) 25 – 250 178 ± 14 166 ± 14 211 ± 21 244 ± 25 
GGT     (IU/L) 0 – 74 236 ± 33a 176 ± 22a 88 ± 8a 70 ± 6a 
a
 – P<0.05; BUN – blood urea nitrogen; AST – aspartate aminotransferase; ALP – alkaline phosphatase; GGT – γ-glutamyltransferase  
1
0
2
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Table 2. Pharmacokinetic parameters for firocoxib administered IV (0.5 mg/kg) to 10 
healthy calves.  Data were fit to a 2-compartment model with first-order elimination.  
Parameter 
IV 
Geometric 
mean 
Minimum Median Maximum 
AUC (h•ng/mL) 4109.5 3190.8 4248.9 4996.9 
A (ng/ml) 388.8 325.3 367.0 498.3 
B (ng/ml) 30.6 5.8 32.6 88.8 
K10 (l/h) 0.104 0.072 0.110 0.152 
K12 (1/h) 0.049 0.020 0.049 0.124 
K21 (1/h) 0.031 0.006 0.034 0.069 
T1/2 K10 (h) 6.7 4.6 6.3 9.7 
α (1/h) 0.17 0.10 0.18 0.26 
T1/2α (h) 4.0 2.7 3.9 7.2 
β (1/h) 0.019 0.004 0.022 0.029 
T1/2β (h) 37.2 23.5 31.8 160.4 
Vc (L/kg) 1.17 0.95 1.16 1.43 
Vss (L/kg) 3.10 2.10 2.93 7.22 
Varea (L/kg) 6.54 4.01 5.38 23.66 
CL (mL/h/kg) 121.7 100.0 117.7 156.7 
AUC – area under the plasma drug concentration curve; A – Y-intercept for the 
distribution phase; B – Y-intercept for the elimination phase;  K10 – elimination rate 
constant for central compartment; K12 – intercompartmental distribution rate constant 
from central to peripheral compartment;  K21 – intercompartmental redistribution rate 
constant from peripheral to central compartment;  T1/2 K10 – elimination half-life; α – 
distribution slope; T1/2α – distribution half-life; β – elimination slope; T1/2β – terminal 
half-life; Vc – volume of distribution of the central compartment; Vss – volume of 
distribution in a steady state; Varea – volume of distribution during the elimination phase;  
CL – plasma clearance  
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Table 3. Pharmacokinetic parameters for firocoxib administered PO (mean dose, 0.5 
mg/kg; range, 0.48 to 0.52 mg/kg) to 10 healthy calves.  Data were fit to a 1-compartment 
model with first-order elimination.  
Parameter 
PO 
Geometric 
mean 
Minimum Median Maximum 
AUC (h•ng/mL) 4043.8 3190.5 3931.0 5617.0 
Cmax (ng/mL) 127.9  102.5 128.5 151.3 
Tmax (h) 4.0  2.6 4.0 5.6 
K01 (l/h) 0.815 0.492 0.801 1.473 
K10 (l/h) 0.037 0.027 0.037 0.049 
T1/2 K10 (h) 18.8  14.2 18.9 25.5 
V/F (L/kg) 3.36 2.86 3.27 3.91 
CL/F (mL/h/kg) 123.6  89.0 127.2 156.7 
F (%) 98.4 83 96 118 
AUC – area under the plasma drug concentration curve; Cmax – maximum plasma 
concentration; Tmax – time to maximum plasma concentration; K01 –absorption rate 
constant for central compartment;  K10 – elimination rate constant for central 
compartment; T1/2 K10 – elimination half-life; V/F – volume of distribution per 
bioavailability; CL/F – plasma clearance per bioavailability; F – Bioavailability 
calculated from data collected from both study populations 
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CHAPTER 4 
THE EFFECTS OF FIROCOXIB ON CAUTERY DISBUDDING PAIN AND 
STRESS RESPONSES IN PREWEANED DAIRY CALVES 
Modified from a manuscript accepted for publication in the Journal of Dairy Science 
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Abstract 
Perioperative analgesic effects of oral firocoxib following cautery disbudding 
were investigated in preweaned calves. Twenty Holstein calves approximately 4-6 weeks 
old received a single oral dose of firocoxib, a non-steroidal anti-inflammatory, at 0.5 
mg/kg (n=10) or placebo (n=10) in a randomized controlled clinical trial.  Responses, 
including ocular temperature determined by infrared thermography, pressure algometry 
measuring mechanical nociception threshold, and heart rate, were evaluated at 2, 4, 7, 8, 
and 24 h after cornual nerve block and cautery disbudding. Blood samples were collected 
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over 96 h and analyzed for plasma cortisol and substance P concentrations by 
radioimmunoassay. Additionally, ex-vivo prostaglandin E2 concentrations were 
determined over a 72 h study period using an enzyme immunoassay. Data were analyzed 
using a linear mixed effects model with repeated measures. An inhibition of ex-vivo 
PGE2 synthesis was observed from 12 to 48 h following disbudding in calves treated with 
firocoxib. Cautery disbudding was associated with an increased nociception for the 
duration of sampling (24 h). During the initial 24 h period following disbudding, there 
was no difference in response between treatment groups. Following 24 h, mean cortisol 
concentrations diverged between the two study groups with placebo treated calves having 
increased cortisol concentrations at approximately 48 h after disbudding. Furthermore, 
the overall integrated cortisol response as calculated as area under the effect curve tended 
to be reduced in firocoxib treated calves. The prolonged effects of cautery dehorning 
require further investigation.  Moreover, the effect of firocoxib on cortisol reduction 
observed in this study requires additional exploration.  
 
Introduction 
 Dehorning or disbudding cattle is a management procedure commonly performed 
on nearly 95% of US dairy operations (USDA, 2010). Horns or horn buds are primarily 
removed to accommodate production practices and prevent economic loss due to 
carcass bruising. Many techniques have been described with the use of a hot iron 
reported to be the most commonly employed method in the United States (USDA, 
2010). Although the American Veterinary Medical Association (2012) supports 
methods to minimize pain and distress associated with disbudding and dehorning, 
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methods to evaluate this response can be challenging given the need to use indirect 
measures to assess an affect state. 
 Behavioral, physiologic, and neuroendocrine changes have been reported 
following disbudding or dehorning (Stafford and Mellor, 2005; Stock et al., 2013). 
These observed and reported responses are frequently interpreted as being associated 
with pain and distress (Faulkner and Weary, 2000; McMeekan et al., 1998; Heinrich et 
al., 2010; Stewart et al, 2008). More specifically, indirect measures such as changes in 
the hypothalamic-pituitary-adrenal (HPA) axis activation resulting in cortisol release 
(McMeekan et al., 1998), mechanical nociception threshold (Heinrich et al., 2010), 
autonomic nervous system response (Stewart et al., 2008), and behavior (Faulkner and 
Weary, 2000) have been previously used to assess the pain and distress associated with 
disbudding in calves. The concurrent evaluation of several indices may improve the 
assessment of pain and distress in animals due to individual response variations  
(Molony and Kent, 1997).  
 As a consequence of disbudding or dehorning, acute changes in cortisol release 
(McMeekan et al., 1998), local nociception (Heinrich et al., 2010), ocular temperature 
and heart rate (Stewart et al., 2008), and head shakes and ear flicks (Faulkner and 
Weary, 2000; Stilwell et al., 2009) are reported. Local anesthetics have been useful in 
mitigating these acute effects following removal of the horns or horn buds (McMeekan 
et. al, 1998; Stewart et al., 2008; Stilwell et al., 2009); however, these local anesthetics 
typically demonstrate only temporary reduction of these observed responses once the 
local anesthetic is no longer effective (Doherty et al., 2007; Heinrich et al., 2009; Allen 
et al., 2013).  
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 Subsequent to the initial tissue damage involved with horn removal, continued 
cortisol and behavioral changes are observed which may be due to inflammation-related 
pain (McMeekan et al., 1998; Stafford and Mellor, 2005). Behavior responses are 
reported to persist up to 24 to 44 h (Faulkner and Weary, 2000; Heinrich et al., 2010). 
Non-steroidal anti-inflammatory drugs (NSAIDs) including ketoprofen (Faulkner and 
Weary, 2000), meloxicam (Heinrich et al, 2009), carprofen (Stilwell, 2012), and 
flunixin (Glynn et al., 2013; Huber et al., 2013) reduce responses associated with pain 
and distress following dehorning or disbudding.  In order to address both the initial and 
continued responses, a multimodal approach using analgesics that act both acutely and 
at length have been proposed (Stafford and Mellor, 2011)  
 Currently, there are no compounds specifically approved to alleviate pain in 
livestock in the United States (Coetzee, 2013).  Concerns of efficacy and administration 
frequency necessary to maintain analgesia concentrations have been discussed due to 
the number of analgesic drugs available in the United States with short elimination half-
lives (Coetzee, 2011). Heinrich and colleagues (2010) demonstrated the administration 
of meloxicam, an NSAID with a long half-life in cattle, reduced both the acute 
response, which included reductions in cortisol concentrations, local sensitivity as well 
as the prolonged pain-related behaviors. As such, the use of an NSAID with a long half-
life in calves may be the most ideal for pain management.  Moreover, since feed is 
potentially the most practical and pain-free drug delivery method that can be applied in 
commercial livestock production systems, analgesics administered orally should be 
explored. Given the diversity of the pharmacologic properties of NSAIDs, continued 
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investigation for optimal pain relief for disbudding and dehorning pain will benefit 
animal welfare. 
Firocoxib is an NSAID of the coxib class with a prolonged elimination half-life 
and high oral bioavailability in calves (Stock, et al., 2014).  As a potential additional 
benefit, firocoxib is COX-1 sparing in both the horse and dog, which may reduce adverse 
effects (McCann et al., 2002, 2004). The objective of this study is to measure the effects 
of firocoxib on pain and distress in pre-weaned dairy calves immediately prior to cautery 
disbudding. In addition, we assess the neuroendocrine, nociception, and physiologic 
responses observed following cautery disbudding.   
 
Materials and Methods 
Animals and Housing 
 Twenty Holstein calves (11 male and 9 female), 4-6 weeks of age (mean ± SD: 
32.9 ± 3.9 days) weighing 55.2 ± 5.8 kg at the time of disbudding were obtained from 
the Iowa State University Dairy. All calves were determined healthy following a 
physical examination by a veterinarian and normal findings on a complete blood count 
and serum chemistry.  This study protocol was approved by the Institutional Animal 
Care and Use Committee at Iowa State University (Log#: 10-12-7443-B). 
 Study animals were housed in individual three sided closed pens (1.82 m x 1.22 
m) bedded with straw added daily in an enclosed facility at the Iowa State University 
Dairy. Calves are placed in these pens at birth and remained within the pens through the 
entirety of the study. While in these pens, calves have minimal physical contact with 
other calves, although contact to neighboring calves is possible during feeding through 
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the one open side.  Three liters of pasteurized waste milk were fed twice daily for the 
length of the study. In order to control for the variation in waste milk components, both 
treatment groups were given milk from the same batch pasteurization. Calves were fed 
grain, consisting primarily of pelleted corn, oats, molasses and protein/vitamin/mineral 
supplement, and offered water ad libitum. Grain was added daily at 0.45 - 0.90 kg. 
Daily examinations were conducted by a veterinarian, including the monitoring of milk 
consumption and a subjective assessment of grain and water consumption throughout 
the study period.  
 
Study Design  
 A randomized complete block design was used for this investigation with 10 
calves enrolled in each treatment group (Figure 1). The study was conducted in two 
Periods. Calves were enrolled into a treatment group during Period 1 and remained in 
that treatment group for Period 2. Period 1 was conducted two-weeks prior to Period 2. 
Disbudding only occurred during Period 2. The purpose of Period 1 was to obtain IV 
firocoxib concentrations in calves used in a subsequent pharmacokinetic analysis 
(Stock et al., 2014). In Period 1, study animals were blocked by age and randomly 
assigned to receive either firocoxib (0.5 mg/kg) (n=10; male=7) or a placebo (n=10; 
male=4). Randomization of group assignment was mediated by a computer generated 
random number (Microsoft Excel 2011, Microsoft Corp., Redmond, WA, USA). 
During Period 1, calves assigned to the firocoxib group received intravenous firocoxib 
(Equioxx® Injection, NADA 141-313, Merial LLC, Duluth, GA) whereas calves in the 
control group received intravenous saline via a preplaced jugular catheter followed by 
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multiple timed blood collections.  As such, calves in both treatment groups were 
identically handled and experienced placement and maintenance of an indwelling 
catheter prior to Period 2. Following a 14-day washout period from Period 1, 
concentrations of firocoxib were not detected at the start of Period 2. Period 2 was 
conducted in two trials using 10 animals per trial which were balanced for treatment 
(n=5 calves / treatment / trial). The two trials were initiated in consecutive days. In 
Period 2, calves previously receiving IV firocoxib now received oral firocoxib 
(Equioxx® Oral Paste, NADA 141-253, Merial LLC, Duluth, GA) and control calves 
received an oral whey protein placebo (Body Fortress, Bohemia, NY).  
 A jugular catheter was used for blood sample collection. Placement of the jugular 
catheter occurred approximately 12 hours prior to the start of the investigation. A 
handler manually restrained the calves and the area over the jugular vein was clipped 
and surgically prepared with alternating scrubs of 70% isopropyl alcohol and povidone 
iodine. The catheter site was infiltrated with 2% lidocaine injection, 1 mL 
subcutaneously (Hospira Inc, Lake Forest, IL).  Using sterile technique, an 18 G x 55 
mm intravenous catheter (SURFLO®, Terumo Medical Corp., Somerset, NJ) was 
inserted into the vein and sutured to the skin using #3 nylon suture (Ethilon™, Ethicon, 
San Lorenzo, PR).  An injection port (Hospira Inc, Lake Forest, IL) was subsequently 
attached and disinfected with an alcohol swab prior to sample collection. Catheter 
patency was maintained by flushing with 3 mL of a heparin saline solution containing 3 
USP units heparin sodium/mL saline (Heparin Sodium Injection, Baxter Healthcare, 
Deerfield, IL). 
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 Calves assigned to receive firocoxib were administered a single oral dose of 0.5 
mg/kg. Oral firocoxib was administered in a commercially provided dosing syringe 
with syringe weights obtained before and after administration to confirm the dose 
administered. The dose was rounded to the nearest 50 pounds as designated by the 
increments provided on the syringe. Using a concentration of 0.82% firocoxib, the 
actual mean dose of 0.5 mg/kg (range: 0.48 – 0.52 mg/kg) was administered to the 
calves as an oral paste in a dosing syringe. Control animals received an equivalent 
amount of whey protein mixed with water to a similar consistency as the firocoxib 
paste and administered via a similar shaped, voided dosing syringe. In order to control 
for the influence of milk feeding on absorption, all calves were given their milk feeding 
immediately after disbudding, approximately 10 minutes post-firocoxib or placebo 
administration. In relation to disbudding, this feeding time was the same for both 
treatment groups. 
 
Disbudding 
Disbudding was performed in 10 minute intervals by a single, experienced 
veterinarian and the same handler to minimize variation. The disbudding order was 
randomized between treatment groups to control for variation in start time. Cautery 
disbudding was initiated 10 minutes following administration of the local anesthetic and 
oral treatment. All calves received a local anesthetic prior to cautery disbudding. 
Desensitization of the cornual tissue was provided via a cornual nerve block using 2% 
lidocaine (VetOne®, Boise, ID) (5 ml / site) as described by Stock and others (2013). 
Desensitization of the cornual tissue was confirmed using behavior reactions (e.g. ear 
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flicks, head shaking, strong escape behavior) to a needle prick 5 minutes after 
administration of the cornual nerve block. Administration of lidocaine (1-2 ml) was 
repeated in the same manner described above if a response was observed to the initial 
needle prick. Following confirmation of appropriate desensitization, calves were cautery 
disbudded by placement of a pre-heated butane hot-iron (approx. 600 °C) (Express 
dehorner, Guilbert Express, New York, NY) on the horn tissue for approximately 10 
seconds. 
 The disbudding sites were monitored daily for signs of discharge or infection, in 
addition to an assessment of attitude, posture, appetite, lying time, and peri-operative 
swelling. A rescue analgesia protocol of flunixin meglumine at 2.2 mg/kg, IV once 
daily for 3 days was devised if overt pain or distress was evident, such as increased 
lying time, head pressing, inflammation with major drainage of the disbudding site, 
dehydration or inappetence.  
 
Blood Sample Collection 
 Animals were restrained during blood collection by trained handlers. Prior to 
sample collection, blood was aspirated and flushed back through the catheter to 
eliminate the heparin dilution before sample collection. Baseline samples were obtained 
at approximately -1.5 h from disbudding. Plasma drug concentration was confirmed as 
undetectable at this time. Additional blood samples were collected at 15 and 30 minutes 
and 1, 2, 4, 6, 8, 10, 12, 24, 48, 72, and 96 h (-10 min) following disbudding. Sampling 
time points were determined in relation to the time drug or placebo was administered. 
Post-disbudding cortisol and substance P concentrations were subsequently analyzed in 
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relation to the time of disbudding. Samples were immediately transferred to a blood 
collection tube with either heparin for cortisol and drug concentration or 
ethylenediaminetetraacetic acid (EDTA) for substance P (Vacutainer®, BD 
Diagnostics, Franklin Lakes, NJ) and stored on ice before processing. EDTA tubes 
were spiked with 1 mM of benzamidine (Santa Cruz Biotechnology, Santa Cruz, CA) 
prior to blood collection.  Blood samples were centrifuged for 15 minutes at 1,500g at 
room temperature. Collected plasma was placed in cryovials and frozen at -70 °C until 
analysis. 
 
Cortisol 
 Plasma cortisol samples were determined using a commercial radioimmune assay 
kit (Coat-A-Count® Cortisol, Siemens Medical Solutions Diagnostics (formally 
Diagnostic Products Corp.), Los Angeles, CA) previously used for bovine plasma 
(Stilwell et al, 2008; Rialland et al, 2014). Samples were assayed in duplicate with the 
reported concentration equaling the average cortisol concentration between duplicates. 
Samples were reanalyzed if there were subjectively large discrepancies between the 
duplicates. The average intra- and inter-assay coefficients of variation were 12.8 and 
13.2%, respectively. Area under the effect curve (AUEC) was calculated using the 
linear trapezoidal rule as previously described (Glynn et al., 2013).  
 
Substance P  
Substance P (SP) concentrations were analyzed as described by Van Engen and 
others (2013) using non-extracted plasma.  Samples were assayed in duplicate with the 
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reported concentration equaling the average SP concentration between duplicates.  The 
coefficient of variation for intra-assay variability was at 7.9% and the inter-assay 
variability was calculated at 7.7%. 
 
Prostaglandin E2  
Ex-vivo prostaglandin E2 (PGE2) synthesis inhibition was determined as described 
by Fraccaro and others (2013). Blood collected at 4, 8, 12, 24, 48, and 72 h from calves 
was placed into sterile vacuum tubes containing heparin. LPS obtained from E. coli 
0111:B4 (Sigma-Aldrich, Co. St. Louis, MO) in PBS was added at 10 µg/mL to the 
heparinized whole blood and incubated for 24 h at 37°C. Baseline samples were 
incubated with and without LPS. At the end of incubation, all samples were centrifuged 
at 400 g for 10 minutes at room temperature to obtain plasma. Methanol was added to 
plasma in a 1:5 plasma to methanol dilution, facilitating protein precipitation. Following 
centrifugation at 3,000 g for 10 minutes, the supernatant was collected and stored at -80 
°C. A commercial PGE2 ELISA kit (Cayman Chemical, Ann Arbor, MI) previously 
described using methanol precipitated bovine plasma was used for determination of PGE2 
concentration (Donalisio et al., 2013; Fraccaro et al, 2013). The coefficient of variation 
for intra-assay variability was at 8.9% and the inter-assay variability was calculated at 
12.2%. 
 
Nociception and Autonomic Nervous System Responses 
 Calves were restrained using a modified calf-restraining device (Easy B-Z 
Portable Calf Restraint, eNasco, Fort Atkinson, WI) approximately 10 minutes prior to 
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determination of ocular temperature (OT), heart rate (HR), and mechanical nociception 
threshold (MNT). Additionally, following infrared thermography imaging and heart 
rate determination, calves were blindfolded for MNT to avoid withdrawal reflex based 
on visual cues. Baseline samples for OT, HR, and MNT were obtained on the same day 
for both trials thus 16 and 21 hours prior to initiation of the first trial and 38 and 42 
hours prior to initiation of the second trial. Baseline data for each animal were averaged 
for use in statistical analysis. In addition to baseline samples, response variables were 
collected at approximately 2, 4, 7, 8 and 24 h post-disbudding. All individuals 
collecting data were blinded to calf treatment group assignment. 
  
 Infrared Thermography. 
 A thermography camera (FLIR SC 660, FLIR Systems AB, Boston, MA) with a 
thermal sensitivity of 0.05 Celsius, 320 x 240 pixel display, precision > 98%, supported 
by research grade data analysis software, was utilized to quantify changes in ocular 
temperature. The camera was internally calibrated to ambient temperature prior to 
image collection; however additional minute adjustments to ambient temperature and 
humidity were utilized during software processing. Images were obtained from the left 
side of the calf, at an approximately 45° angle, and 0.5 meter distance from the eye. 
Maximum temperature (°C) within a circumferential area of the eye including the 
medial posterior palpebral border of the lower eyelid and the lacrimal caruncle was 
obtained as previously described (Stewart et al., 2008). Images were analyzed using 
FLIR Tools (v. 4.1; FLIR Systems Inc, Boston, MA) following collection. At each 
timepoint, three images were obtained and averaged for statistical analysis. 
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 Heart Rate.  
 Heart rate was evaluated via auscultation using a stethoscope (3M™, Littmann®, 
St, Paul, MN, USA) placed between the 3
rd
 and 5
th
 intercostal space and beats were 
counted over a 30 second period. The value obtained was used to calculate beats per 
minute.  
 
Mechanical Nociception Threshold.  
Pain sensitivity was measured using a hand held pressure algometer (Wagner 
Force Ten™ FDX 25 Compact Digital Force Gage, Wagner Instruments, CT, USA) 
around the disbudding site as previously described with modifications (Tapper et al., 
2011, Heinrich et al., 2010; Allen et al., 2013). Two landmark locations around each horn 
bud as well as a control landmark were used (Figure 2). The mechanical nociceptive 
threshold (MNT) was determined as the peak applied force resulting in a withdrawal 
response defined as a directed movement of the head away from the applied pressure 
(Tapper et al., 2011). Using a rate of approximately 1.0 kgf/second, the stimulus was 
applied perpendicular to the landmarks. A maximum force ceiling was established at 10 
kgf. In order to prevent bias, the mechanical nociceptive threshold output was not 
visualized by the individual operating the algometer. Moreover, the order of MNT 
landmarks and the calf side from which the pressure algometrist stood to apply the 
stimulus was randomized between each calf to control for potential effects on MNT 
determination. Each algometry site was assessed three times for each timepoint with the 
values averaged for the statistical analysis.   
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Average Daily Gain 
 Animals were weighed using a Way-Pig® 505 (Raytec Manufacturing, Ephrata, 
PA) scale 24 hours prior to the disbudding (d -1), and 7 days following disbudding (d7). 
Average daily gains were calculated by dividing the total weight gained between 
measurements and then dividing by the number of days. 
 
Statistical Analysis 
 Analyses were performed in SAS 9.3 (SAS Institute, Cary NC) using a linear 
mixed effects model with repeated measures. Data obtained from response variables 
including MNT, cortisol, substance P, and PGE2 were log transformed for normality. 
Baseline values were used as covariates for all variables analyzed. The fixed effects 
were treatment (firocoxib, placebo), time, the interaction between treatment and time. 
The effect of sex was tested in the statistical model and since there was no effect 
(P>0.1), sex of calf  was removed to improve the fit of the statistical analysis. Trial was 
a random effect and calf was the subject of repeated measures. F-tests were used to test 
the significance of main effects and interactions. If significant overall differences were 
identified among levels of a factor, pairwise comparisons were performed using 
Tukey's t-tests. Additionally, paired t tests were performed to test the differences 
between response variable baselines as well as LPS-stimulated and unstimulated 
baseline ex-vivo PGE2 concentrations.  Statistical significance was designated as a P 
value < 0.05; P values ranging between 0.05 and 0.1 were discussed as a tendency to 
significance. 
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Results 
No animals required rescue analgesia or were removed throughout the course of 
the study. There was no effect of sex observed on any measured responses (P>0.1). As 
such, sex was removed from the statistical analysis.  
 
Cortisol 
Mean cortisol concentrations were not significantly different between treatment 
groups (P=0.80) (Table 1). Both a time effect (P<0.0001) and time x treatment interaction 
(P=0.0076) were observed in cortisol concentrations throughout the 96 h sampling period 
(Table 1). Initially, cortisol concentrations increased following disbudding, peaking, on 
average, at approximately 20 minutes following the hot-iron procedure. Mean cortisol 
concentrations decreased thereafter. At 50 minutes post disbudding, placebo-treated 
calves had a significant reduction (2.2 nmol/L) in cortisol concentrations compared with 
firocoxib treated calves (P=0.012) (Figure 3a).  In contrast, at approximately 48 h post-
disbudding, a significant increase in cortisol concentrations was observed in placebo 
treated calves compared with firocoxib treated calves (22.8±2.9 nmol/L  vs. 11.5±1.7 
nmol/L) (P=0.0006) (Figure 3b). Furthermore, the integrated cortisol response calculated 
as the area under the effect curve (AUEC) tended to be reduced in firocoxib treated 
calves (1157.0±179 nmol.h/L vs. 1610.8±255 nmol.h/L) (P=0.093) (Figure 4).  
Substance P 
Mean±SE substance P concentrations in firocoxib treated calves (22.7±0.7 pg/ml) 
were not significantly different compared with calves receiving placebo (20.8±0.4 pg/ml) 
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(P=0.61) (Table 1). Additionally, there was no effect of time (P=0.42) or a time x 
treatment interaction (P=0.66) observed for the 96 h sampling period.  
 
Prostaglandin E2 
Due to laboratory error in sample processing, samples collected and processed for 
ex-vivo PGE2 synthesis at 4 and 8 h were removed from the statistical analysis. An 
overall treatment effect was observed with PGE2 synthesis reduced in firocoxib treated 
calves (770.4±97.9 pg/ml) compared with placebo treatment (1,249.7±105.5 pg/ml) 
(P=0.0012). Moreover, an effect of time (P<0.0001) and a time x treatment interaction 
(P=0.019) was observed. Firocoxib treatment resulting in decreased PGE2 concentrations 
at 12 h (P<0.0001), 24 h (P=0.0073), and 48 h (P=0.0005) (Figure 5). At 72 h, no 
difference was observed between treatment groups (P=0.34). Baseline LPS-stimulated 
blood resulted in a significant increase in PGE2 concentrations compared to non-LPS 
stimulated control samples for both treatment groups (P<0.0001).  
 
Infrared thermography 
Mean ocular temperatures were not significant between treatment groups 
(P=0.85). A time effect was observed in ocular temperature response following 
disbudding (P<0.0001) (Table 1) (Figure 7). For both firocoxib and placebo treated 
calves, ocular temperatures numerically decreased 0.12±0.10 °C and 0.15±0.10 °C from 2 
to 4 h following disbudding.  Ocular temperature significantly increased thereafter with a 
mean peak temperature recorded at 8 h for both treatment groups. Additionally, a 
significant temperature reduction was observed 24 h post-disbudding for both treatment 
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groups in comparison to all previous time points, including baseline (P<0.0001). No 
interaction between time and treatment (P=0.98) was observed.  
 
Heart rate 
No treatment effects were observed between treatment groups (P=0.96). A time 
effect was observed with heart rate altered following disbudding (P=0.019) (Table 1). 
There was no time x treatment interaction (P=0.16). Interestingly, heart rate significantly 
decreased in firocoxib treated calves 24 hours post-disbudding compared to both 7 h 
(P=0.021) and 8 h (P=0.0030). This response was not observed in placebo treated calves.  
 
Mechanical Nociception Threshold (MNT) 
Numerically, firocoxib treated calves tolerated more pressure around the horn bud 
area (1.15±0.16 kg) compared to placebo treated controls (0.96±0.14), however this 
effect was not significant (P=0.56) (Table 1). Overall there was a time effect on MNT 
(P<0.0001). Post-disbudding measurements were reduced below baseline values 
throughout the 24 hour testing period (Figure 6).  There was no evidence of an interaction 
of time and treatment (P=0.84).  
 
Average Daily Gain 
Initial weights were determined the day prior to disbudding. The mean weights 
(LSM±SE) prior to disbudding were 55.5±1.7 kg and 55.0±2.0 for the firocoxib and 
placebo groups, respectively. All calves gained weight throughout the study period with 
final mean weights (LSM±SE) equaling 59.1±2.0 and 59.0±2.4 for firocoxib and placebo 
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treated groups, respectively. There was no difference in average daily gain for firocoxib 
and placebo treated calves (0.5±0.1 kg vs. 0.5±0.1 kg) (P=0.61) (Table 1). 
 
Discussion 
Cautery disbudding in calves resulted in an increased cortisol concentrations as 
well as an increased sensitivity as determined by mechanical nociception threshold.  
Moreover, changes in nociception persisted throughout the 24 h study period where local 
pressure tolerated by calves did not return to baseline values. Firocoxib administration 
did not alter the tested responses observed between treatment groups over the initial 24 h 
period; however, cortisol concentrations between treatment groups diverged at 48 h post-
disbudding where firocoxib treated calves had reduced cortisol concentration. 
Furthermore, the integrated cortisol response tended to be decreased in firocoxib treated 
animals compared with calves administered a placebo. These differences observed 
following the initial 24 h could be attributed to the administration of an NSAID with 
persistent concentrations; however, additional study is required to determine its long-term 
effects. 
Historically, perioperative analgesics administered to calves prior to dehorning or 
disbudding  have used non-steroidal anti-inflammatories (NSAIDs) that have data, both 
public and proprietary, to support an anti-inflammatory claim (Stilwell et al. 2009; 
Heinrich et al, 2010; Duffield et al., 2010; Glynn et al. 2013). This aids in the dose 
determination for an investigation into its analgesic potential. However, for this study 
there is no information publicly available concerning the analgesic use of firocoxib in 
preweaned calves. As such, the dose of 0.5 mg/kg used in this study was based on 
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pharmacokinetic information available in the horse labeled for use at 0.1 mg/kg. The 
equine approved dose demonstrated analgesia in naturally occurring lameness following 
multiple daily doses (Orsini et al., 2012). More recently, it has been suggested to use a 
loading dose in horses to achieve steady state drug concentrations more quickly (Cox et 
al., 2013). As a result, effective concentrations may be reached more quickly. In our 
study, a one-time dose administration was anticipated for the practical application of this 
analgesic in calves. As such, the increased dose compared with the horse was chosen to 
best provide potentially effective concentration of drug as well as remain practical in its 
administration. However, we cannot rule out that differences in pharmacokinetic 
properties of firocoxib between species may also have contributed to the differences in 
analgesic response. 
A primary property of most NSAIDs is reducing eicosanoid production via 
inhibition of cyclooxygenase isoenzymes. Therefore, a potential method of dose 
evaluation involves an investigation into a drugs ability to decrease PGE2 concentrations, 
a major eicosanoid metabolite associated with inflammation and nociception signaling 
threshold reduction (Basbaum et al., 2009). An investigation of the PGE2 in this study 
indicates the administered dose reduced ex vivo PGE2 synthesis from 12 to 48 h 
compared to placebo treated controls. Although further evaluation is required to 
determine concentrations necessary to achieve analgesia, it should be noted that the 
administration of firocoxib at the study dose attained concentrations necessary to 
significantly inhibit ex-vivo PGE2 concentrations for at least 2 days. This is similar to the 
findings of Allen and others (2013) who observed a suppression of ex-vivo PGE2 
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synthesis for 48 h after oral administration of meloxicam at 1 mg/kg at the time of 
disbudding. 
During the first 24 h, cortisol concentrations were similar over time for both 
treatment groups. Although placebo treated calves had decreased cortisol concentrations 
50 minutes post-disbudding, the effect size was small and the response may be 
confounded with the desensitization of the local anesthetic. The initial increase in cortisol 
concentrations peaking at 20 minutes post-disbudding and returning to pre-treatment 
levels within approximately 1 h is similar to that presented in previous literature (Stafford 
and Mellor, 2005). Moreover, in combination with a local anesthetic, the use of cautery 
following amputation dehorning nearly eliminated the cortisol response for 24 h 
(Sutherland et al, 2002) to 36 h (Sylvester et al, 1998) after dehorning. It should be noted 
that in the former study, both lidocaine and then bupivacaine 2 h later were used to 
provide local anesthesia for a duration of 5 h (Sutherland et al., 2002). This significantly 
reduced cortisol response is also observed in lambs undergoing cautery tail docking, 
suggesting that cautery may attenuate the nociception signal below the pain threshold for 
transmission (Lester et al., 1991; Stafford and Mellor, 2011). An attenuation of this 
systemic response using cautery may contradict the MNT profile observed in this study; 
however, the pressure algometer evaluates local sensitivity surrounding the horn bud and 
may not reflect a systemic distress response. 
Following 24 h, the mean cortisol response diverges between the two treatment 
groups with placebo treated calves increasing in cortisol with a peak at approximately 48 
h post-disbudding. Using cortisol as a measure of distress, firocoxib administration may 
have mitigated the distress associated with disbudding. This statement is further 
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supported with evidence suggesting that firocoxib concentrations between 24 and 48 h 
continued to reduce ex-vivo PGE2 synthesis. Prolonged changes in cortisol associated 
with dehorning and disbudding have been difficult to routinely characterize. Morisse and 
others (1995) reported elevated cortisol concentrations 24 h post-dehorning compared to 
control calves 8 wk of age. More recently, in 8 to 10 wk old calves, Allen and others 
(2013) reported a mean increased cortisol concentration from 96 to 120 h in calves 
treated with meloxicam 12 h prior to dehorning.  Calf behavior, including ear flicks, 
grazing time, and rumination responses, provide further support that disbudding and 
dehorning pain may continue for 24 to 48 h (Heinrich et al., 2010, Faulkner and Weary, 
2000; Stafford and Mellor, 2005). These changes in cortisol and behavior may be 
mediated by an increased inflammatory response evidenced by an increased haptoglobin 
concentration reported 24 to 48 h following amputation dehorning in 6 mo old calves 
(Glynn et al., 2013). In contrast, other studies report cortisol concentrations return to and 
are maintained at baseline values 24 h (Sutherland et al., 2002) to 36 h (Sylvester et al., 
1998) in 3-4 mo or 5-6 mo old calves, respectively, that were scoop dehorned followed 
by wound cauterization.  
Substance P (SP), a neuropeptide previously indicated as a pain biomarker in 
cattle, was not different between treatment groups (Coetzee et al, 2008). Moreover, there 
was no significant change in SP over time. These data differ from other investigations 
evaluating substance P following dehorning. In 8 to 10 wk old calves, Allen and others 
(2013) reported a time by treatment interaction with a significant increase in SP 
concentrations at 120 h post-cautery dehorning in control animals compared with those 
receiving meloxicam. Furthermore, Coetzee and others (2012) reported a significant 
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reduction in SP following administration of an NSAID, meloxicam, following scoop 
dehorning in 4 to 5 mo old calves. Differences in the length of sample collection time, 
disbudding / dehorning method, and analytical method used to measure SP may be the 
reason for the observed disagreement with the present study. Moreover, age differences 
in these study populations may significantly influence SP response. Dockweiler and 
others (2013) reported a decreased response in SP in cattle castrated at ≤8 wk in 
comparison to cattle ≥6 mo. The authors suggest a reduced pain response or different 
physiological parameters contributing to this difference. Coupled with data collected in 
the present study, SP may be a poor indicator of pain in young animals.  Both in this 
study and demonstrated by Allen and others (2013), no significant differences in SP were 
reported for the first 96 h following dehorning. As SP release is thought to be associated 
with pain, evidence from this study support the hypothesis that cautery may destroy 
nearby nociceptors necessary to reach pain thresholds needed for central hyperalgesia 
transmission (Sylvester et al., 1998; Sutherland et al., 2002). It should be noted this 
hypothesis was derived from the evaluation of the cortisol response following local 
anesthesia and scoop then cautery dehorned calves greater than 3 mo of age.   
Local nociception changes persisted for 24 h in both treatment groups as observed 
in the MNT profiles such that nociception thresholds did not return to baseline values 
during the measured response period. This duration of sensitivity appears to be consistent 
with other reports indicating a prolonged response following dehorning / disbudding 
based on behavior (Faulkner and Weary, 2000; Heinrich et al., 2010) and on nociceptive 
thresholds (Tapper et al., 2011). Average MNT profiles were similar between treatment 
groups, suggesting firocoxib did not significantly demonstrate anti-nociceptive effects 
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over the 24 h investigation period post-disbudding.  This response differs from MNT 
values reported following perioperative administration of meloxicam (Heinrich et al., 
2010) and ethanol as a local anesthetic (Tapper et al., 2011). Repeated handling for data 
collection may have heightened the avoidance responses of calves in the current study 
when compared to the nociception threshold testing performed at one time point by 
Heinrich and colleagues (2010). Reduction in subtle dehorning pain related behaviors, 
such as ear flicking and head rubbing, have been associated with perioperative 
administration of meloxicam (Heinrich et al., 2010), ketoprofen (Faulkner & Weary, 
2000; Duffield et al., 2010) and carprofen (Stilwell et al., 2012), but this was not assessed 
in the current study. 
Changes to the autonomic nervous system (ANS) response including heart rate 
and ocular temperature were observed post disbudding. Although not statistically 
significant, the decrease in ocular temperature observed between 2 and 4 h most likely 
was due to the loss of the local anesthetic effect as previously described by Stewart and 
others (2009). The significant decrease of ocular temperature at 24 h for both treatment 
groups may also suggest a continued ANS response caused by disbudding; however, 
changes in temperatures due to diurnal core temperature changes or environment cannot 
by eliminated (Vickers et al., 2010; Church et al., 2014). Although prior studies have 
indicated a reduced volatility of the ANS with the use of an NSAID following cautery 
disbudding or dehorning (Stewart et al., 2009; Heinrich et al., 2009; Coetzee et al., 2012), 
no treatment differences were observed over the 24 h sampling period for both ocular 
temperature and heart rate in the present study. Animals were frequently handled prior to 
disbudding in order to help reduce response variations associated with sample collection. 
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However, responses of the autonomic nervous system may vary according to novel 
stimuli and exertion; frequent handling required for blood collection may result in 
elevated responses regardless of the administration of an analgesic. As no analgesic 
effects were noted in any response variable during the first 24 h, firocoxib administration 
at the study dose may be ineffective at managing the acute nociception and distress 
associated with cautery disbudding. 
 
Conclusion 
Evidence provided in the current study indicates cautery disbudding resulted in 
changes in nociception and cortisol concentrations. The study dose of firocoxib was 
sufficient to effectively reduce ex-vivo PGE2 synthesis, however, determination of 
analgesic concentrations require further investigation as no significant differences in 
analgesic response variables were observed in the first 24 h. As such, the relationship 
between response variables and ex-vivo PGE2 inhibition requires further exploration. 
Overall, a one-time oral administration of firocoxib reduced cortisol concentrations at 48 
h and contributed to the attenuated integrated concentration of plasma cortisol; however 
the acute response (<24 h) as measured by ocular temperature, heart rate, MNT, cortisol, 
and substance P was unaffected by treatment. Further research is needed to determine the 
significance of the prolonged cortisol response following disbudding and the potential for 
firocoxib to ameliorate this effect. 
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Table 1. Summary table of untransformed response variables of firocoxib and placebo 
treated calves post-disbudding  
Response 
Firocoxib 
LSM±SE
 
Placebo 
LSM±SE 
Treatment 
(P value) 
Time 
(P value) 
Time x 
Treatment 
(P value) 
Cortisol 
(nmol/L) 
13.1 ± 0.9 15.1 ± 1.0 0.80 <0.0001 0.0076 
Substance P 
(pg/mL) 
22.7 ± 0.7 20.8 ± 0.4 0.61 0.42 0.66 
Ocular 
temperature 
(ºC) 
37.7 ± 0.1 37.5 ± 0.1 0.85 <0.0001 0.98 
Heart rate 
(bpm) 2 
109.5 ± 1.7 109.8 ± 2.2 0.96 0.019 0.16 
MNT1 
(kgf) 
1.15 ± 0.16 0.96 ± 0.14 0.56 <0.0001 0.84 
ADG 
(kg/day) 
0.5 ± 0.1 0.5 ± 0.1 0.61 NA NA 
1
 Mechanical Nociception Threshold  
2
 Beats per minute 
  
134 
 
 
 
Figure 1. Flow Chart outlining the timing of the study events. During Period 1, firocoxib or 
placebo was administered IV to calves to provide data to be analyzed for a pharmacokinetic 
study. In Period 2, calves were disbudded and monitored for cortisol, substance P (SP), 
mechanical nociception threshold (MNT), ocular temperature (OT), heart rate (HR), average 
daily gain (ADG), ex-vivo prostaglandin E2 (PGE), and firocoxib concentration. The times in 
parentheses represent the duration of data collection for each variable. 
20 Holstein calves 
(4 – 6 weeks) 
Day -15: Enrollment, weight, randomization 
Firocoxib  
Dose: 0.5 mg/kg 
Local Anesthetic 
(n=10) 
Placebo 
Saline / Whey protein 
Local Anesthetic 
(n=10) 
Day 0: Drug or Placebo administration (PO) and cautery disbudding 
Cortisol 
(96 h) 
SP 
(96 
h) 
HR 
(24 h) 
MNT 
(24 h) 
OT 
(24 h) 
ADG 
(7 d) 
PGE
 (72 h)
 
Day -14 (Period 1: PK): Drug or Placebo administration (IV) and handling (5d) 
Day -1 or -2 (Period 2): Baseline data collection for disbudding 
Day 0-7: Data collection 
Drug 
(96 h) 
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Figure 2. Pressure algometry locations at each horn bud 
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(a)   
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Figure 3. Untransformed cortisol concentrations over 12 h (a) and 96 h (b) for firocoxib 
and placebo treated calves post cautery disbudding. Baseline values are graphically 
represented at Time 0, the time of disbudding. Significant differences (P<0.05) between 
time points are indicated by different letters (a, b).   
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Figure 4. Area under the effect curve (AUEC) of untransformed cortisol concentrations 
over the 96 h study period for firocoxib and placebo-treated calves post-disbudding. 
Values were calculated using the linear trapezoid method. * indicates differences between 
treatment groups (P=0.093). 
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Figure 5. Untransformed ex-vivo prostaglandin E2 concentrations over 72 h in firocoxib 
and placebo treated calves post-disbudding. Significant differences (P<0.05) between 
time points are indicated by different letters (a, b). Baseline values are represented at time 
0. 
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Figure 6. Untransformed Mechanical Nociception Threshold (MNT) as measured 
through pressure algometry over 24 h for firocoxib and placebo treated calves. Pressure 
tolerance did not return to baseline values by the conclusion of MNT measurement. 
Baseline values are indicated.  
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Figure 7. Untransformed ocular temperature as measured through infrared thermography 
over 24 h for firocoxib and placebo treated calves. Baseline values are indicated.  
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Abstract 
The objective of this study was to investigate the effects of carprofen 
administered immediately prior to cautery dehorning on nociception and stress. Forty 
Holstein calves aged approximately 6 to 8 weeks old were either sham dehorned (n=10) 
or cautery dehorned following administration of carprofen (1.4 mg/kg) subcutaneously 
(n=10), orally (n=10) or a placebo (n=10) in a randomized, controlled trial. All animals 
received local anesthesia via a cornual nerve block using lidocaine prior to dehorning. 
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Response variables including mechanical nociception threshold, ocular temperature, heart 
rate and respiratory rate were measured prior to and following cautery dehorning for 96 
h. Blood samples were also collected over 96 hours following dehorning and analyzed for 
plasma cortisol and substance P concentrations by radioimmune assay. Plasma carprofen 
concentration and ex-vivo prostaglandin E2 concentrations were also determined for this 
time period. Average daily gain was calculated for 7 days post dehorning. Data were 
analyzed using a linear mixed effects model with repeated measures, controlling for 
baseline values by their inclusion as a covariate in addition to planned contrasts. 
Dehorning was associated with decreased nociception thresholds throughout the study 
and a stress response immediately after dehorning, following the loss of local anesthesia, 
and 48 h post-dehorning compared to sham dehorned calves. Carprofen was well 
absorbed after administration and reached concentrations that moderately inhibited ex-
vivo prostaglandin E2 concentrations and were reduced for 72 h (SQ) and 96 h (PO) 
compared with placebo treated calves (P<0.05). Carprofen-treated calves tended to be 
less sensitive (P=0.096) to nociceptive threshold tests and had a decreased cortisol 
(P=0.10) and substance P (P=0.016) release at 8 h following dehorning, however, 
increases in cortisol at 12 h (P=0.069) and respiratory rate at 48 h (P=0.0040) were 
observed in carprofen treated calves compared to placebo treated calves. Oral carprofen 
administration resulted in the largest average daily gain, albeit not different than placebo 
treated calves (P=0.23) but increased compared with calves administered carprofen 
subcutaneously (P=0.0039). Overall, at the study dose, the effect of carprofen on 
sensitivity and stress following dehorning was minimal; although given the observed 
143 
 
tendency towards reduction of nociception and stress associated with dehorning as well 
as the prolonged prostaglandin inhibition, further dose titration studies may be warranted.    
 
Introduction 
 The pain and distress associated with disbudding and dehorning has been 
evaluated using changes to physiology, behavior, and the neuroendocrine system 
(Stafford and Mellor, 2011; Stock et al, 2013). Analysis of affective states such as pain 
and distress are often achieved through the measurement of indirect measures such as 
changes in the hypothalamic-pituitary-adrenal axis (McMeekan et al., 1998), autonomic 
nervous system response (Stewart et al., 2008), and behavior (Faulkner and Weary, 
2000). Despite these previously reported changes indicative of pain and distress 
following a noxious event, there are currently no approved analgesics for cattle in the 
United States (Coetzee, 2013a). 
 Several pain mitigating strategies have been evaluated. Through reductions in 
cortisol, a multimodal approach to analgesia including the use of local anesthesia 
(McMeekan et. al, 1998), non-steroidal anti-inflammatory drugs (NSAID) (Huber et al., 
2013), or sedatives (Stilwell et al., 2010) may provide optimal pain relief (Stafford and 
Mellor, 2005; Coetzee, 2013b). Furthermore, additional benefits may be observed from 
use of an analgesic with persistent activity (Heinrich et al, 2010; Coetzee, 2011; Allen 
et al., 2013).  
 Carprofen is an NSAID with a prolonged half-life in cattle that is administered as 
a racemic (RS±) mixture with efficacy primarily attributed to the S(+) enantiomer 
(Brentnall et al., 2012). Currently, it is approved in countries in Europe and Asia as an 
adjunctive treatment for inflammation associated with pneumonia in young calves. 
144 
 
Carprofen has demonstrated both COX-dependent (Micelleta et al., 2014) and COX-
independent mechanisms including attenuating IL-6, a proinflammatory cytokine in 
equine synoviocytes and chondrocytes (Armstrong and Lees, 2002). Together with the 
significance of IL-6 mediating the pain associated with burns in rodents, carprofen may 
be ideally suited to manage pain associated with cautery dehorning in cattle (Summer et 
al, 2008).  
 The objective of our study is to investigate the effect of peri-operatively 
administered carprofen on nociception and stress following cautery dehorning.    
 
Materials and Methods 
Animals and Housing 
 Forty Holstein calves (18 castrated males and 22 females) with a mean ± SD age 
of 50.9 ± 5.3d and mean weight ± SD of 63.8 ±8.7 kg at dehorning were included in 
this study.  The Iowa State University Dairy provided the calves used in the study. A 
veterinarian determined all calves were healthy based on physical examination prior to 
enrollment. This study protocol was approved by the Institutional Animal Care and Use 
Committee at Iowa State University (IACUC Log # 5-13-7566-B) 
 Calves were housed on the Iowa State University Dairy in a naturally-ventilated, 
group housing facility. A total of five groups of eight animals were moved from 
individual 3-sided pens into group housing 6 days prior to dehorning for environmental 
and social acclimatization. Group pens (3.7 x 6.4 m) were bedded with straw added 
daily. Both water and grain were provided to the calves ad libitum for the duration of 
the trial. Grain consisted of primarily pelleted corn, oats, molasses 
145 
 
protein/vitamin/mineral supplement, and monensin (Table 1). The study was conducted 
in July and August.      
 Animals were monitored twice daily for health observations. Animals appearing 
depressed or lethargic were examined by a veterinarian and monitored or treated 
accordingly. Veterinarian diagnosed respiratory disease was diagnosed based on 
persistent elevated rectal temperature (>103.5°C), spontaneous cough, and ocular 
and/or nasal discharge. Respiratory disease was treated using tulathromycin (2.5 
mg/kg) (Draxxin®, Pfizer Inc., New York, NY) with resolution of clinical signs 
following treatment. Overall, one animal was treated in the SHAM group, two animals 
were treated in the both the PO and PLCBO groups, and 3 animals were treated in the 
SQ group throughout the length of the study. Calves did not require further treatment 
for any other disease process.  
 
Study Design 
 A randomized controlled trial design was used for this investigation. Study 
animals were randomly assigned to receive carprofen orally (1.4 mg/kg) (PO) (n=10), 
subcutaneously (1.4 mg/kg) (SQ) (n=10), or sterile saline subcutaneous placebo and 
oral lactose placebo with actual dehorning (PLCBO) (n=10) or with sham dehorning 
(SHAM) (n=10) (Figure 1). In addition, an oral and SQ placebo was administered to all 
calves not administered carprofen such that all animals received an oral bolus and SQ 
injection. Randomization of group assignments was accomplished using a computer 
generated random number using calf weight (Microsoft Excel, Redmond, WA, USA) as 
described by Theurer et al. (2012). In addition, animals were blocked by sex to ensure 
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equal distribution of sex within the treatment groups. Following randomization and 
group assignment, calves were enrolled in one of 4 treatment groups (n=10) containing 
equal number of animals. Five phases of 8 calves per phase were used during a 6 week 
period of time. Two animals from each treatment group were represented in each phase 
(n=2 calves / treatment / phase) and were group housed in equivalent pens. 
Investigators collecting data were masked to the treatment groups. 
 A jugular catheter was placed for the purpose of blood sample collection as 
previously described in Stock et al., 2014. Briefly, a trained handler manually 
restrained the calves during catheter placement. The jugular area to be catheterized was 
clipped and surgically prepared using 70% isopropyl alcohol and povidone iodine. 
Local anesthesia consisting of subcutaneously administered 1 mL of 2% lidocaine was 
provided in the intended catheterized area (Phoenix™, Sparhawk Laboratories, Inc., 
Lenexa, KS).  A 18 G x 55 mm intravenous catheter (SURFLO®, Terumo Medical 
Corp., Somerset, NJ) with injection plug (Hospira Inc, Lake Forest, IL) was inserted 
into the vein. The catheter was sutured using #3 nylon suture (Ethilon™, Ethicon, San 
Lorenzo, PR). Using 3 mL of a heparin saline solution containing 3 USP units heparin 
sodium/mL saline (Heparin Sodium Injection, Baxter Healthcare, Deerfield, IL), 
catheter patency was maintained. The catheter port was disinfected with an alcohol 
swab prior to sample collection. 
 Study animals (n=10) were administered SQ carprofen (1.4 mg/kg) (Rimadyl® 
Injectable, 50 mg/mL; NADA 141-199, Pfizer Inc.) under the skin in the cervical 
muscular region in compliance with Beef Quality Assurance (BQA). The test article 
was stored according to manufacturer’s instructions.  A 3 ml syringe was used to 
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administer the dose which was rounded to the nearest tenth mL. Calves enrolled in the 
other groups not receiving SQ carprofen (PO, PLCBO, and SHAM) received an 
equivalent amount of 0.9% saline subcutaneously in the same manner previously 
described.  
Oral carprofen (1.4 mg/kg) administration was completed using tablets of two 
different concentrations in order to provide the most accurate targeted dose. Either 100 
mg tablets (Novox® Caplets, ANADA #200-498, Vedco, Inc.) or 75 mg tablets 
(Novox® Caplets, ANADA #200-498, Vedco, Inc) were provided to calves in a small 
gelatin capsule (Torpac®, Fairfield, NJ) administered using an oral balling gun. The 
test article was stored according to manufacturer’s instructions. Using the two different 
formulations, the dose was rounded to the nearest tablet of the weight determined 24 
hrs prior to administration. Using these two tablet formulations, the actual mean dose of 
1.40 mg/kg (range: 1.13 – 1.63 mg/kg) was administered to the calves as an oral bolus. 
Animals not receiving oral carprofen (SQ, PLCBO, SHAM) were identically 
administered a placebo (lactose powder) encapsulated in the same gelatin bolus.    
 
Dehorning 
Dehorning was performed in 10 minute intervals. Calves were restrained during 
dehorning using a modified calf restraining device (Easy B-Z Portable Calf Restraint, 
eNasco, Fort Atkinson, WI).  Cautery dehorning was initiated 10 minutes following 
administration of the oral bolus, subcutaneous injection and local anesthetic. A local 
anesthetic (2% lidocaine; VetOne®, Boise, ID) (5 ml / site) was administered to all 
calves using a cornual nerve block as described by Stock and others (2015). Effective 
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local anesthesia of the cornual tissue was confirmed using behavior reactions (e.g. ear 
flicks, head shaking, strong escape behavior) to a needle prick 5 minutes after 
administration of the cornual nerve block. Following confirmation of appropriate 
desensitization, calves were cautery dehorning by placement of a pre-heated electrical 
hot-iron (approx. 600 °C) (Dehorner X-50, Rhinehart Development Corporation, 
Spencerville, IN) on the horn tissue for approximately 15-20 seconds until a 
circumferential copper-colored ring surrounding the horn bud was formed similarly 
described by Stock and others (2015).  A duplicate, non-heated electric dehorner 
(Dehorner X-50, Rhinehart Development Corporation, Spencerville, IN) was used 
identically for SHAM animals. Each group of eight study animals was dehorned by the 
same person to minimize variation within the phase. 
 The dehorning sites were monitored daily for signs of discharge or infection, in 
addition to an assessment of attitude, posture, appetite, lying time, and peri-operative 
swelling. A rescue analgesia protocol of flunixin meglumine at 2.2 mg/kg, IV once 
daily for 3 days was devised if obvert pain or distress was evident, such as increased 
lying time, head pressing, inflammation with major drainage of the dehorning site, 
dehydration or inappetence. 
 
Blood Sample Collection 
 Trained handlers manually restrained animals for blood collection. Baseline 
samples were obtained immediately prior to drug administration. Blood samples were 
collected for animals receiving carprofen or placebo via the catheter at 0.5, 0.75, 1, 2, 4, 
6, 8, 10, 12, 24, 48, 72, and 96 h (-10 m) following dehorning. Samples were 
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immediately transferred to a blood collection tube with either sodium heparin or 
ethylenediaminetetraacetic (EDTA) (Vacutainer®, BD Diagnostics) and stored in a 
cooler with ice packs before processing. Blood samples were centrifuged for 15 
minutes at 1,500g at ambient temperature. Collected plasma was placed in cryovials 
and frozen at -80°C until analysis. 
 Calves were restrained using the same head restraint as previously described 
approximately 5 minutes prior to nociception threshold detection via pressure 
algometry and infrared thermography. Blood collection would occur before calves were 
placed in the head restraint. After this brief period of acclimatization in the restraint 
device, infrared images were obtained. Following infrared thermography imaging, 
calves were blindfolded for pressure algometry nociception threshold testing to avoid 
conditioned withdrawal reflex based on visual cues. Baseline samples for heart rate, 
respiratory rate, ocular temperature, and mechanical nociception threshold were 
obtained 14±2 h prior to the initiation of the study.  
 
Ocular Temperature 
 A thermography camera (FLIR SC 660, FLIR Systems AB, Boston, MA) with a 
thermal sensitivity of 0.05 Celsius, 320 x 240 pixel display, precision > 98%, was used 
to quantify changes in ocular temperature similarly described in Stock and others 
(2015). The camera was internally calibrated to ambient temperature prior to image 
collection; however additional minute adjustments to ambient temperature and 
humidity were used during software processing. Images were obtained from the left 
side of the calf, at an angle of approximately 45°, and a distance of 0.5 meters distance 
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from the eye. Maximum temperature (°C) within a circumferential area of the eye 
including the medial posterior palpebral border of the lower eyelid and the lacrimal 
caruncle was obtained as previously described (Stewart el al., 2008). Images were 
analyzed using FLIR Tools (v. 4.1; FLIR Systems Inc, Boston, MA) following 
collection. At each time point, three images were obtained and the minimum 
temperature recorded was used for statistical analysis. 
 
Mechanical Nociception Threshold (MNT) 
MNT, as defined by a maximum force which induces a withdrawal response, was 
determined at 4, 8, 12, 24, 48, 72 and 96 h post-dehorning as described in Tapper et al. 
2012 and Stock et al., 2015. Briefly, using a hand held pressure algometer (Wagner Force 
Ten™ FDX 25 Compact Digital Force Gage, Wagner Instruments, CT, USA), a force 
was applied perpendicular at a rate of approximately 1 kg of force per second at 2 
locations (lateral and caudal) adjacent to the horn bud. The 1 cm2 rubber tip of the 
algometer was placed immediately adjacent to cauterized skin. Additionally, a third 
control location between the eyes on the frontal bone was used to evaluate MNT of an 
area that was not adjacent to cauterized skin. A withdrawal response was indicated by an 
overt movement away from the applied pressure algometer. The obtained pressure value 
was recorded by a second researcher prior to observation from the investigator applying 
the pressure. A maximum value of 10 kgf was determined a priori. Calves were 
blindfolded prior to MNT to avoid a response associated with visual cues. Both the order 
of locations tested and the side of the calf the researcher stood on was randomized 
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between each calf. Locations were tested three times in sequential order and the value 
was averaged for statistical analysis. 
 
Heart and Respiratory Rate 
 Heart and respiratory rates and heart rates were obtained prior to placement within 
the restraining device, with respiratory rates obtained by a recorder outside of the group 
pen and heart rates determined following a brief period of acclimatization of the 
recorder in the group pen. In this way, the restraining device would not influence 
respiratory and heart rates. 
 Heart and respiratory rate was evaluated via auscultation at 3.5, 7.5, 11.5, 23.5, 
47.5, 71.5, and 95.5 ± 0.5 hrs. The bell of a stethoscope (3M™, Littmann®, Master 
Classic II, St, Paul, MN, USA) was placed between the 3rd and 5th intercostal space 
and beats were counted over a 15 second period. The value obtained was used to 
calculate beats per minute. Respiratory rate was determined without handling by 
observing the movements of the thoracic cavity over a 15 second period.   
 
Average Daily Gain 
 Animals were weighed using a Brecknell digital scale (PS500-36S, Avery 
Weight-Tronix, Fairmont, MN). Average daily gain was calculated using weights 
obtained approximately 24 hours prior to the carprofen administration (d -1), and 7 
days following dehorning (d7). The scale was calibrated with weights of a known mass 
immediately prior to obtaining the weight of a calf.  
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Cortisol 
 Plasma cortisol samples were determined using a commercial radioimmune assay 
kit (Coat-A-Count® Cortisol, Siemens Medical Solutions Diagnostics (formally 
Diagnostic Products Corp.), Los Angeles, CA) previously used for bovine plasma 
(Stilwell et al., 2008a; Stock et al., 2015). Samples were assayed in duplicate with the 
reported concentration equaling the average cortisol concentration between duplicates. 
The average intra- and inter-assay coefficients of variation were 8.2% and 7.8%, 
respectively. Area under the effect curve (AUEC) was calculated using the linear 
trapezoidal method as previously described (Glynn et al., 2013). 
 
Substance P 
Substance P (SP) concentrations were analyzed as described by Van Engen and 
others (2013) using non-extracted plasma.  Samples were assayed in duplicate with the 
reported concentration equaling the average SP concentration between duplicates.  The 
coefficient of variation for intra-assay variability was at 8.6% and the inter-assay 
variability was calculated at 8.4%. Area under the effect curve (AUEC) was calculated 
using the linear trapezoidal method. 
 
Prostaglandin E2  
 Ex-vivo prostaglandin E2 (PGE2) synthesis inhibition was determined as 
described by Fraccaro and others (2013). Blood collected from calves was placed into 
sterile vacuum tubes containing heparin at 2, 6, 12, 24, 48, 72, 96 h. LPS obtained from 
E. coli 0111:B4 (Sigma-Aldrich, Co. St. Louis, MO) in PBS was added at 10 µg/mL to 
153 
 
the heparinized whole blood and incubated for 24 h at 37°C. Baseline samples were 
incubated with and without LPS. The same volume of PBS was added to the negative 
control baseline samples. Plasma was subsequently collected post-incubation following 
centrifugation at 400 g for 10 minutes at ambient temperature. Methanol was added to 
plasma in a 1:5 plasma to methanol dilution, facilitating protein precipitation. 
Following centrifugation at 3,000 g for 10 minutes, the supernatant was collected and 
stored at -80 °C. A commercial PGE2 ELISA kit (Cayman Chemical, Ann Arbor, MI) 
previously described using methanol precipitated bovine plasma was used for 
determination of PGE2 concentration (Donalisio et al., 2013; Fraccaro et al, 2013). 
Samples were assayed in duplicate with the reported concentration equaling the average 
PGE2 concentration between duplicates. The coefficient of variation for intra-assay 
variability was at 9.8% and the inter-assay variability was calculated at 14.6%. One 
animal from each of the PLCBO and SQ treatment groups were removed from analysis 
due to laboratory error.  
 
Carprofen Plasma Concentration 
Plasma concentrations of carprofen (R & S enantiomers) were determined using 
high-pressure liquid chromatography (Agilent 1100 Pump and Autosampler, Agilent 
Technologies, Santa Clara, CA, USA) coupled with ion trap mass spectrometry detection 
(LTQ , Thermo Scientific, San Jose, CA, USA).   Plasma samples, plasma spikes, and 
blanks, 100 µL, were mixed with 400 µL of acetonitrile to precipitate plasma proteins.  
Diclofenac (10 µL of 5 ng/ µL) was added as an internal standard to all samples.   The 
samples were vortexed for 5 seconds and centrifuged for 20 minutes at 2,000 x g to 
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sediment the protein pellet.   The supernatant was poured off into dry down tubes and 
evaporated at 50
o
C with a flow of nitrogen in a Turbovap.  The contents were 
reconstituted with 150 µL of 25% acetonitrile in water.  The samples were transferred to 
an autosampler vials fitted with a glass insert and centrifuged at 2,000 x g prior to 
analysis.  
For LC-MS analysis the injection volume was set to 15 μL.  The mobile phases 
consisted of A: 0.1% formic acid in water and B: 0.1% formic acid in acetonitrile at a 
flow rate of 0.225 mL/min.  A solvent gradient beginning at 40% B with a linear gradient 
to 60% B in 5 minutes was used for analysis.  Separation was achieved with a LUX 
Cellulose-1 chiral column, 50 mm x 2 mm , 3 µm particles (Phenomenex, Inc., Torrance, 
CA, USA) maintained at 40°C.  S+ and R- carprofen eluted at 4.4 and 4.9  minutes, 
respectively, while diclofenac eluted at 4.5 minutes.   Electrospray ionization (ESI) and 
full scan MS was used for analyte detection.  Carprofen was detected with negative ESI 
with MS3 fragmentation (272→228). Wideband activation in positive ESI mode was 
used to aid the loss of water from diclofenac during transition from the parent (m/z 297) 
to the fragment ions.  The sum of the intensities of ions at m/z of 190, 226, and 228 were 
used for carprofen quantitation.  The internal standard, diclofenac, was quantitated with 
the sum of the fragment ion intensities at m/z of 215, 250, and 252.  Sequences consisting 
of plasma blanks, calibration spikes, and bovine plasma samples were batch processed 
with a processing method developed in the Xcalibur software (Thermo Scientific, San 
Jose, CA, USA).  The processing method automatically identified and integrated each 
peak in each sample and calculated the calibration curve based on a weighted (1/X) linear 
fit.  Plasma concentrations of carprofen in unknown samples were calculated by the 
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Xcalibur software based on the calibration curve.  Results were then viewed in the Quan 
Browser portion of the Xcalibur software.   Twelve calibration spikes were prepared in 
blank bovine plasma covering the concentration range of 5 to 20,000 ng/mL.  Calibration 
curves exhibited a correlation coefficient (r2) exceeding 0.996 across the entire 
concentration range.  QC samples at 15, 150, and 1500 ng/mL were prepared in bulk and 
run with each set of samples/calibrators.  The variance of the QC samples was within 2-
10% of the nominal value. 
 
Pharmacokinetic Analysis 
A non-compartmental pharmacokinetic analysis was performed using computer 
software. The following parameters were evaluated: area under the curve from time 0 to 
infinity (AUC0-∞) and time 0 to last collected sample (AUC0-96) using the linear 
trapezoidal rule, as well as the percent of the AUC extrapolated to infinity (AUC 
extrapolated). The extrapolated portion of the AUC was determined by multiplying the 
last measured plasma concentration by the λz, the first-order terminal rate constant (λz). 
The range of the λz was determined by visual inspection of the plasma profile and 
determined by linear regression of time and natural log (ln) of the plasma concentration. 
The volume of distribution per bioavailability Vz/F was determined by diving the dose by 
λz•AUC. Clearance per bioavailability (Cl/F) was determined by dividing the dose by 
AUC. In addition, T½λz, maximum plasma concentration (Cmax) and time to maximum 
concentration (Tmax) was determined.  The relative F was estimated by dividing the oral 
(mean AUC/Dose) by the subcutaneous (mean AUC/Dose). 
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Statistical Analysis 
 Analyses were performed in SAS 9.3 (SAS Institute, Cary NC) using a general 
linear mixed effects model with repeated measures. Data obtained from response 
variables including cortisol, substance P, MNT, heart rate, respiratory rate, and PGE2 
were natural log transformed for normality. Baseline values were used as covariates. 
The fixed effects were treatment (carprofen PO, carprofen SQ, PLCBO, SHAM), time, 
and the interaction between treatment and time. The effect of sex was included for all 
statistical models. Phase was a random effect and calf was the subject of repeated 
measures. F-tests were used to test the significance of main effects and interactions. If 
significant overall differences were identified among levels of a factor, pairwise 
comparisons were performed using Tukey's t-tests. Paired t tests were performed to test 
the differences between LPS-stimulated and unstimulated baseline ex-vivo PGE2 
concentrations. Planned contrasts were performed evaluating the responses of carprofen 
(PO &SQ) versus PLCBO treated calves following dehorning as well as the response 
following actual (PO, SQ, & PLCBO) or sham (SHAM) dehorning. These three 
contrasts are analyzed for the entire study along with at different time points (4, 8, 12, 
24, 48, 72, 96). 
 
Results & Discussion   
Animal Medicinal Drug Use Clarification Act (AMDUCA) permits the use of 
medicines to be used in an extra-label manner provided specific requirements are met 
(FDA, 1994). As no drugs are currently labeled in cattle for analgesia or those that are 
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labeled as anti-inflammatory have unknown analgesic properties following a single dose, 
the use of carprofen would constitute extra-label drug use permitted under AMDUCA. 
Following an IV or SQ dose of 1.4 mg/kg, a 14 d slaughter withhold period is required in 
the European Union using the approved European formulation. Since there is a zero 
tolerance on the presence of violative residues under AMDUCA for extra-label drug use, 
and carprofen demonstrates age-related pharmacokinetics, additional tissue residues 
studies would be necessary prior to any recommendation for use in young calves.  
 
Carprofen 
 Carprofen was well absorbed following both subcutaneous and oral 
administration (Table 2 and 3). Although carprofen is administered as a racemic 
mixture, the S(+) enantiomer has been reported to be primarily responsible for the 
observed prostaglandin inhibition (Brentnall et al., 2012). Using AUC0-∞, the observed 
enantiomer ratio, R:S, was 57:43 for both oral and subcutaneous administration. This 
ratio is nearly identical to that previously reported following IV administration 
(Delatour et al., 1996).  In the present study, both SQ and PO administration of 
carprofen demonstrated a small volume of distribution as well as a slow clearance 
resulting in prolonged median half-lives, S(+) = 52.8 h (range: 38.3 – 180.7 h), S(+) = 
49.7 h (range: 38.4 – 79.2 h), respectively. These values are marginally longer in 
comparison to those previously published in calves of similar age (Delatour et al., 
1996).   Carprofen-S(+) achieved a mean maximum concentrations of 5.3±0.9 µg/mL at 
9 h following SQ administration and 3.9±0.8 µg/mL at 18 h following PO dosing. The 
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relative bioavailability of PO carprofen in comparison to SQ calculated using mean 
AUC0-∞ was approximately 70%.  
 The pharmacokinetics in the present study indicated a marginally longer half-life 
than previously reported in animals of similar age (Delatour et al., 1996). This may be a 
result of using a younger population of animals in the present study. Age dependent 
pharmacokinetics of carprofen has been reported in calves with concentrations 
persisting longer in younger animals (Delatour et al., 1996; Brentnall et al, 2012). 
Longer half-lives in younger calves are suggested to be a result of a reduction in 
clearance which is consistent with our findings (Lees et al., 1996, Delatour et al., 1996). 
It should be noted that the AUC0-∞ observed in our study should be interpreted with 
caution due to the large percent of the AUC extrapolated. 
 Analgesic concentrations of NSAIDs have been previously estimated using a 
calculated IC80 concentration of COX-2 inhibition (Lees et al., 2004; Huntjens et al, 
2005). A recent study evaluating in-vitro COX-2 inhibition using a bovine whole blood 
assay indicted an IC80 equal to a mean total carprofen (RS±) concentration of 8.9 
µg/mL (range: 1.9 – 42.9 µg/mL) (Miciletta et al., 2013).  Interestingly, it was reported 
that the R(-) enantiomer may attenuate COX inhibitory activity of the S(+) enantiomer 
(Miciletta et al., 2013). Assuming these concentrations provide pain relief, the use of 
total carprofen concentrations with a similar enantiomer ratio as derived in our study, 
SQ administration would provide analgesia from approximately 4 h to 24 h of time; 
however, a direct comparison between studies should be interpreted with caution given 
differences in study design. Oral administration did not achieve this target mean 
concentration throughout the course of the study.  These data would potentially support 
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the current daily regimen of SQ administration to achieve the previously reported IC80; 
however, the duration above the IC80 observed in this study is shorter than that 
previously reported using the S(+) enantiomer alone (Brentnall et al, 2012). This may 
due to the interaction of the R(-) enantiomer given the enantioselectivity observed 
following administration of the racemic mixture in calves as reported by Miciletta and 
collegues (2013). 
 
Prostaglandin E2 
 An effect of treatment (P<0.0001) and time (P<0.0001) was observed on 
prostaglandin E2 (PGE) percent inhibition (Table 4). Moreover, there was an 
interaction of time and treatment (P<0.0001). Percent inhibition was increased for 
calves administered carprofen subcutaneously compared to placebo treated controls 
from the initial collection time point of 2 h through 72 h (P<0.05) (Figure 2). In 
addition, the percent inhibition was decreased in calves treated orally with carprofen 
from 6 h through 96 h compared to placebo treated controls (P<0.05)(Figure 2). 
Prostaglandin percent inhibition was significantly increased in sham dehorning calves 
compared to calves treated with carprofen for all time points (P<0.05). No difference 
was observed in prostaglandin inhibition between placebo-treated dehorning calves 
compared with those sham dehorning (P>0.1). Baseline PGE concentrations of LPS 
stimulated blood was greater than unstimulated blood (P<0.0001). 
 NSAIDs inhibit COX isoenzymes responsible for producing prostaglandins which 
increase nociception thereby increasing the sensitivity for nerve transmission at the site 
of injury (Basbaum et al. 2009). Carprofen is known to be a weak inhibitor of 
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cyclcoxygenase (Delatour et al., 1996; Lees et al., 1996). As such the mechanism of 
action for analgesia is thought to be both COX-dependent and COX-independent. In 
addition to inhibition of prostaglandins (Miciletta et al., 2013; Brentnall et al, 2012), the 
effect of carprofen may be mediated through changes in proinflammatory cytokines 
such as IL-6 (Armstrong and Lees, 2002). In our study, ex-vivo PGE concentrations 
were persistently decreased for the duration of the study in carprofen treated calves 
compared to placebo treated controls; however, only a moderate overall reduction was 
observed in comparison to other NSAIDs demonstrating up to 100% PG inhibition 
using tissue cage models (Lees et al., 2004).   
 Multiple studies have used in vitro assays to measure the effect and potency of 
carprofen on PGE inhibition (Brentnell et al., 2012; Miciletta et al., 2013). However in 
our study, ex-vivo PGE inhibition was used to determine the duration of effect 
following a single dose. Determination of ex-vivo PGE concentrations includes the 
effect of the parent compound in in vivo enantiomer ratios as well as any contribution 
from circulating metabolites. Although it is unknown if carprofen metabolites are 
important for producing analgesia, active metabolites are known to contribute to the 
analgesic effect in humans following administration of morphine (Penson et al., 2000). 
Moreover, glucuronide and coenzyme A thioester metabolites of ketoprofen, an NSAID 
of the same 2-arylpropionic acid class as carprofen, demonstrate potent prostaglandin 
inhibition in vitro (Levoin et al., 2004). Although not measured in this study, active 
metabolites may explain the observed difference in inhibition of PGE between 
carprofen and placebo treated calves that persisted longer than 48 h with decreasing 
parent drug concentrations. 
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 Although no differences were observed throughout the study between placebo 
treated controls and animals sham dehorned, an insignificant decrease in PGE 
production in placebo treated controls was observed. This may be due to increased 
glucocorticoid concentrations associated with dehorning which are reported to down 
regulate the induction of PG concentrations (Santini et al., 2001).  
 
Cortisol 
 There was no effect of treatment on cortisol concentrations (P=0.48). Cortisol 
concentrations were affected over time (P<0.0001); however there was no interaction of 
time and treatment (P=0.22) (Table 4) (Figure 3). No treatment differences were 
observed in evaluating the overall AUEC0-96h (P=0.51) (Figure 4). Furthermore, no 
treatment differences were observed when the AUEC was divided as follows: 0-2 h 
(P=0.64), 2-8 h (P=0.34) and 8-96 h (P=0.55) (Table 5). 
 In contrast evaluations, calves that were dehorned compared to sham dehorned 
had greater cortisol concentrations at 20 m (P=0.042), and approximately 4 h 
(P=0.0048) following actual or sham dehorning. Additionally, dehorned calves tended 
to have greater cortisol concentrations at 48 h (P=0.060) compared to those sham 
dehorned. In comparison with calves receiving carprofen, placebo treated calves tended 
to have increased cortisol concentrations at 8 h (P=0.10) and decreased cortisol at 12 h 
(P=0.069).  
 Cortisol concentrations have been previously described to increase in calves 
dehorned compared to those sham dehorned (Stafford and Mellor, 2005). Although 
changes in cortisol concentrations were observed over time in this study, no overall 
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treatment differences among the groups were observed. Contrast statements reveal that 
time points at 20 m, 4 h and 48 h post-dehorning appear to be potentially sensitive time 
points in detecting differences in cortisol concentrations following dehorning compared 
to those sham dehorned. This is consistent with previous literature reporting increases 
in cortisol concentrations immediately following dehorning, and after the loss of local 
anesthesia (McMeekan et al., 1998; Doherty et al., 2004, Allen et al., 2013). 
Furthermore, changes in both cortisol and behavior are noted to persist up to 24 to 48 h 
in placebo treated controls compared to calves dehorned with NSAIDs (Faulkner and 
Weary, 2000; Heinrich et al., 2009; Stock et al., 2014). This response may be due to the 
delayed amplification of acute phase proteins observed at this time post-dehorning 
(Glynn et al., 2013). 
 Carprofen did not have an overall treatment effect on cortisol concentrations 
compared to placebo treated calves in this study. This differs from a previous study 
which reported decreased cortisol concentrations at 1 h post cautery disbudding 
compared to placebo treated controls (Stilwell et al., 2012). These differences may be 
due to the route of administration as carprofen was administered intravenously in the 
previous study potentially achieving greater concentrations rapidly.  
 Administration of carprofen has been reported to decrease cortisol concentrations 
and pain related behaviors at 24 h and 48 h following non-surgical castration (Pang et 
al., 2006; Stilwell et al., 2008b). We did not observed this analgesic effect following 
dehorning which may be due to a muted cortisol response in non-surgical castration or 
due to the potential of amputation dehorning resulting in a greater stress response in 
comparison to surgical castration (Robertson et al., 1994; Mosher et al, 2013; Ballou et 
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al, 2013). Consequently, concentrations necessary to achieve analgesia for calves 
following cautery dehorning may need to be greater in comparison to castration. 
 
Substance P 
 There was no effect of treatment (P=0.77), time (P=0.23) or interaction of time 
and treatment (P=0.53) on substance P (SP) concentrations (Table 4). Area under the 
effect curve and maximum substance P concentrations were not different among 
treatment groups (Table 5). Contrasts statements indicated decreased SP concentration 
at 8 h post dehorning for calves treated with carprofen compared to placebo treated 
calves (P=0.016). Moreover, SP concentrations for calves treated with carprofen tended 
to be increased at 20 m (P=0.096) and decreased at approximately 6 h (P=0.082) and 96 
h (P=0.093) following dehorning compared to placebo treated dehorned controls 
(Figure 5). The decreased SP concentrations at approximately 8 h in calves treated with 
carprofen correlate with decreasing cortisol concentrations at 8 h as well. Taken 
together, carprofen administration may attenuate the pain and distress associated with 
cautery dehorning at 8 h. 
 Interestingly, an effect of gender was observed (P=0.005) with substance P 
concentrations greater (0.11±0.039 pg/ml) in female calves compared to male calves. 
Differences in pain responses between sexes have been previously well documented 
(Fillingim et al, 2009). More recently, SP differences between sexes were reported in a 
rat model using a formalin-evoked pain model resulting in SP release (Nazarian et al., 
2014). Consistent with our study, female rats had an increase in SP release which was 
determined to be mediated by estradiol concentrations. In our study, although a 
164 
 
difference was noted, the effect size was small. Additional studies are needed to further 
elucidate the role of sexual dimorphism in SP release in cattle.  
 
Mechanical Nociception Threshold 
 An effect of treatment was observed (P<0.0001) on mean mechanical nociception 
threshold (MNT). Furthermore there was an effect of time (P<0.0001) but there was no 
interaction between treatment and time (P=0.99) (Table 4). Sham dehorned calves had 
an increased MNT at all collection timepoints (P<0.001) (Figure 6). No treatment 
differences were observed among treatment groups of dehorned calves; however, there 
was a tendency for calves treated with carprofen to tolerate more pressure around the 
dehorning site compared to placebo treated controls (P=0.097).  
 Previous studies have evaluated MNT differences following actual or sham 
dehorning of calves (Heinrich et al, 2010; Tapper et al, 2012, Allen et al. 2013, Glynn 
et al. 2013). In these previous studies, calves were initially sham dehorned prior to 
actual dehorning to determine baseline MNT information. In this study, in addition to 
determining baseline MNT values, sham dehorned calves were included throughout the 
data collection period to help control for the effects of the study on the pressure 
algometry response. Due to the MNT differences observed between sham and actual 
dehorned calves throughout the study period, MNT appears to be a reliable measure of 
increased pain sensitivity associated with cautery dehorning. Although MNT did not 
return to baseline values following the duration of the study (4 d) for calves dehorned, 
partial thickness epidermal burns have been noted to induce mechanical hyperalgesia 
for up to 4 weeks in rat thermal injury models (Summer et al., 2007). 
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 MNT has been useful in detecting nociception differences in dehorned calves 
treated with an analgesic. Heinrich and others (2010) demonstrated decreased 
sensitivity as determined by increased MNT following the use of IM meloxicam. 
Moreover, Tapper et al., (2012) reported an increased MNT in calves administered 
local anesthesia using ethanol for at least 3d post-dehorning compared to lidocaine.  
Although, carprofen administration tended to increase MNT throughout the study 
period, further investigation is warranted to determine the improved sensitivity 
associated with carprofen administration. 
 
Ocular Temperature 
 There was no effect of treatment on ocular temperature (P=0.65). An effect of 
time was observed (P<0.0001), however, there was no interaction of time and treatment 
(P=0.26) (Table 4). Previous studies have indicated an equivocal response of ocular 
temperature following dehorning. Stewart and colleagues (2009) reported a decreased 
ocular temperature associated with the loss of local anesthesia following dehorning. 
Moreover, administration of meloxicam attenuated the decreased ocular temperature 
observed in placebo treated calves post-dehorning (Stewart et al., 2009); however, other 
investigations have not observed this same response (Glynn et al., 2013; Allen et al., 
2013; Stock et al., 2014). As this response is hypothesized to result from activation of 
the autonomic nervous system (ANS) producing peripheral vasoconstriction, brief 
handling and restraint may confound this observed effect. In our study, calves were 
placed in a head restraint device prior to obtaining the image. This was to maintain the 
collection of a consistent image. Calves were allowed to adjust to the restraint device 
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briefly before the infrared image was collected which may have masked the ANS 
response on ocular temperatures associated with dehorning. The similar ocular 
temperature profiles throughout the study of sham and actual dehorned calves might 
further support this statement.   
 
Heart Rate 
 There was no effect of treatment on heart rate (P=0.43). An effect of time was 
observed (P=0.0092), however, there was no interaction between treatment and time 
(P=0.96) (Table 4). Contrast statements revealed sham animals tended to have a 
decreased heart rate at 47.5 h (P=0.10) and 95.5 h (P=0.064) post-dehorning compared 
with calves dehorned. 
 Heart rate has been previously used to evaluate changes in the ANS following 
noxious events in cattle (Stewart et al., 2009; Heinrich et al., 2010; Coetzee et al. 2012). 
Increased heart rate variability has been reported in castrated or dehorned cattle as a 
result of an imbalance in the autonomic nervous system (Stewart et al., 2009; Stewart et 
al., 2010). Although previous reports have indicated a significant reduction in heart rate 
in calves administered meloxicam prior to dehorning, this effect was not observed in 
our study (Heinrich et al., 2010; Coetzee et al., 2012). Differences in analgesic potential 
between NSAIDs and method of data collection may be reasons for the reported 
differences. In previous investigations, heart rates were collected using an electrical 
heart rate monitor (Coetzee et al., 2012) or obtained following blood collection 
(Heinrich et al., 2009), which differs from our study. It is noteworthy that no 
differences were observed between calves actually or sham dehorned in the first 24 h 
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post-dehorning potentially indicating the influence of the repeated handling for data 
collection. The decreased heart rate observed at 47.5 h in sham dehorned calves 
coincides with the observed reduction in cortisol concentration in sham animals.  Taken 
together, these responses may indicate a persistent stress response in calves following 
dehorning.       
 
Respiratory Rate 
 Statistical analysis was performed with and without calves treated for respiratory 
disease. Using data from all calves, respiratory rate was not affected by treatment 
(P=0.20) or time (P=0.086) (Table 4). Moreover, treatment groups did not differ in 
response over time (P=0.25). Although carprofen calves tended to have an increased 
respiratory rate in comparison to placebo treated calves (P=0.094), this effect was not 
observed if calves treated for respiratory disease were removed from the statistical 
analysis (P=0.38). Interestingly, carprofen treated calves had an increased respiratory 
rate at 47.5 h (P=0.0040) post dehorning compared to placebo treated dehorned calves 
despite removing pneumonia treated calves from the analysis. A previous report 
indicated that respiratory rates increase in placebo treated calves in comparison with 
calves treated with meloxicam. (Heinrich et al. 2009). Although the lack of agreement 
between studies may be due to differences in analgesic potential between NSAIDs 
used, respiratory rates were not assessed past 24 h in the previous study (Heinrich et al., 
2009). The increase in respiratory rate observed in our study at 47.5 h may correspond 
with the reduction of carprofen’s effect.  
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Average Daily Gain 
 Calves treated with oral carprofen had an increased average daily gain compared 
with those treated with subcutaneous carprofen (0.92±0.10 kg/d vs. 0.48±0.10 kg/d) 
(P=0.0039). No other differences were observed between treatment groups (P>0.1). 
Changes in average daily gain are equivocal with previous studies reporting no changes 
or increases compared to placebo treated controls (Baldridge et al., 2011; Glynn et al. 
2013; Coetzee et al., 2012; Stock, et al., 2014). Greater increases were observed in 
older study populations suggesting the potential that dehorning has a larger impact on 
weight gain in older calves (Baldridge et al., 2011; Glynn et al. 2013; Coetzee et al., 
2012). Improved appetite and weight gain has been observed in calves administered 
meloxicam subcutaneously on the onset of diarrhea (Todd et al., 2010). NSAIDs may 
attenuate the production of proinflammatory cytokines associated with sickness 
behavior including inappetance as observed in sheep (Baile et al., 1981) and swine 
(Johnson and von Borell, 1994) endotoxin models. We do not completely understand 
the exact mechanism of the difference in ADG observed between carprofen treatments 
in our study. Parameters that contribute to changes in ADG such as grain consumption 
were not measured in our study. Potentially, oral carprofen administration may act 
locally on the gastrointestinal tract inhibiting proinflammatory cytokines, thereby 
improving appetite and grain consumption. Further investigations into changes in 
average daily gain following carprofen administration are warranted using an increased 
sample size.    
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Conclusion 
  Cautery dehorning in dairy calves resulted in increased nociception throughout 
the 96 h study period. Moreover, the stress response was increased immediately 
following dehorning, after the loss of local anesthesia, and 48 h following dehorning in 
comparison to sham dehorned calves. Carprofen administration reached concentrations 
that moderately inhibited ex-vivo prostaglandin and were decreased for 72 h (SQ) and 
96 h (PO) after administration compared with placebo treated controls; however, 
analgesic responses between treatment groups subsequent to dehorning were minimal. 
The observed tendency to reduced nociception and stress associated with dehorning in 
addition to the prolonged prostaglandin inhibition potentially warrants future dose 
titration studies.    
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Table 1. As fed (%) components of the grain diet provided to calves throughout the 
study. 
Component As Fed (%) 
Corn 50 
Oats 5 
Commercial Supplement* (38% protein) 30 
Commercial Supplement (34% protein) 10 
Liquid Molasses 5 
*contains monensin 
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Table 2. Pharmacokinetic parameters following a non-compartmental analysis for carprofen (RS±) administered orally prior to 
cautery dehorning (mean dose, 1.4 mg/kg; range, 1.13 to 1.63 mg/kg).  
Parameter, Units 
R(-) S(+) 
Mean SD Min Median Max Mean SD Min Median Max 
AUCExtrapolatedto∞, 
(%) 
37.1 10.6 21.0 35.6 57.2 31.0 9.5 19.2 31.6 49.6 
AUC0→∞, (h*µg/mL) 518.2 143.4 321.1 519.5 786.8 394.5 114.6 239.8 371.0 565.5 
AUC0→96h, 
(h*µg/mL) 
314.1 50.5 242.8 318.1 382.9 265.6 60.8 193.7 257.9 358.6 
Cl/F, 
(mL/kg/h) 
1.45 0.41 0.89 1.36 2.18 1.92 0.57 1.24 1.89 2.92 
Cmax, 
(µg/mL) 
4.41 0.63 3.53 4.58 5.16 3.94 0.84 2.82 3.70 5.14 
T ½ λz,  
(h) 
62.8 18.5 39.3 58.1 97.0 52.9 14.5 38.4 49.7 79.2 
λz, 
(1/h) 
0.012 0.0032 0.0071 0.012 0.018 0.014 0.0032 0.0088 0.014 0.018 
Tmax, 
(h) 
26.4 12.4 12 24 48 22.8 14.4 12 18 48 
Vz/F, 
(mL/kg) 
124.0 23.7 93.2 117.7 161.2 140.8 36.5 90.3 138.1 210.1 
 
AUC – area under the plasma drug concentration curve; Cmax – maximum plasma concentration; Tmax – time to maximum plasma 
concentration; T1/2λz  – elimination half-life; λz – elimination rate constant; V/F – volume of distribution per bioavailability; CL/F – 
plasma clearance per bioavailability
1
7
6
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Table 3. Pharmacokinetic parameters following a non-compartmental analysis for carprofen (RS±) administered subcutaneously prior 
to cautery dehorning (1.4 mg/kg).  
Parameter,Units 
R(-) S(+) 
Mean SD Min Median Max Mean SD Min Median Max 
AUCExtrapolatedto∞, 
(%) 
43.1 16.1 26.5 42.1 77.2 33.9 15.5 19.3 29.7 70.3 
AUC0→∞, 
 (h*µg/mL) 
753.6 458.5 383.5 656.3 1969.6 557.7 368.6 266.2 433.1 1526.5 
AUC0→96h, 
(h*µg/mL) 
369.6 59.6 284.1 369.4 463.2 319.6 77.7 214.9 307.0 452.7 
Cl/F, 
(mL/kg/h) 
1.14 0.45 0.34 1.06 1.80 1.58 0.63 0.46 1.62 2.63 
Cmax, 
(µg/mL) 
5.74 0.57 4.76 5.66 6.74 5.27 0.85 4.24 5.10 6.61 
T ½ λz,  
(h) 
89.3 58.6 47.9 75.7 242.7 66.7 42.6 38.3 52.8 180.7 
λz, 
(1/h) 
0.0098 0.0040 0.0029 0.0092 0.014 0.013 0.0043 0.0038 0.013 0.018 
Tmax, 
(h) 
  6 6 12   6 9 12 
Vz/F, 
(mL/kg) 
118.3 16.1 79.3 122.2 138.3 124.5 20.6 90.9 130.5 147.3 
AUC – area under the plasma drug concentration curve; Cmax – maximum plasma concentration; Tmax – time to maximum plasma 
concentration; T1/2λz  – elimination half-life; λz –elimination rate constant; V/F – volume of distribution per bioavailability; CL/F – 
plasma clearance per bioavailability 
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Table 4. Summary table of backtransformed response variables (geometric means (95% confidence interval)) of carprofen and 
placebo treated calves post-dehorning. N=10 unless otherwise noted. Within a row, means without a common superscript differ 
(P<0.05) . 
 Carprofen Controls    
Response, 
(Units) 
SQ 
 Mean  
(95%CI) 
PO 
Mean 
 (95%CI) 
PLCBO 
Mean 
(95%CI) 
SHAM 
 Mean 
 (95%CI) 
Treatment 
(P value) 
Time 
(P 
value) 
Time x 
Treatment 
(P value) 
MNT,1 
(kgf) 
0.71
a
 
(0.56 to 0.88) 
0.72
a
 
(0.57 to 0.90) 
0.58a 
(0.46 to 0.73) 
1.84b 
(1.47 to 2.32) 
<0.0001 <0.0001 0.99 
Ocular 
temperature, 
 (ºC) 
38.4
a
 
(37.7 to 39.0) 
38.5
a
 
(37.9 to 39.2) 
38.1a 
(37.5 to 38.8) 
38.2a 
(37.6 to 38.9) 
0.65 <0.0001 0.26 
Heart rate, 
(bpm)2 
94.3
a
 
(87.3 to 101.9) 
98.5
a
 
(91.3 to 106.2) 
97.0a 
(89.9 to 104.6) 
90.4a 
(83.7 to 97.8) 
0.43 0.0092 0.96 
Respiratory rate, 
(bpm)2 
40.5a 
(37.1 to 44.1) 
38.4a 
(35.2 to 41.8) 
36.1a 
(33.1 to 39.3) 
38.4a 
(35.2 to 41.8) 
0.20 0.086 0.25 
ADG, 
(kg/day) 
0.48
a
 
(0.27 to 0.68) 
0.92
b
 
(0.71 to 1.12) 
0.69ab 
(0.48 to 0.90) 
0.68ab 
(0.47 to 0.88) 
0.0081   
Cortisol, 
(nmol/L) 
10.5
a
 
(8.4 to 13.2) 
11.0
a 
 
(8.7 to 13.8) 
11.9a 
(9.5 to 15.0) 
9.4a 
(7.5 to 11.9) 
0.48 <0.0001 0.22 
Substance P, 
(pg/mL) 
16.3
a
 
(14.2 to 18.7) 
17.0
a
 
(14.8 to 19.5) 
17.0
a
 
(14.8 to 19.5) 
16.4
a
 
(14.3 to 18.9) 
0.77 0.23 0.53 
Prostaglandin E2, 
(%) 
-65.6
3a
 
(-73.7 to -55.2) 
-62.2
a
 
(-70.7 to -51.5) 
-21.73b 
(-39.8 to 1.6) 
-8.3b 
(-28.5 to 17.5) 
<0.0001 <0.0001 <0.0001 
1: Mechanical Nociception Threshold; 2: Beats per minute; 3: n=9 
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Table 5. Area under the effect curve and maximum cortisol and substance P concentration (geometric means (95% confidence 
intervals)) of carprofen (SQ & PO) and placebo (PLCBO) treated calves post-dehorning. N=10 for all response variables evaluated. 
Within a row, means without a common superscript differ (P<0.05). 
 Carprofen Controls  
Response 
SQ 
 Mean (95%CI) 
PO 
Mean (95%CI) 
PLCBO 
Mean (95%CI) 
SHAM 
 Mean (95%CI) 
P value 
Cortisol, 
(nmol*h/L) 
     
AUEC0-96 
1087.9
a 
(814.1 to 1453.7) 
1145.8
a 
(850.9 to 1542.9) 
1201.8
a 
(896.1 to 1612.0) 
898.4a  
(669.6 to 1205.3) 
0.51 
AUEC0-2 
16.3
a 
(12.1 to 21.8) 
17.5
a 
(13.0 to 23.7) 
20.0a 
(14.8 to 26.9) 
19.5a 
(14.5 to 26.3) 
0.64 
AUEC2-8 
80.1a 
(55.7 to 115.2) 
94.0a 
(64.8 to 136.5) 
108.4a 
(75.1 to 156.6) 
69.6a 
(48.2 to 100.6) 
0.34 
AUEC8-96 
978.7
a 
(715.4 to 1338.9) 
1022.1
a 
(740.9 to 1409.9) 
1058.1a 
(770.3 to 1453.2) 
789.6a 
(574.6 to 1084.9) 
0.55 
Cmax, (nmol/L) 
30.5
a 
(24.3 to 38.4) 
29.4
a 
(23.3 to 37.2) 
35.7a 
(28.3 to 45.0) 
28.1a 
(22.3 to 35.4) 
0.41 
Substance P, 
(pg*h/mL) 
     
AUEC0-96 
1599.3
a 
(1342.8 to 1904.7) 
1625.5
a 
(1364.9 to 1936.2) 
1622.0a 
(1361.6 to 1932.4) 
1586.5a 
(1332.0 to 1889.9) 
0.96 
AUEC0-8 
124.6
a 
(107.4 to 144.5) 
129.7
a 
(111.8 to 150.5) 
134.8a 
(116.1 to 156.4) 
131.0a 
(112.9 to 152.0) 
0.70 
AUEC8-96 
1473.9
a 
(1232.4 to 1762.9) 
1494.4
a 
(1249.5 to 1787.5) 
1486.7a 
(1242.6 to 1778.5) 
1454.5a 
(1215.9 to 1739.9) 
0.96 
Cmax, (pg/ml) 
23.1
a 
(18.9 to 28.2) 
23.1
a 
(18.9 to 28.3) 
23.6a 
(19.3 to 28.8) 
22.9a 
(18.7 to 27.9) 
0.98 
 AUEC: area under the effect curve; Cmax: maximum concentration
180 
 
 
Figure 1. Flow chart outlining the timing of the study events. Calves were dehorned and 
monitored for cortisol, substance P (SP), mechanical nociception threshold (MNT), 
ocular temperature (OT), heart rate (HR), average daily gain (ADG), ex-vivo 
prostaglandin E2 (PGE), and carprofen (CARP) concentration. The times in parentheses 
represent the duration of data collection for each variable.  
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Figure 2. Back transformed geometric mean (±SE) ex-vivo prostaglandin E2 
concentrations over 96 h in carprofen and placebo treated calves post-dehorning.  
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(b) 
Figure 3. Back transformed geometric mean (±SE) cortisol concentrations over 12 h (a) 
and 96 h (b) for carprofen and placebo treated calves post cautery dehorning. Time 0 
signifies the time of dehorning.   
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Figure 4. Box-and-whisker plots depict area under the effect curve (AUEC) for cortisol 
concentrations over the 96 h study period for carprofen and placebo-treated calves post-
dehorning. Values were calculated using the linear trapezoid method.  
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Figure 5. Backtransformed geometric mean (±SE) substance P concentrations over 12 h 
for carprofen and placebo treated calves post cautery dehorning. Time 0 signifies the time 
of dehorning. 
 
  
10
20
0 4 8 12
Su
b
st
an
ce
 P
 (
p
g/
m
L)
 
Time (h) 
PO SQ PLCBO SHAM
185 
 
 
Figure 6. Backtransformed geometric mean (±SE) mechanical nociception threshold 
(MNT) as measured through pressure algometry over 96 h for carprofen and placebo 
treated calves. Time 0 signifies the time of dehorning. Pressure tolerance did not return to 
baseline values by the conclusion of MNT measurement for animals dehorned. Sham 
dehorned animals were significantly different at all time points post-dehorning 
(P<0.0001).  
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CHAPTER 6 
A FIELD TRIAL COMPARING FOUR ORAL NON-STEROIDAL ANTI-
INFLAMMATORY DRUGS ON CONTROLLING CAUTERY DEHORNING 
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Abstract 
The purpose of this study was to compare a one-time oral administration of four 
non-steroidal anti-inflammatory drugs in their ability to control the pain and distress 
associated with cautery dehorning in dairy calves. The NSAIDs investigated have 
pharmacokinetic properties in cattle that produce a persistent plasma concentration, 
which may allow for prolonged analgesia with the added practicality of a simple 
administration regimen. One hundred and eighty five calves aged approximately 6 to 9 
weeks old were either sham dehorned (n=31) or cautery dehorned following oral 
administration of carprofen (n=31), firocoxib (n=31), flunixin meglumine (n=30), 
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meloxicam (n=31) or a placebo in randomized, controlled trial. A standard dose of 2.0 
mg/kg was given to all calves receiving an oral NSAID. In addition, all calves received 
local anesthesia prior to actual or sham dehorning. Cortisol concentrations, heart rate, 
mechanical nociception thresholds, ocular and dehorning area temperatures and average 
daily gains were evaluated. A linear mixed effects model with repeated measures was 
used for statistical analysis. Planned contrasts evaluating analgesic treated calves and 
placebo treated controls were also analyzed. Analgesia administration was associated 
with changes in ocular and dehorning area temperature differences (P=0.020). In 
addition, administration of oral meloxicam, flunixin meglumine, and firocoxib resulted in 
decreased cortisol concentrations compared to placebo treated controls for the first 24 h 
post-dehorning (AUEC0-24) (P=0.0499). Moreover, meloxicam attenuated the maximum 
cortisol released compared to placebo treated calves (P=0.018). Although carprofen 
administration reduced heart rates after 24 h (P=0.0466), it was unable to control the 
acute stress associated with cautery dehorning during the initial 24 h. Although a 
treatment effect (P<0.0001) was observed in the determination of mechanical nociception 
threshold among all treatment groups, no differences were observed among treatment 
groups dehorned. Average daily gain was not affected by treatment (P=0.91). A one-time 
dose of 2.0 mg/kg of oral meloxicam, flunixin meglumine, or firocoxib reduced the acute 
stress response associated with cautery dehorning; however, carprofen administration was 
associated with increased cortisol concentrations and dehorning area temperatures for the 
initial 24 h. Given the reduction in maximum cortisol concentrations, meloxicam appears 
to the most potent NSAID evaluated.  
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Introduction 
Pain and distress associated with noxious husbandry procedures in cattle have 
resulted in changes in behavior, physiology, and the neuroendocrine response (Stafford 
and Mellor, 2011). Moreover, production losses including decreased average daily gain, 
and increased respiratory disease diagnosis and treatment can be associated with these 
painful procedures in cattle (Glynn et al., 2013; Coetzee et al., 2012a). Strategies to 
address the pain associated with dehorning have demonstrated the reduction of responses 
associated with this noxious stimulus.  
 Multimodal analgesia is currently recommended to address both the acute injury 
of horn removal performed by cautery or amputation as well as controlling the 
subsequent inflammatory pain (Stafford and Mellor, 2011; Stock et al., 2013). Local 
anesthesia such as lidocaine provides immediate pain relief lasting for approximately 2-3 
h (Doherty et al., 2007; Stewart et al., 2008, 2009); however, the response following the 
loss of anesthetic activity indicates continued pain and distress. Non-steroidal anti-
inflammatory drugs (NSAID) have been investigated to determine their analgesic effect 
during this prolonged response including sodium salicylate (Baldridge et al., 2011), 
ketoprofen (McMeekan et al., 1998; Faulkner and Weary, 2000; Duffield et al., 2010), 
meloxicam (Heinrich et al., 2009, 2010; Coetzee et al., 2012a; Allen et al., 2013; Glynn 
et al., 2013; Stewart et al., 2009), flunixin meglumine (Stilwell et al., 2008, 2009; Glynn 
et al., 2013; Huber et al., 2013), carprofen (Stilwell et al., 2012), and firocoxib (Stock et 
al., 2015).  
 Given the variation in pharmacokinetic properties of NSAIDs as well as the 
pharmacokinetic pharmacodynamic relationship, these investigated NSAIDs provided a 
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variety of analgesic responses. It is noteworthy that Heinrich and colleagues (2009, 2010) 
demonstrated the clinical efficacy of IM meloxicam following cautery dehorning. As 
meloxicam has a prolonged half-life in cattle (~27 hrs), we hypothesized that NSAIDs 
with persistent concentrations would reduce the pain responses associated with dehorning 
following a one-time administration (Coetzee et al., 2009). As such, the objective of this 
study is to compare the analgesic properties of four NSAIDs administered at 2.0 mg/kg 
once orally in calves following cautery dehorning under the same experimental field 
conditions. These NSAIDs used in this study have demonstrated long half-lives in calves 
and can be administered orally, a practical method for drug delivery in the field. In 
addition, the prolonged physiology response post-cautery dehorning will be further 
characterized.  
       
Materials and Methods 
Animals  
One hundred and eighty-five female Holstein calves approximately between 6 and 
9 weeks of age (mean, range; 50.6 d, (41 d – 60 d)) at dehorning were included in this 
study. The mean weight (range) for the calves at disbudding was determined to be 64.1 
kg (range: 45.5 – 88.6 kg). Weight and age at dehorning were not different between 
treatment groups (Table 1).  All calves were determined healthy by a physical 
examination by a veterinarian. This study protocol was approved by the Institutional 
Animal Care and Use Committee at Iowa State University (IACUC Log # 4-14-7789-B). 
Calves were housed in individual three sided pens (1.82 m x 1.22 m) bedded with 
straw, which was added as needed determined by the calf manager. Calves were placed in 
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these pens at birth and remained within the pens through the entirety of the study. Two 
liters of pasteurized waste milk were fed once daily in the morning for the length of the 
study. Water was provided twice daily and grain, consisting of corn, oats, molasses, 
protein/vitamin/mineral supplement, and monensin was added daily at approximately 
0.45 – 1.36 kg. During the study period, a veterinarian conducted observational 
examinations which included assessment of milk and grain consumption. Calves were 
briefly handled in their pens daily for 2 days prior to baseline data collection to aid in the 
acclimatization of handling. The study was conducted May through July.      
Animals were monitored twice daily for health observations. Animals appearing 
depressed or lethargic were examined by a veterinarian and monitored or treated 
accordingly. Removal of animals due to disease was determined following an 
examination by a veterinarian. Disease and study removal were diagnosed based on an 
elevated rectal temperature (>103.5°C), spontaneous cough, ocular and/or nasal discharge 
and inappetance. Three animals were removed from the study and the data collected prior 
to removal were not included in the analysis. Due to a recent history of respiratory 
disease with confirmed cases of Mycoplasma bovis, all animals received prophylactic 
tulathromycin (2.5 mg/kg) (Draxxin®, Pfizer Inc., New York, NY) according to the 
manufacturer’s instructions during the initial weight determination at -24 h.    
 
Study Design 
 A randomized controlled clinical trial was used for this investigation (Figure 1). 
Study animals that were dehorned were randomly assigned to receive an oral target dose 
of 2.0 mg/kg carprofen (Novox® caplets, Vedco, Inc. St. Joesph, MO; ANADA 200-498) 
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(actual dose 2.05 mg/kg; range 1.71 – 2.50 mg/kg) (n=31), firocoxib (Previcox®, Merial 
LLC, Duluth, GA; NADA 141-230) (actual dose 2.02 mg/kg; range 1.66 – 2.51 mg/kg) 
(n=31), flunixin meglumine (Banamine® Paste, Merck & Co., Inc. Whitehouse Station, 
NJ; NADA #137-409) (actual dose 2.30 mg/kg; range 1.61 – 3.73 mg/kg) (n=30), 
meloxicam (Meloxicam tablets, Carlsbad Technology, Inc., Carlsbad, CA; NDC: 61442-
127-10) (actual dose 1.99 mg/kg; 1.72 – 2.11 mg/kg) (n=31) or a lactose (NOW®, 
Bloomingdale, IL) placebo with dehorning (PLCBO) (n=31) or without dehorning 
(SHAM) (n=31) (Table 1). SHAM animals were not dehorned prior to study enrollment. 
The test articles were administered as either a paste (flunixin meglumine) using the 
commercially provided dosing syringe or in an oral gelatin bolus using an oral balling 
gun. The calculated dose was rounded to the nearest tablet or dosing syringe notch based 
on the weights determined 24 h prior to administration (Table 1). The actual dose for 
flunixin meglumine was based on weights of the commercial tube obtained before and 
after administration. Calves treated with flunixin meglumine received an increased dose 
by approximately 0.3 mg/kg compared to the other treatment groups due to difficulties 
controlling the administered amount using the provided dosing syringe. Animals not 
receiving oral NSAIDs (PLCBO and SHAM) received a placebo (lactose powder) 
encapsulated in a gelatin capsule administered identically.    
Randomization of group assignment was based on age and mediated by a 
computer generated random number (Microsoft Excel 2011, Redmond, WA, USA) as 
described in Theurer et al, 2012. Following randomization and treatment group 
assignment, calves were enrolled in one of 6 groups containing equal number of animals 
from each treatment group (1 animal / treatment group / replicate). In order to facilitate 
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the number of calves enrolled in the study, animals were in enrolled in 7 phases with 3 to 
6 replicates of the treatment groups. 
 
Dehorning 
Dehorning was performed in approximately 5 min intervals by a single dehorner 
and handler per phase similarly described in Chapter 5. Calves were manually restrained. 
Cautery dehorning was initiated approximately 5 minutes following administration of the 
oral bolus and local anesthetic. A cornual nerve block using 2% lidocaine was provided 
to all calves prior to actual or sham cautery dehorning (VetOne®, Boise, ID) (5 ml / site) 
as described by Stock and others (2013). Effective local anesthesia of the cornual tissue 
was confirmed using behavior reactions (e.g. ear flicks, head shaking, strong escape 
behavior) to a needle prick approximately 3 minutes after administration of the cornual 
nerve block. Administration of lidocaine (1-2 ml) was repeated in the same manner 
described above if a response was observed to the initial needle prick. Following 
confirmation of appropriate desensitization, calves were cautery dehorning by placement 
of a pre-heated electrical hot-iron (approx. 600 °C) (Dehorner X-50, Rhinehart 
Development Corporation, Spencerville, IN) on the horn tissue for approximately 15-20 
seconds until a circumferential copper-colored ring surrounding the horn bud was 
formed.  A duplicate, non-heated electric dehorner (Dehorner X-50, Rhinehart 
Development Corporation, Spencerville, IN) was used identically for SHAM animals.  
 The dehorning sites were monitored daily for signs of discharge or infection, in 
addition to an assessment of attitude, posture, appetite, lying time, and peri-operative 
swelling. A rescue analgesia protocol of flunixin meglumine at 2.2 mg/kg, IV once 
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daily for 3 days was devised if obvert pain or distress was evident, such as increased 
lying time, head pressing, inflammation with major drainage of the dehorning site, 
dehydration or inappetence. 
 
Data Collection 
Variables of interest were evaluated in order from least to most invasive as 
determined by the investigators to limit the effect of the assessment on the subsequently 
tested variable. As such, the order was determined as follows: thermography images, 
heart rate, pressure algometry, and blood collection via jugular puncture. Calves were 
briefly manually restrained for infrared thermography, heart rate and blood collection. 
Investigators collecting data were masked to the treatment groups.  
 
Mechanical Nociception Threshold (MNT) 
MNT, as defined by a maximum force which induces a withdrawal response, was 
determined at 4, 8, 24, 48, 96, 144, and 192 h post-dehorning as described in Tapper et al. 
2012 and Allen et al., 2013. Briefly, calves were restrained using a loose halter for 
mechanical nociception threshold determination. Using a hand held pressure algometer 
(Wagner Force Ten™ FDX 25 Compact Digital Force Gage, Wagner Instruments, CT, 
USA), a force was applied perpendicular at a rate of approximately 1 kg of force per 
second at 2 locations (lateral and caudal) adjacent to the horn bud. The 1 cm
2
 rubber tip 
of the algometer was placed immediately adjacent to cauterized skin. Additionally, a third 
control location between the eyes on the frontal bone was used to evaluate MNT of an 
area that was not adjacent to cauterized skin. A withdrawal response was indicated by an 
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overt movement away from the applied pressure algometer. The obtained pressure value 
was recorded by a second researcher prior to observation from the investigator applying 
the pressure. A maximum value of 10 kgf was determined a priori. Prior to placement of 
the pressure algometer, the investigator placed a hand on the posterior aspect of the poll 
and removed it immediately prior to placement of the pressure algometer. This method 
was employed to avoid provoking withdrawal associated with a startle response. Calves 
were blindfolded prior to MNT to avoid a response associated with visual cues. Both the 
order of locations tested and the side of the calf the researcher stood on was randomized. 
Locations were tested three times in sequential order and the value was averaged for 
statistical analysis. 
 
Infrared Thermography  
 Using infrared thermography, eye and horn temperatures were recorded at 4, 8, 
24, 48, 96, 144, 192 h post-dehorning. Baseline samples for the eye were determined at    
-24 h whereas the baseline sample for the horn was determined at -1 h. Horns were not 
imaged at -24 h as this was also when the hair around the horn buds was removed using 
electrical clippers, and the investigators were concerned about confounding effects of 
response to the recent hair removal.  The maximum temperature (°C) within a 
circumferential area of each eye was recorded using an infrared thermography camera 
(FLIR SC 660, FLIR Systems AB, Boston, MA) as described by Stewart el al., 2008. In 
addition, a maximum temperature was recorded for a standard area surrounding each 
cauterized horn bud. A standardized method was used to collect images and record 
maximum ocular and dehorned area temperatures as previously described in Chapter 5. 
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Images were obtained from the left and right side of the calf, at an approximately 90° 
angle, and 0.5 meter distance from the head. Ambient temperature (°C) and relative 
humidity (%) recorded using a weather meter (Acurite®, Chaney Instrument Co., Lake 
Geneva, WI) were entered into the camera in addition to the automatic calibration. 
Images were analyzed using FLIR Tools (v. 4.1; FLIR Systems Inc, Boston, MA) 
following collection. At each time point, two images were obtained and averaged for 
statistical analysis. 
 
Heart Rate 
Heart rate was evaluated via auscultation at 4, 8, 24, 48, 96, 144, and 192 h. The 
bell of a stethoscope (Littmann®, St, Paul, MN, USA) was placed between the 3rd and 
5th intercostal space and beats were counted over a 15 second period. The value obtained 
was used to calculate beats per minute. Baseline values were obtained at -24 h.  
 
Average Daily Gain  
Animals were weighed using a digital scale (Brecknell 200E, Avery Weigh-
Tronix, LLC, Fairmont, MN) 24 hours prior to the dehorning (d -1) and 8 days following 
dehorning (d8). The scale was calibrated with weights of a known mass immediately 
prior to obtaining the weight of a group of calves. Average daily gains were determined 
using this data.  
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Blood sample collection 
Trained handlers manually restrained animals during blood collection. Baseline 
samples were obtained at -24 h and immediately prior to drug administration. Blood 
samples were collected for animals receiving NSAID or placebo via jugular puncture at 
approximately 4, 8, 24, 48, 96, 144, and 192 h. Samples were immediately transferred to 
a blood collection tube with either sodium heparin or ethylenediaminetetraacetic (EDTA) 
with benzamidine (Vacutainer®, BD Diagnostics) and stored in a cooler with ice before 
processing. Blood samples were centrifuged for 15 minutes at 1,500g. Collected plasma 
was placed in cryovials and frozen at -70 °C until analysis. 
 
Cortisol  
Plasma cortisol samples were determined using a commercial radioimmune assay 
kit (Corti-Cote™, MP Biomedicals, LLC, Soton, OH) previously used and validated for 
bovine plasma (Fisher et al, 1996). Samples were assayed in duplicate with the reported 
concentration equaling the average cortisol concentration between duplicates. Samples 
were reanalyzed if there were subjectively large discrepancies between the duplicates. 
The average intra- and inter-assay coefficients of variation were 13.8% and 14.5%, 
respectively. Area under the effect curve (AUEC) was calculated using the linear 
trapezoidal rule as previously described (Glynn et al., 2013). Baseline values were 
obtained immediately prior to the administration of local anesthesia and drug 
administration. 
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Statistical analysis 
Analyses were performed in SAS 9.3 (SAS Institute, Cary NC) using a linear 
mixed effects model with repeated measures. Data obtained from response variables was 
converted into a percent change from baseline and used for statistical analysis. 
Additionally, cortisol Cmax and AUEC were log transformed for normality and baseline 
values were used as covariates. The fixed effects were treatment (CARP, FIRO, FLU, 
MEL, PLCBO, SHAM), time, the interaction between treatment and time. Phase was a 
random effect and calf was the subject of repeated measures. F-tests were used to test the 
significance of main effects and interactions. If significant overall differences were 
identified among levels of a factor, pairwise comparisons were performed using Tukey's 
t-tests. The statistical analysis was performed for 3 time periods: 0 – 192 h, 0 – 24 h, and 
24 h – 192 h. Planned contrasts were performed evaluating the responses of analgesia 
(CARP, FIRO, FLU, MEL) versus PLCBO treated calves following dehorning.  
 
Results & Discussion 
Calves treated with an NSAID at the time of dehorning resulted in reduced 
physiological responses compared with placebo treated controls. Evidence suggests that 
meloxicam, flunixin meglumine, and firocoxib may decrease the associated stress in the 
acute period (<24 h) following dehorning, with meloxicam reducing the maximum 
cortisol concentration compared to placebo treated controls. Interestingly, carprofen did 
not attenuate the stress response in the immediate period following dehorning suggesting 
it is unable to reduce pain acutely. Although not investigated in this current study, the 
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timing of maximum pain relief as well as persistence may reflect the pharmacokinetics of 
the NSAID administered. 
Currently, there is a lack of pharmacokinetic-pharmacodynamic (PK/PD) models 
evaluating NSAIDs as analgesics in cattle. As such, accurate dose regimens 
demonstrating pain control are missing from the literature especially when compared to 
other veterinary species. For the drugs used within the study, a species dependent range 
of doses has been approved for use. For example, firocoxib has an approved dosing 
regimen of 0.1 mg/kg daily in horses while in dogs the approved dosing regimen is 5.0 
mg/kg administered once daily. Although a multitude of factors affect dose 
determination, this dose range for the same NSAID in different species supports the 
necessity to determine an effective dose regimen in the target species through 
development of PK/PD models. 
  Given the uncertainty of an analgesic dose of NSAIDs in cattle, in order to 
control for the potential variation of drug concentrations resulting in analgesia, we choose 
to administer the same dose and route for all NSAIDs used in this study. Despite the 
pharmacokinetic and pharmacodynamic properties that determine plasma drug 
concentrations and potentially the analgesic effect, the use of the same dose and route 
provides conditions where the response observed is not influenced by the dose or route. It 
should be noted that although a dose of 2.0 mg/kg was targeted, flunixin meglumine was 
administered as a paste using a commercially available dosing syringe. As the dosing 
syringe used is based on 250 lbs increments for horses, the accurate actual dose 
administered was difficult to obtain in comparison with our calculated dose. 
Consequently, calves treated with flunixin meglumine received an actual mean dose of 
199 
 
2.3 mg/kg (range: 1.61 – 3.73 mg/kg). Due to the difficulty in controlling the actual dose 
administered, the authors refrain from recommending its use.    
 
Cortisol  
There was no treatment effect throughout the study in the percent change from 
baseline of cortisol concentrations (0.427); however a time effect (P<0.0001) and a time 
by treatment interaction (P=0.021) were observed (Figure 2). The percent change of 
cortisol at 4 h was reduced in flunixin meglumine treated calves (P=0.037) and tended to 
be reduced in meloxicam treated calves (P=0.056) compared to placebo treated controls. 
Moreover, the percent change of cortisol in carprofen treated calves was increased at both 
4h (P<0.01) and 8h (P<0.05) compared to calves treated with firocoxib, flunixin 
meglumine, and meloxicam. Although no treatment effect was observed when evaluating 
the AUEC0-192 (P=0.485), AUEC0-24 indicates an overall treatment effect (P=0.0499) with 
placebo treated calves producing approximately 25% greater cortisol concentrations over 
the first 24 h compared to flunixin meglumine, meloxicam, and firocoxib treated calves 
(Table 2). In addition, maximum cortisol concentrations were attenuated in meloxicam 
treated calves compared to placebo treated controls (P=0.018) (Table 2). 
The cortisol response following dehorning has been well characterized (Stafford 
and Mellor 2011). Moreover, attenuation of the cortisol response using NSAIDs 
following dehorning has been reported in previous studies for meloxicam (Heinrich et al., 
2009; Allen et al., 2013), flunixin meglumine (Huber et al., 2013), carprofen (Stilwell et 
al., 2012) and firocoxib (Stock et al., 2015). As such these data are consistent with other 
published effects of NSAIDs reducing the cortisol response. Reduction in cortisol for the 
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first 24 h was similar between the treatment groups except for carprofen compared with 
placebo treated dehorned calves. In addition, meloxicam decreased cortisol Cmax 
compared to placebo treated controls, an effect not observed in the other treatment 
groups.  
Carprofen treatment resulted in increased cortisol percent change for the first 8 h 
compared to the other NSAID treatment groups demonstrating the inability to control 
acute cortisol release and the stress response. This differs from previous reports using 
intravenous carprofen administration at the time of dehorning (Stillwell et al., 2012), but 
consistent with results presented by our group (unpublished data, presented in Chapter 5). 
The incongruity is most likely due to the route of administration. A prolonged time to 
reach maximum concentrations (median; range: 18 h; 12 h to 48 h) following oral 
administration may be responsible for the lack of pain relief during the acute period 
following dehorning (unpublished data, presented in Chapter 5). Although not 
significantly different, an 11% reduction in cortisol AUEC24-192 was observed in 
carprofen treated calves compared to placebo treated suggesting a possible delay in effect 
of carprofen reducing stress.        
 
Heart Rate 
A treatment effect was observed throughout the study (P=0.024). A decreased 
percent change in heart rate observed in SHAM treated calves was greater than placebo 
treated calves over the study period (P=0.041).  Moreover, analgesia administration 
tended to decrease percent change in heart rate for the duration of the study compared to 
placebo treated controls (P=0.085). Following the statistical analysis of the percent 
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change in heart rate in two distinct periods, 0-24 h and 24-192 h, the reported treatment 
effect in SHAM treated calves was observed during the first 24 h. In addition, percent 
change in heart rate was reduced in carprofen treated calves compared to placebo treated 
calves between 24 h to 192 h (P=0.0466). During this same time period SHAM treated 
calves tended to have a decreased percent change in heart rate compared to placebo 
treated calves (P=0.0667).      
The percent change of heart rate for all treatment groups was decreased 
throughout the study (Figure 3). Most likely this was a result of an increased baseline 
heart rate collected. Although calves remained in their home pens during their study and 
were briefly handled daily for 2 days prior to the start of the study, multiple novel stimuli 
including multiple unfamiliar people in the calf area were introduced during the 
collection of baseline data. This may have resulted in stimulation of an increased heart 
rate during the initial collection. 
Multiple studies have reported the reductions in heart rate following dehorning 
with the use of meloxicam (Heinrich et al., 2009; Stewart et al., 2009; Coetzee et al., 
2012a). While reductions in heart rates were observed in meloxicam treated calves, these 
were not significantly different compared with placebo treated dehorned calves in our 
study. Different methodology of heart rate collection may account for the differences 
between studies.  Interestingly, heart rates were significantly decreased in carprofen 
treated calves compared to placebo treated calves from 24 h to 192 h indicating the 
possible attenuation of the autonomic nervous system (ANS) response once drug 
concentrations reached effective concentrations. This reduction in heart rate corresponds 
202 
 
with the decrease in AUEC24-192 observed in carprofen treated calves compared to 
placebo treated controls. 
 
Infrared Thermography: Dehorn area  
 SHAM dehorned calves had a greater increase in horn bud temperature 
throughout the duration of the study compared to all treatment groups (P<0.0001). A time 
effect (P<0.0001) and a time by treatment interaction (P=0.0005) were also observed. 
Among the dehorned treatment groups, carprofen treated calves had an increased percent 
change in dehorned area temperature at 4 h compared to firocoxib treated calves 
(P=0.025). Furthermore, this percent change in carprofen treated calves tended to be 
increased at 8 h (P=0.075) and 24 h (P=0.057) compared to firocoxib treated calves and 
at 8 h (P=0.075) for flunixin meglumine treated calves. An analysis of the initial 24 h 
indicates carprofen was associated with 1.4% greater increase in dehorned area 
temperature compared to firocoxib treated calves (P=0.0010) and 1.1% greater than 
flunixin treated calves (P=0.030). There were no treatment differences among dehorned 
treatment groups during the period 24 h to 192 h. 
 Infrared thermography has been used previously to demonstrate the effects of 
lameness on the surface temperature of the coronary band in cattle (Alsaaod et al., 2012). 
Changes in inflammatory patterns as observed in lame conditions result in differences 
between thermal profiles. Thermal imaging has not been used previously to determine the 
effect of cautery dehorning on the dehorning site. Skin temperature decreases with full or 
partially burned skin most likely due to disruption of peripheral blood perfusion 
(Hardwicke et al., 2013). As such, the increased temperature of non-dehorned SHAM 
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calves observed in this study was consistent with these findings most likely due to the 
maintenance of blood flow in non-cauterized skin.  
 In this study, we report differences in the temperature of dehorned skin among 
treatment groups following cautery dehorning. Calves treated with carprofen resulted in a 
greater increase in temperature during the first 24 h post-dehorning in comparison to both 
flunixin and firocoxib treated groups. If this effect correlates to increase inflammation as 
demonstrated in lame cattle, this change in temperature parallels the increase in cortisol 
percent change observed in carprofen treated calves. Although dehorning site temperature 
in carprofen treated calves resulted in a greater numerical increase during the first 24 h 
compared to placebo treated calves, it was not statistically different. Additional research 
would be necessary to determine the contribution of carprofen administration to an acute 
inflammatory response. Inflammation associated with burns is promoted by pro-
inflammatory cytokines such as IL-6 (Summer et al., 2008). In cattle, carprofen is 
reported to affect both IL-6 (Pang et al., 2008) and IL-6 receptor (Vailati et al., 2015) 
gene expression potentially leading to increased local concentrations of IL-6 in tissues. 
An upregulation of proinflammatory cytokines resulting in a greater inflammatory 
response may support the larger stress response observed.      
             
Infrared Thermography: Ocular  
Although the percent change from baseline of ocular temperatures changed over 
time through the study (P<0.0001), no treatment effect (P=0.532) or time by treatment 
interaction (P=0.712) were observed among treatment groups. These findings were 
consistent when evaluating the response during the first 24 h as well as 24 h to 192 post 
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dehorning. However, comparing all analgesic treated calves to placebo treated controls 
indicated a decreased percent change in ocular temperature during the first 24 h in those 
animals receiving an NSAID (P=0.026). In addition, a treatment effect was observed 
when evaluating the difference between the eye and dehorn area temperatures over the 
study period (P<0.001). SHAM treated calves had a more narrow temperature difference 
compared to the other treatment groups (Figure 4). Moreover, a greater difference in 
temperature was observed between the dehorn area and the eye in calves treated with an 
NSAID compared to placebo (P=0.029). 
Ocular temperature has been reported to decrease due to stimulation of the 
autonomic nervous system resulting in peripheral vasoconstriction (Stewart et al., 2010). 
In studies reporting this effect, ocular temperature was measured every 20 to 40 seconds 
and cattle were acclimated and restrained using a cattle chute with a head gate. The 
differences in methodology may be the reason for the incongruities in our studies 
evaluating ocular temperature over the course of the study period. In addition to 
collecting data at only specific time points, animals were manually restrained briefly to 
obtain a consistent image. Using our study methodology, no difference was observed 
between SHAM treated calves and placebo treated calves indicating a poor sensitivity in 
detecting differences associated with a noxious event. Despite obtaining the image before 
other data were collected, to avoid confounding factors of handling, the change in ocular 
temperature was increased in placebo treated controls in comparison to those treated with 
an NSAID during the initial 24 h period. This effect may be a result of the activity of an 
NSAID to inhibit prostaglandin production potentially resulting in alterations of 
peripheral blood flow (Przygodzki et al., 2015). 
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Mechanical Nociception Threshold (MNT) 
A treatment effect was observed in the percent change of mechanical nociception 
threshold with SHAM treated animals tolerating increased pressure throughout the length 
of the study (P<0.0001). Moreover, a time effect (P<0.001) and a time by treatment 
interaction (P<0.0001) was observed with SHAM treated calves having increased MNT 
at all study time points post-dehorning (Figure 5). There was no treatment difference 
observed among treatment groups dehorned throughout the study. 
The use of MNT to measure pain sensitivity following dehorning remains 
equivocal. Attenuation of the observed decrease in MNT post-disbudding has been 
previously reported following administration of IM meloxicam (Heinrich et al., 2010) 
and ethanol local anesthesia (Tapper et al., 2010); however other studies do not report 
treatment differences (Glynn et al., 2013; Allen et al., 2013; Stock et al., 2015). 
Methodology may remain a primary determinant of the ability to detect differences 
between treatment groups. In our study, MNT was useful in determining differences 
between animals dehorned compared to animals sham dehorned. However, MNT was 
insensitive in determining a treatment effect.  
Heinrich and colleagues (2010) reported increased MNT at 4 h following cautery 
dehorning in calves treated with IM meloxicam relative to calves that were dehorned with 
a placebo injection. MNT was assessed only at this one time point. Although capable of 
determining differences between dehorned and not dehorned in our study, the evaluation 
of MNT at multiple time points may not be useful in characterizing subtle differences in 
nociception thresholds resulting from NSAID administration. This may be due to an 
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increase in learned avoidance behaviors in calves throughout the course of the study. As 
such, the timing of the initial data collection would be critical in determining the 
possibility of a treatment effect and should correspond with the time the analgesic drug 
has reached maximum concentrations. 
 
Average Daily Gain (ADG) 
 Mean weight gain of 0.84 to 0.92 kg per day was observed during the study 
period. No treatment effect was observed in average daily gain among treatment groups 
including animals dehorned compared to those sham dehorned (P = 0.91). Equivocal 
results concerning ADG have been previously reported with multiple studies indicating 
increases in ADG (Glynn et al., 2013; Faulkner and Weary, 2000; Coetzee et al., 2012a) 
as well as those investigations resulting in no observed differences in weight gain 
(Grøndahl-Nielsen et al., 1999; Baldridge et al., 2011; Stock et al., 2015). The 
relationship between pain, stress, the neuroendocrine system and the immune system is 
complex. Investigations into castrations in cattle have indicated the benefits of using an 
NSAID at the time of castration resulting in a 50% reduction of bovine respiratory 
disease treatment (Coetzee et al., 2012b). All calves enrolled in this trial received 
metaphylaxic antibiotics to control respiratory disease 1 day prior to dehorning. This 
treatment may have masked the effect of using analgesia to control the pain and stress 
associated with cautery dehorning on weight gain. Moreover, individual housing used in 
this study may decrease competition for resources potentially influencing weight gain.  
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Conclusion 
 Cautery dehorning resulted in physiological, neuroendocrine, and nociception 
changes most dramatically during the first 24 h post-procedure. Perioperative oral 
NSAID administration resulted in the attenuation of the cortisol and heart rate response. 
Furthermore, NSAID use was associated with changes in temperature differences 
between the ocular and dehorning area. Based on cortisol response carprofen 
administration was not effective at controlling the associated stress in the first 24 h 
following cautery dehorning; however, meloxicam, firocoxib, and flunixin meglumine 
administration help to reduce cortisol release during the acute period post-dehorning. 
Moreover, meloxicam administration resulted in an attenuation of the maximum cortisol 
release. Despite the reduction in heart rate after 24 h, carprofen administration is not 
recommended based on its inability to control acute distress. Although not evaluated in 
this study, the variation in analgesic affect may be due to the variation in 
pharmacokinetic properties. Given the difficulties of controlling for an accurate dose 
using the oral flunixin paste in this dosing regimen, the authors would recommend 
meloxicam to control stress and pain associated with cautery dehorning.         
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Table 1. Treatment groups characteristics at the time of dehorning and dose administered. Significant differences (P<0.05) between 
time points are indicated by different letters (a, b).  
 
 Carprofen Firocoxib Flunixin Meloxicam Placebo Sham P value 
N 31 31 30 31 31 31  
Age (d) 
51.0 
(41-60) 
50.5 
(41-60) 
50.6 
(42-60) 
50.6 
(42-59) 
50.4 
(42-59) 
50.7 
(41-60) 
0.996 
Weight 
64.2 
(49.1 – 77.3) 
63.7 
(45.5 – 80.5) 
64.1 
(54.5 – 80.0) 
63.9 
(47.3 – 88.6) 
64.0 
(47.7 – 80.5) 
64.6 
(49.1 – 81.8) 
0.999 
Breed: 
Holstein cross 
3 3 4 3 2 5 0.871 
Actual dose 
(mg/kg) 
2.05
a
 
(1.71 – 2.50) 
2.01
a
 
(1.66 – 2.51) 
2.30
b
 
(1.61 – 3.73) 
1.99
a
 
(1.73 – 2.11) 
0 0 <0.0001 
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Table 2. Summary table of back-transformed cortisol concentrations of treatment groups post-dehorning. Significant differences 
(P<0.05) between time points are indicated by different letters (a, b).  
 
 
 
Carprofen 
LSM 
(95% CI) 
Firocoxib 
LSM 
(95% CI) 
Flunixin 
LSM 
(95% CI) 
Meloxicam 
LSM 
(95% CI) 
Placebo 
LSM 
(95% CI) 
Sham 
LSM 
(95% CI) 
Treatment 
(P value) 
Cortisol 
AUEC 
(0-192) 
2034.9 
(1645.0 – 
2517.4) 
2202.6 
(1783.4 –
2720.3) 
2217.4 
(1791.5 – 
2744.6) 
1851.4 
(1498.9 – 
2286.6) 
2198.7 
(1780.1 – 
2716.0) 
1925.6 
(1559.2 –
2378.0) 
0.485 
Cortisol 
AUEC 
(0 -24h) 
376.8 
(307.4 – 
461.9) 
290.4 
(237.2 – 
355.5) 
291.6 
(237.7 – 
357.9) 
285.8 
(233.5 – 
349.9) 
384.1 
(313.7 – 
470.2) 
324.9 
(265.4 – 
397.7) 
0.0499 
Cortisol 
AUEC 
(24-192h) 
1568.9 
(1214.4 - 
2027.0) 
1856.8 
(1440.0 - 
2394.4) 
1810.8 
(1400.8 - 
2340.5) 
1509.9 
(1171.0 - 
1947.1) 
1758.6 
(1363.6 - 
2268.1) 
1491.7 
(1156.9 - 
1923.5) 
0.410 
Cortisol 
Cmax 
39.7
ab 
(35.0 – 44.9) 
36.1
ab 
(31.8 – 40.8) 
36.7
ab 
(32.4 – 41.7) 
32.8
b 
(29.0 – 37.2) 
43.8
a 
(38.6 – 49.6) 
41.7
ab 
(36.8 – 47.2) 
0.0187 
AUEC: area under the effect curve; Cmax: maximum concentration
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Figure 1. Flow chart outlining the timing of the study events. Calves were dehorned and monitored for cortisol, mechanical 
nociception threshold (MNT), ocular temperature (OT), dehorning area temperature (DT), heart rate (HR), and average daily gain 
(ADG). The times in parentheses represent the duration of data collection for each variable.  
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Figure 2. Mean percent change (±95% CI) in cortisol concentration from 0-192 h, 0-24h, and 24-192h for sham and carprofen, 
firocoxib, flunixin, meloxicam, placebo treated calves following actual or sham cautery dehorning. 
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Figure 2. Mean percent change (±95% CI)  in heart rate from 0-192 h, 0-24h, and 24-192h for sham and carprofen, firocoxib, flunixin, 
meloxicam, placebo treated calves following actual or sham cautery dehorning. 
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Figure 4. Mean (±SE) difference between ocular and dehorn are temperatures as measured using infrared thermography for sham and 
carprofen, firocoxib, flunixin, meloxicam and placebo treated calves following actual or sham cautery dehorning.  
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Figure 5. Mean percent change (±95% CI) in mechanical nociception threshold from 0-192 h, 0-24h, and 24-192h for sham and 
carprofen, firocoxib, flunixin, meloxicam, placebo treated calves following actual or sham cautery dehorning.  
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CHAPTER 7 
DERIVATION OF A PAIN-STRESS INDEX 
Introduction 
The evaluation of pain is challenging. In disease states, using a single validated 
biomarker are advantageous; however, investigations validating biomarkers and 
responses in pain states continue to be elusive. As discussed by Molony and Kent (1997) 
the assessment of multiple indices of pain and stress are more likely to support the 
identification of a pain state. As such, we investigated the construction of a pain-stress 
index (PSI) where all response variables were standardized to derive a summary graph 
describing the response over time using one variable.      
 
Methods 
 Response variable data was collected as described in Chapter 6 and used to 
generate the summary graph. In order to equally weight all variables in determination of 
the pain-stress index (PSI), responses were standardized on a scale of 0 – 10 using the 
following formula: 
Pain-Stress Index (PSI) = ((a + (X - Min) * (b – a)) / (Max  - Min)) 
X: value of variable at given time point 
a: 0; lowest value in normalized range 
b: 10; highest value in normalized range 
Max: maximum response value observed in all calves for the variable calculated 
Min: maximum response value observed in all calves for the variable calculated 
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PSI was calculated for heart rate, mechanical nociception threshold (MNT), 
cortisol concentration, ocular temperature, and dehorned area temperature. As a decrease 
in MNT is associated with an increased nociception and pain, the inverse of the response 
was used in calculating the variables PSI. Additionally, due to increased dehorned area 
temperature observed in sham treated calves as a result of continued blood perfusion, this 
response was removed from sham PSI determination. As such, the average PSI for all 
response variables was used to determine the overall PSI at each calf at each time point in 
order to reduce the impact of removing a variable from a treatment group. The difference 
from baseline PSI was used for statistical analysis. 
   Analyses were performed in SAS 9.3 (SAS Institute, Cary NC) using a linear 
mixed effects model with repeated measures. Baseline PSI values were used as 
covariates. The fixed effects were treatment (CARP, FIRO, FLU, MEL, PLCBO, 
SHAM), time, and the interaction between treatment and time. Phase was a random effect 
and calf was the subject of repeated measures. F-tests were used to test the significance of 
main effects and interactions. If significant overall differences were identified among 
levels of a factor, pairwise comparisons were performed using Tukey's t-tests. The 
statistical analysis was performed for 3 time periods: 0 – 192 h, 0 – 24 h, and 24 – 192 h.  
 
Results & Discussion 
 There was an overall treatment effect (P<0.0001), time effect (P<0.0001) and 
time by treatment interaction (P<0.001) throughout the study period (Figure 1). SHAM 
treated animals had a decreased PSI difference compared to all other treatment groups 
(P<0.0001) at every time point (P<0.01). In addition, flunixin treated calves had a 
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decreased PSI at 8 h compared to carprofen (P=0.015) and placebo (P=0.052) treated 
calves. An analysis of the first 24 h indicates both sham (P<0.001) and meloxicam 
(P=0.044) treated calves had a decreased PSI compared to placebo treated controls 
(Figure 2). Other than a decreased PSI in SHAM animals compared to the other treatment 
groups, no treatment differences were observed in calves dehorned after 24 h. 
 The pain-stress index accurately detected differences between actual and sham 
dehorned calves. Moreover, placebo treated calves had an increased PSI for 24 h 
compared to meloxicam treated calves. This may provide further support for the 
analgesic superiority of meloxicam for a 24 h period of time at the current dosing 
regimen compared to other evaluated NSAIDs. Additionally, the calculated PSI indicated 
a reduction in pain and stress responses at 8 h for flunixin meglumine treated calves 
compared to placebo treated controls. This response may correlate to the plasma drug 
concentration profile and pharmacokinetic properties of oral flunixin meglumine 
(Odensvik, 1995). As previously reported in chapter 6, oral carprofen was not effective in 
comparison to other evaluated NSAIDs regarding the reduction of the pain-stress index 
for the initial 24 h.  Although preliminary, the following model could be used to further 
investigate analgesic compounds providing a summary variable of multiple indices.       
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Figure 1. Pain-Stress Index difference from baseline as calculated using the average of 
values obtained from equally weighted response variables over the course of the 192 h 
study.  
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Figure 2. Pain-Stress Index difference from baseline as calculated using the average of 
values obtained from equally weighted response variables over the first 24 h. 
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CHAPTER 8 
GENERAL CONCLUSIONS 
The pain and distress resulting from cautery dehorning in cattle has been well 
documented and reviewed (Stafford and Mellor, 2005, 2011). Changes in cortisol 
concentrations (Heinrich et al., 2009, Doherty et al., 2007, Allen et al., 2013), heart rate 
(Heinrich et al., 2009; Coetzee et al., 2012), respiratory rate (Heinrich et al., 2009), ocular 
temperature (Stewart et al., 2009), heart rate variability (Stewart et al., 2009), mechanical 
nociception threshold (Heinrich et al., 2010; Allen et al., 2013), time budget (Theurer et 
al., 2012), and behavior indices (Faulkner and Weary, 2000) are responses that have been 
evaluated to determine the changes due to cautery dehorning. The importance of 
investigating multiple indices of pain has been stressed as a method to accurately assess 
the affect state (Molony and Kent, 1997). As such, I examined multiple response 
variables previously investigated to evaluate the analgesic potential of non-steroidal anti-
inflammatory drugs to relieve pain associated with cautery dehorning. 
Treating pain in cattle is challenging. In addition to the lack of overt responses 
observed in cattle following a noxious event, there is scant information publicly available 
such as pharmacokinetic/pharmacodynamic (PK/PD) models to evaluate appropriate 
analgesic dosing regimens. The goal of these investigations was to determine a simple 
analgesic regimen that would optimize pain relief following cautery dehorning. A 
literature review indicated a multimodal approach using both local anesthesia and an 
NSAID reduced the signs of pain and distress associated with cautery dehorning (Stafford 
and Mellor, 2005, 2011; Stock et al., 2013). Moreover, investigations supporting the 
analgesic properties of meloxicam, an NSAID with a prolonged half-life may optimally 
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treat pain with the added benefit of complying with a simple dosing regimen (Heinrich et 
al., 2009). 
In the wake of studies indicating the pain relieving effects of meloxicam 
following cautery dehorning, I investigated firocoxib, an NSAID with a long half-life that 
produces analgesia in lame horses (Orsini et al., 2012). Chapter 3 describes the 
pharmacokinetics of firocoxib in calves, which demonstrated high oral bioavailability as 
well as a prolonged elimination half-life. Interestingly, firocoxib has a large volume of 
distribution, which is unique compared to other NSAIDs. As a result, firocoxib may 
accumulate in tissues throughout the body more so than most NSAIDs with a low volume 
of distribution. The pharmacokinetics of oral firocoxib detailed in our study would most 
likely support a once daily analgesic regimen for preweaned calves. 
In the same study, I investigated the analgesic response of oral firocoxib (0.5 
mg/kg) following cautery dehorning using a randomized controlled trial. The dosing 
regimen used resulted in plasma drug concentrations that inhibited ex-vivo prostaglandin 
E2 (PGE2) production for up to 48 h compared to placebo treated calves; however, this 
finding did not translate to attenuated stress and nociception responses during the initial 
24 h post dehorning. Although reductions in cortisol concentrations were observed in 
firocoxib treated calves at 48 h, responses evaluating physiology, neuroendocrine system, 
and nociception in the acute period did not differ from placebo treated controls.  As such, 
further research would be required prior to making a conclusion on the analgesic effect of 
firocoxib in calves including dose titration studies following predictive PK/PD modeling.  
Similar to firocoxib, carprofen is an NSAID often used in veterinary medicine 
primarily in dogs with pain associated with osteoarthritis. More recently, the oral 
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formulation has become available as a generic product significantly reducing its price. 
Carprofen has been previously investigated in calves, and is gaining approval as an anti-
inflammatory for respiratory disease in Europe. PK/PD modeling of its use as an anti-
inflammatory support, at most, a once daily administration supported by a prolonged 
terminal half-life in young calves (>44 hrs) (Brentnall et al., 2013; Delatour et al., 1996). 
Given the persistent anti-inflammatory activity observed, I hypothesized a one-time 
administration of carprofen would provide a prolonged analgesic effect in calves 
following cautery dehorning.  
Using a similarly designed randomized controlled trial as previously employed for 
evaluating firocoxib, oral carprofen was investigated for its analgesic potential and 
compared to subcutaneously administered carprofen using a dose of 1.4 mg/kg. The 
pharmacokinetics of oral carprofen indicated a prolonged half-life (~50 h) with 
approximately 70% bioavailability relative to subcutaneously administered carprofen. In 
addition, the time to reach maximum concentration was prolonged at a median of 18 h 
(range: 12 – 48 h). Prostaglandin inhibition was similar between routes of administration 
with moderate inhibition observed over the 96 h study period. This moderate inhibition 
has been previously reported leading investigators to label carprofen as both a COX-
dependent and COX-independent anti-inflammatory drug (Delatour et al., 1996; Lees et 
al., 1996).  
Despite the persistent concentrations and prolonged reduction of prostaglandin E2, 
responses suggestive of an attenuated pain and stress response were minimal in carprofen 
treated calves. Although carprofen treated calves tended to have an increased mean 
nociception threshold compared to placebo treated dehorned calves, other responses were 
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equivocal. As such, it was concluded that using the anti-inflammatory dose of 1.4 mg/kg 
administered orally at the time of dehorning was unsuccessful at controlling the 
associated pain. However, given the reduction in ex-vivo prostaglandin E2 suggesting a 
prolonged activity, dose titration studies may be warranted. 
Following studies evaluating the pharmacokinetics and analgesic responses of 
oral firocoxib and carprofen in calves at the time of dehorning, I addressed the question 
concerning the optimal NSAID to use to treat and control pain associated with cautery 
dehorning. My final study compared the analgesic effect of a one-time oral dose of 
carprofen, firocoxib, meloxicam, and flunixin meglumine in a randomized controlled 
field trial. In the absence of PK/PD analgesic modeling conducted in cattle using non-
steroidal anti-inflammatory drugs, a single standard dose administered the same route 
was used to avoid the uncertainty of an observed response being related to the dose and 
route used.  
 Based on the cortisol concentrations, calves treated with meloxicam, flunixin, and 
firocoxib had reductions in stress during the first 24 h compared to placebo treated 
controls. Moreover, meloxicam and flunixin had a decreased percent change cortisol 
response at 4 h and meloxicam decreased the maximum cortisol response. In contrast, 
carprofen treated calves had a similar cortisol response during the acute period (<24h) as 
placebo treated controls. This may be due to an increase in inflammation around the 
dehorning site evidence by the observed increased temperature compared to other 
treatment groups. Overall, meloxicam, flunixin and firocoxib may reduce the stress 
associated with dehorning; however, given the reduction of maximum cortisol release in 
meloxicam treated calves, the results of this field trial support the use of oral meloxicam 
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for the treatment of dehorning pain. This conclusion is further reinforced through the 
derivation and statistical analysis of the pain-stress index, which compiled equally 
weighted responses post-dehorning into one summary variable. 
Given the lack of PK/PD modeling for analgesia in cattle, future research and 
growth should be directed towards the development of these models. Using the plasma 
NSAID concentration data as well as the prostaglandin data generated from these studies, 
preliminary PK/PD models can be generated to calculate a preliminary analgesic dose. 
Previous literature using animal models have suggested targeting drug concentration that 
inhibit PGE2 by 80% to 95% (IC80 or IC95) to provide analgesia in rheumatoid arthritis in 
humans (Huntjens et al., 2005) or inflammatory conditions in cats (Giraudel et al., 2005a; 
Lees et al., 2004). Additionally, PK/PD models can be derived from already examined 
response variables including skin temperature or nociception thresholds in order to best 
elucidate the response most correlated with analgesia following cautery dehorning 
(Giraudel et al., 2005b).  
In order to optimize a PK/PD model, it is necessary to further investigate and 
refine biomarkers and response variables. Concentrations of inflammatory mediators 
found in plasma or cerebral spinal fluid such as bradykinin, serotonin, prostaglandins, 
histamine, calcitonin gene related peptide, and substance P that are responsible for 
hyperalgesia and allodynia may provide a better measurement of pain in cattle.  
Determination of key pharmacokinetic parameters including maximum plasma drug 
concentration or area under the curve could potentially lead to generating accurate PK/PD 
models already present in antimicrobial research.    
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In the advent of determining a PK/PD model of NSAIDs in cattle, preliminary 
calculated doses can be examined in-vivo to determine the accuracy of the modeled dose. 
Moreover, the preliminary dosing regimens should be evaluated in both healthy animals 
as well as in painful animals to best elucidate the optimal pain relief in the given disease 
state. In other animal models, pharmacokinetics (Day et al., 2015) and 
pharmacodynamics (Zhang et al., 2012) have demonstrated altered parameters in disease 
states compared to healthy subjects. 
Taken together, conclusions from this research continue to support the use of 
NSAIDs in cattle to control the pain associated with cautery dehorning. To best serve the 
welfare of the animal, it is important that the provision of analgesia has demonstrated 
effectiveness for the dosing regimen administered. Continued research both in-vivo and 
in-silico will be necessary to fully optimize pain relief in cattle. 
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